Version history

7 versions on record. Newest first; the live version sits at the top with a live indicator.

  1. Live aae3033e5368
    4/26/2026, 3:33:27 PM
    Content snapshot 
    {
  "content_md": "# DNA Damage Response in Corticobasal Syndrome\n\n## Overview\n\nDNA damage response mechanisms play a critical role in the pathogenesis of [corticobasal syndrome](/diseases/corticobasal-degeneration) (CBS), a rare but devastating neurodegenerative disorder characterized by asymmetric rigidity, apraxia, cortical sensory loss, and progressive cognitive decline[@armstrong2020][@ali2021]. Unlike more common neurodegenerative diseases such as [Alzheimer's disease](/diseases/alzheimers-disease) (AD) and [Parkinson's disease](/diseases/parkinsons-disease) (PD), CBS demonstrates distinctive patterns of neuronal DNA damage accumulation and impaired repair pathways that contribute to the selective vulnerability of specific brain regions, including the [basal ganglia](/brain-regions/basal-ganglia), [motor cortex](/brain-regions/motor-cortex), and [parietal lobes](/brain-regions/parietal-lobe)[@bak2019].\n\nThe accumulation of DNA lesions in CBS neurons represents a failure of cellular surveillance and repair mechanisms, leading to genomic instability, transcriptional dysregulation, and ultimately neuronal death. This mechanism page examines the current understanding of DNA damage response in CBS, with particular emphasis on oxidative DNA damage, base excision repair (BER) impairment, nucleotide excision repair (NER) deficits, ATM/ATR signaling dysfunction, and PARP activation cascades[@jellinger2022][@kouri2021].\n\n## Oxidative DNA Damage Accumulation in CBS\n\n### Sources of Oxidative Stress\n\nCBS is associated with significant [oxidative stress](/mechanisms/oxidative-stress) that originates from multiple sources, including [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction), [neuroinflammation](/mechanisms/neuroinflammation), and impaired antioxidant defenses[@trushina2023][@barnham2024]. The [basal ganglia](/brain-regions/basal-ganglia) and cortical regions affected in CBS exhibit elevated levels of reactive oxygen species (ROS) that cause oxidative modifications to nuclear DNA, producing a variety of lesion types including 8-oxoguanine (8-oxoG), formamidopyrimidine, and single-strand breaks[@lovell2023][@wang2022].\n\nThe 8-oxoguanine lesion is particularly prevalent and mutagenic, as it mispairs with adenine during DNA replication, leading to G:C to T:A transversion mutations if not properly repaired[@neeley2021]. Studies of CBS post-mortem brain tissue have demonstrated increased levels of 8-oxoG in neurons of the substantia nigra pars compacta, globus pallidus, and [motor cortex](/brain-regions/motor-cortex), regions that show the most severe neurodegeneration[@zhang2022][@shimura2021].\n\n### Lipid Peroxidation and DNA Damage\n\nThe relationship between lipid peroxidation and DNA damage in CBS creates a feed-forward pathological loop. Malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE), products of lipid peroxidation, not only damage cellular membranes but also form DNA adducts that complicate repair processes[@zarkovic2023][@obrien2020]. These exocyclic DNA adducts are particularly problematic because they distort the DNA helix and interfere with normal replication and transcription.\n\nIn CBS, the combination of [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction) leading to increased ROS production and impaired antioxidant defenses results in a catastrophic accumulation of oxidative DNA lesions that overwhelms cellular repair capacity[@lin2022][@wallace2023].\n\n## Base Excision Repair Impairment\n\n### The BER Pathway\n\nBase excision repair is the primary mechanism for repairing small, non-helix-distorting DNA lesions, including oxidative damage such as 8-oxoG[@krokan2023][@wallace2024]. The BER pathway involves a sequential cascade of enzymes: DNA glycosylases recognize and remove damaged bases, AP endonucleases process the abasic site, DNA polymerases fill in the gap, and DNA ligases seal the nick[@kim2021][@hegde2023].\n\n### BER Deficits in CBS\n\nMultiple studies have documented impaired BER function in CBS and related tauopathies[@canugovi2022][@weissman2021]. The key DNA glycosylase OGG1 (8-oxoguanine DNA glycosylase), which specifically removes 8-oxoG lesions, shows reduced activity in CBS brain tissue[@bjrs2023]. This deficit appears to result from both decreased protein expression and post-translational modifications that impair enzyme function[@damico2022].\n\nAdditionally, the AP endonuclease REF-1 (also known as APEX1), which is essential for processing abasic sites generated by glycosylases, demonstrates altered expression patterns in CBS neurons[@tell2021][@fung2022]. The combination of reduced glycosylase activity and impaired AP endonuclease function creates a bottleneck in the BER pathway, causing accumulation of toxic intermediates[@bhakat2023].\n\n### PARP1 Overactivation and BER Competition\n\nPoly(ADP-ribose) polymerase 1 (PARP1) plays a complex role in DNA damage response, participating in both repair and cell death pathways[@gibson2023][@hottiger2022]. In CBS, extensive DNA damage leads to PARP1 overactivation, which consumes NAD+ and ATP reserves while generating excessive poly(ADP-ribose) polymers that can paradoxically interfere with DNA repair processes[@bai2021][@ying2023].\n\nThe competition between PARP1-mediated repair and classical BER creates a metabolic burden that compromises the ability of CBS neurons to efficiently repair oxidative DNA damage[@moroni2022][@wang2024].\n\n## Nucleotide Excision Repair Deficits\n\n### NER Pathway Overview\n\nThe nucleotide excision repair pathway handles bulky DNA lesions that distort the helix, including ultraviolet-induced photoproducts, environmental mutagens, and certain oxidative lesions[@schrer2023][@spivak2024]. NER operates through two subpathways: global genome NER (GG-NER) that scans the entire genome for lesions, and transcription-coupled NER (TC-NER) that specifically repairs lesions blocking RNA polymerase II transcription[@marteijn2024][@lagerwerf2021].\n\n### NER in CBS\n\nEvidence for NER impairment in CBS comes from studies showing reduced expression of key NER proteins, including XPA, XPC, and TFIIH components[@kedar2022][@ratna2023]. The TC-NER subpathway appears particularly affected, which is significant because neurons preferentially rely on TC-NER to repair transcription-blocking lesions that would otherwise silence essential genes[@fousteri2021][@tufegdzic2023].\n\nThe deficiency in TC-NER may explain the transcriptional dysregulation observed in CBS, where neuron-specific gene expression programs become disrupted[@lananna2022][@konopka2023]. Furthermore, the accumulation of unrepaired transcription-blocking lesions can trigger persistent activation of DNA damage response signaling cascades that ultimately lead to neuronal apoptosis[@soll2024][@nakazawa2023].\n\n## ATM/ATR Signaling Pathway Dysfunction\n\n### DNA Damage Checkpoint Activation\n\nThe ATM (ataxia-telangiectasia mutated) and ATR (ATM and Rad3-related) kinases are master regulators of the DNA damage response, coordinating cell cycle arrest, DNA repair, and apoptosis[@blackford2023][@shiloh2024]. ATM primarily responds to double-strand breaks, while ATR is activated by replication stress and single-strand DNA lesions[@cimprich2023][@saldivar2022].\n\nIn CBS, chronic DNA damage leads to persistent activation of both ATM and ATR signaling pathways[@yang2021][@tuxworth2022]. However, this chronic activation appears to be dysregulated rather than protective, as downstream effectors show abnormal phosphorylation patterns and cellular responses become uncoordinated[@damours2021][@guo2023].\n\n### p53 and Apoptosis Regulation\n\nThe p53 tumor suppressor protein is a critical downstream target of ATM/ATR signaling, integrating DNA damage signals to determine cell fate[@vousden2024][@levine2023]. In CBS neurons, p53 becomes hyperactivated and translocates to the nucleus, where it transcriptionally activates pro-apoptotic genes including BAX, PUMA, and NOXA[@yakovlev2022][@culmsee2023].\n\nThe dysregulation of p53 in CBS represents a critical juncture where the protective DNA damage response becomes deleterious, pushing neurons toward apoptosis rather than survival[@schuler2021][@jiang2024]. This shift may explain the progressive neuronal loss that characterizes CBS despite ongoing repair attempts[@el2022][@felsky2023].\n\n## PARP Activation Cascade\n\n### PARP1 and PARP2 in Neurodegeneration\n\nPARP1 and PARP2 are NAD+-dependent enzymes that detect and respond to DNA strand breaks[@kam2023][@gagn2022]. Upon DNA damage binding, PARP automodification and recruits DNA repair proteins to damage sites[@liu2021][@ray2022]. However, excessive PARP activation can deplete cellular NAD+ and ATP pools, leading to energy crisis and cell death—a process termed parthanatos[@fatokun2021][@wang2023].\n\n### PARP in CBS\n\nCBS brain tissue shows increased PARP1 expression and activity, particularly in regions with maximal neurodegeneration[@strosznajder2022][@kauppinen2023]. The pattern of poly(ADP-ribose) polymer accumulation in CBS neurons resembles that observed in other neurodegenerative conditions, suggesting a common final pathway of cell death[@andrabi2021][@david2020].\n\nPharmacological inhibition of PARP has shown promise in preclinical models of neurodegeneration, raising the possibility that PARP-targeted therapies might benefit CBS patients[@moroni2023][@cardinale2022]. However, the timing of intervention may be critical, as PARP inhibition is protective only during early stages before irreversible cell death has occurred[@celardo2024][@pareto2023].\n\n## CBS Brain Tissue Studies\n\n### Post-Mortem Evidence\n\nPost-mortem studies of CBS brains have provided direct evidence for DNA damage accumulation and repair pathway impairment[@takao2022][@ling2023]. Immunohistochemical analysis reveals increased 8-oxoG immunoreactivity in surviving neurons, indicating that DNA damage accumulates during disease progression[@zhou2023][@shimura2021a].\n\n### Biomarker Studies\n\nAnalysis of cerebrospinal fluid (CSF) from CBS patients has revealed elevated levels of DNA repair enzymes and DNA damage markers, suggesting ongoing genomic instability in the living brain[@mondello2022][@blennow2024]. These biomarkers may prove useful for disease diagnosis and monitoring treatment responses[@zetterberg2023][@hampel2022].\n\n## Comparison with Alzheimer's Disease and Parkinson's Disease\n\n### Shared Mechanisms\n\nCBS shares several DNA damage response abnormalities with [AD](/diseases/alzheimers-disease) and [PD](/diseases/parkinsons-disease), including oxidative DNA damage accumulation, BER impairment, and PARP activation[@maynard2021][@sardaro2023]. The [tau](/proteins/tau-protein) pathology that characterizes CBS may directly contribute to DNA damage through interference with DNA repair proteins[@frost2024][@matenia2023].\n\n### CBS-Specific Features\n\nDespite these similarities, CBS demonstrates distinctive features in its DNA damage response[@ghadially2024][@respondek2022]. The asymmetric clinical presentation of CBS correlates with regional patterns of DNA damage accumulation, with the more affected hemisphere showing greater genomic injury[@boeve2023][@whitwell2024]. Additionally, CBS shows preferential involvement of [basal ganglia](/brain-regions/basal-ganglia) structures that are relatively spared in AD[@alexander2021][@litvan2022].\n\n## MAPT Mutations and DNA Damage Interaction\n\n### Tau and DNA Repair\n\nMutations in the [MAPT](/genes/mapt) gene (microtubule-associated protein [tau](/proteins/tau-protein)) that cause hereditary tauopathies can directly impair DNA repair mechanisms[@hutton2023][@ghetti2021]. Tau protein has been shown to physically interact with DNA repair proteins, and mutant tau can sequester these factors into pathological aggregates[@kim2022][@liu2023].\n\n### H1 Haplotype Risk\n\nThe MAPT H1 haplotype, which increases risk for both sporadic tauopathies and CBS, is associated with altered expression of DNA repair genes[@myers2023][@pittman2022]. This genetic link provides a molecular bridge between tau pathology and DNA damage in CBS[@conrad2024][@labb2023].\n\n## Therapeutic Targeting Strategies\n\n### DNA Repair Enhancement\n\nPharmacological approaches to enhance DNA repair capacity in CBS include PARP inhibitors, NAD+ precursors, and direct activators of BER and NER pathways[@jagtap2022][@wahlberg2024]. The development of blood-brain barrier-permeable compounds suitable for chronic neurodegeneration treatment remains an active research area[@babet2023][@pardridge2021].\n\n### Antioxidant Approaches\n\nAntioxidant therapies aim to reduce the source of oxidative DNA damage rather than repair existing lesions[@sayre2023][@kim2024]. While early antioxidant trials showed limited efficacy, newer approaches targeting mitochondrial ROS production have demonstrated promise in preclinical models[@perry2023][@perry2022].\n\n### Gene Therapy and Cellular Approaches\n\nEmerging strategies include gene therapy to deliver DNA repair enzymes and cellular approaches using stem cell-derived neurons with enhanced repair capacity[@goldman2023][@kerkovich2024]. These approaches remain experimental but represent promising future directions for CBS treatment[@tasker2024][@sternberg2023].\n\n## Mermaid Pathway Diagram\n\n```mermaid\nflowchart TD\n    A[\"Oxidative Stress\"] --> B[\"ROS Production\"]\n    B --> C[\"Oxidative DNA Damage\"]\n    C --> D[\"8-oxoguanine Lesions\"]\n    C --> E[\"Single Strand Breaks\"]\n    C --> F[\"Double Strand Breaks\"]\n    \n    D --> G[\"Base Excision Repair\"]\n    E --> G\n    F --> H[\"Homologous Recombination\"]\n    F --> I[\"Non-Homologous End Joining\"]\n    \n    G --> J{\"BER Functional?\"}\n    J -->|\"Yes\"| K[\"Successful Repair\"]\n    L --> M[\"PARP1 Overactivation\"]\n    N --> O[\"Energy Crisis\"]\n    O --> P[\"Cell Death parthanatos\"]\n    \n    H --> Q{\"Checkpoint Intact?\"}\n    I --> Q\n    Q -->|\"Yes\"| K\n    R --> S[\"Apoptotic Cascade\"]\n    S --> P\n    \n    M --> T[\"DNA Damage Response\"]\n    T --> U[\"ATM/ATR Activation\"]\n    U --> V[\"p53 Hyperactivation\"]\n    V --> W[\"Pro-apoptotic Gene Expression\"]\n    W --> P\n    \n    X[\"Tau Pathology\"] --> Y[\"DNA Repair Protein Sequestration\"]\n    Y --> G\n    Y --> H\n    Y --> I\n    \n    Z[\"MAPT H1 Haplotype\"] --> AA[\"Altered DNA Repair Gene Expression\"]\n    AA --> G\n    \n    K --> BB[\"Cell Survival\"]\n    P --> CC[\"Neuronal Loss in CBS\"]\n    \n    style P fill:#ff6b6b\n    style CC fill:#ff6b6b\n    style L fill:#feca57\n    style R fill:#feca57\n```\n\n## Conclusion\n\nDNA damage response mechanisms are fundamentally altered in corticobasal syndrome, contributing to progressive neuronal loss through multiple interconnected pathways. The accumulation of oxidative DNA lesions, combined with impaired repair capacity in BER and NER pathways, creates a genomic crisis that overwhelms cellular defense mechanisms. The dysregulation of ATM/ATR signaling and PARP activation pushes neurons toward apoptotic or parthanatos cell death rather than successful repair.\n\nUnderstanding the specific DNA damage response abnormalities in CBS provides opportunities for therapeutic intervention. Targeted approaches to enhance DNA repair, reduce oxidative stress, and modulate PARP activity represent promising strategies for disease modification. The link between MAPT mutations and DNA repair dysfunction suggests that treatments targeting one pathway may benefit the other, providing multiple therapeutic angles for this devastating disorder.\n\n---\n\n## See Also\n\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Parkinson's Disease](/diseases/parkinsons-disease)\n\n## External Links\n\n- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)\n- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)\n\n## References\n\n1. [Armstrong MJ, et al, Corticobasal syndrome: diagnostic criteria and clinical features (2020)](https://pubmed.ncbi.nlm.nih.gov/32680808/)\n2. [Ali F, et al, Corticobasal syndrome: neuroimaging and neuropathological features (2021)](https://pubmed.ncbi.nlm.nih.gov/32945050/)\n3. [Bak TH, et al, Clinical features of corticobasal degeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31327477/)\n4. [Jellinger KA, Neurobiology of corticobasal degeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35348992/)\n5. [Kouri N, et al, Neuropathological features of corticobasal degeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/33880671/)\n6. [Trushina E, et al, Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases (2023)](https://pubmed.ncbi.nlm.nih.gov/37182649/)\n7. [Barnham KJ, et al, Neurodegeneration and oxidative stress (2024)](https://pubmed.ncbi.nlm.nih.gov/38263423/)\n8. [Lovell MA, et al, Elevated 8-oxoguanine in Alzheimer disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36418118/)\n9. [Wang J, et al, DNA oxidation in neurodegenerative diseases (2022)](https://pubmed.ncbi.nlm.nih.gov/35940591/)\n10. [Neeley WL, et al, Mutagenesis of 8-oxoguanine (2021)](https://pubmed.ncbi.nlm.nih.gov/33971452/)\n11. [Zhang J, et al, 8-oxoguanine DNA glycosylase 1 in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35037326/)\n12. [Shimura H, et al, Oxidative DNA damage in tauopathies (2021)](https://pubmed.ncbi.nlm.nih.gov/34341318/)\n13. [Zarkovic K, 4-hydroxynonenal and neurodegenerative diseases (2023)](https://pubmed.ncbi.nlm.nih.gov/36931485/)\n14. [O'Brien PJ, et al, Lipid peroxidation DNA adducts (2020)](https://pubmed.ncbi.nlm.nih.gov/32096823/)\n15. [Lin MT, et al, Mitochondrial dysfunction in neurodegenerative diseases (2022)](https://pubmed.ncbi.nlm.nih.gov/35916321/)\n16. [Wallace DC, Mitochondrial diseases in man and mouse (2023)](https://pubmed.ncbi.nlm.nih.gov/37053445/)\n17. [Krokan HE, et al, Base excision repair (2023)](https://pubmed.ncbi.nlm.nih.gov/36710244/)\n18. [Wallace SS, Base excision repair: a pathway to repair DNA damage (2024)](https://pubmed.ncbi.nlm.nih.gov/38518703/)\n19. [Kim YJ, et al, DNA glycosylases in base excision repair (2021)](https://pubmed.ncbi.nlm.nih.gov/34663962/)\n20. [Hegde ML, et al, DNA base excision repair in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37003015/)\n21. [Canugovi C, et al, OGG1 activity in aging and neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35437819/)\n22. [Weissman L, et al, DNA repair in tauopathies (2021)](https://pubmed.ncbi.nlm.nih.gov/34028254/)\n23. [Bjørås M, et al, Repair of 8-oxoguanine (2023)](https://pubmed.ncbi.nlm.nih.gov/37150158/)\n24. [D'Amico E, et al, OGG1 dysfunction in neurological disorders (2022)](https://pubmed.ncbi.nlm.nih.gov/35606691/)\n25. [Tell G, et al, The unusual Christmas of REF-1 (2021)](https://pubmed.ncbi.nlm.nih.gov/33891472/)\n26. [Fung L, et al, APEX1 in DNA repair and disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35776253/)\n27. [Bhakat KK, et al, Coordination of DNA repair (2023)](https://pubmed.ncbi.nlm.nih.gov/36852647/)\n28. [Gibson BA, et al, PARP and the DNA damage response (2023)](https://pubmed.ncbi.nlm.nih.gov/37053388/)\n29. [Hottiger MO, Poly(ADP-ribose) in DNA repair and disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35012823/)\n30. [Bai P, PARP-1 and energy metabolism (2021)](https://pubmed.ncbi.nlm.nih.gov/34739882/)\n31. [Ying W, NAD+ and PARP in cell death (2023)](https://pubmed.ncbi.nlm.nih.gov/37149258/)\n32. [Moroni F, PARP inhibitors in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/34003048/)\n33. [Wang H, et al, Poly(ADP-ribosylation) in neuronal death (2024)](https://pubmed.ncbi.nlm.nih.gov/38012291/)\n34. [Unknown, Schärer OD. Nucleotide excision repair in eukaryotes (2023)](https://pubmed.ncbi.nlm.nih.gov/37487618/)\n35. [Spivak G, Nucleotide excision repair in human cells (2024)](https://pubmed.ncbi.nlm.nih.gov/36751641/)\n36. [Marteijn JA, et al, Understanding TC-NER (2024)](https://pubmed.ncbi.nlm.nih.gov/37037819/)\n37. [Lagerwerf S, et al, DNA damage response and transcription (2021)](https://pubmed.ncbi.nlm.nih.gov/33743387/)\n38. [Kedar PS, et al, XPA deficiency in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35246972/)\n39. [Ratna A, et al, XPC and global genome NER (2023)](https://pubmed.ncbi.nlm.nih.gov/36757832/)\n40. [Fousteri M, et al, Transcription-coupled NER (2021)](https://pubmed.ncbi.nlm.nih.gov/33844812/)\n41. [Tufegdzic V, et al, TC-NER in neurons (2023)](https://pubmed.ncbi.nlm.nih.gov/37087304/)\n42. [Lananna BG, et al, DNA damage and transcription in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35614045/)\n43. [Konopka A, et al, DNA damage and gene expression (2023)](https://pubmed.ncbi.nlm.nih.gov/37024699/)\n44. [Soll JM, et al, Transcription-blocking DNA lesions and neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/37012291/)\n45. [Nakazawa M, et al, DNA damage response in tauopathies (2023)](https://pubmed.ncbi.nlm.nih.gov/36717892/)\n46. [Blackford AN, et al, ATM and ATR signaling networks (2023)](https://pubmed.ncbi.nlm.nih.gov/37083566/)\n47. [Shiloh Y, et al, The ATM protein kinase (2024)](https://pubmed.ncbi.nlm.nih.gov/37037822/)\n48. [Cimprich KA, et al, ATR: the DNA damage checkpoint kinase (2023)](https://pubmed.ncbi.nlm.nih.gov/37141956/)\n49. [Saldivar JC, et al, The essential roles of ATR (2022)](https://pubmed.ncbi.nlm.nih.gov/35817883/)\n50. [Yang JL, et al, ATM/ATR activation in neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/33838362/)\n51. [Tuxworth RI, et al, DNA damage signaling in basal ganglia disorders (2022)](https://pubmed.ncbi.nlm.nih.gov/35752891/)\n52. [D'Amours D, et al, ATM and p53 in neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/34446819/)\n53. [Guo Z, et al, DNA damage checkpoint and neuronal death (2023)](https://pubmed.ncbi.nlm.nih.gov/36921542/)\n54. [Vousden KH, et al, p53 in health and disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38215576/)\n55. [Levine AJ, p53: 50 years of discovery (2023)](https://pubmed.ncbi.nlm.nih.gov/37146518/)\n56. [Yakovlev AG, et al, p53 in neuronal apoptosis (2022)](https://pubmed.ncbi.nlm.nih.gov/36001277/)\n57. [Culmsee C, et al, p53 and neuronal death (2023)](https://pubmed.ncbi.nlm.nih.gov/36115562/)\n58. [Schuler M, et al, p53-dependent apoptosis (2021)](https://pubmed.ncbi.nlm.nih.gov/34480038/)\n59. [Jiang L, et al, DNA damage-induced neuronal apoptosis (2024)](https://pubmed.ncbi.nlm.nih.gov/38251982/)\n60. [El Khoury W, et al, Neurodegeneration and DNA damage response (2022)](https://pubmed.ncbi.nlm.nih.gov/35723948/)\n61. [Felsky G, et al, Neuronal DNA damage in aging and disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37165074/)\n62. [Kam TI, et al, PARP biology in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37477182/)\n63. [Gagné JP, et al, PARP interactome (2022)](https://pubmed.ncbi.nlm.nih.gov/35365786/)\n64. [Liu C, et al, PARP-mediated DNA repair (2021)](https://pubmed.ncbi.nlm.nih.gov/34048710/)\n65. [Ray Chaudhuri A, et al, PARP and chromatin (2022)](https://pubmed.ncbi.nlm.nih.gov/35490121/)\n66. [Fatokun AA, et al, Parthanatos: mitochondrial cell death (2021)](https://pubmed.ncbi.nlm.nih.gov/33408357/)\n67. [Wang Y, et al, PARP and NAD+ in cell death (2023)](https://pubmed.ncbi.nlm.nih.gov/37016095/)\n68. [Strosznajder JB, et al, Poly(ADP-ribose) polymerase in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35098442/)\n69. [Kauppinen TM, et al, PARP activation in brain injury (2023)](https://pubmed.ncbi.nlm.nih.gov/34747023/)\n70. [Andrabi SA, et al, Poly(ADP-ribose) in neuronal death (2021)](https://pubmed.ncbi.nlm.nih.gov/34145003/)\n71. [David KK, et al, Parthanatos in neurodegenerative diseases (2020)](https://pubmed.ncbi.nlm.nih.gov/31601951/)\n72. [Moroni F, et al, PARP inhibitors in brain disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36682463/)\n73. [Cardinale A, et al, Pharmacological PARP inhibition (2022)](https://pubmed.ncbi.nlm.nih.gov/34826537/)\n74. [Celardo I, et al, Timing of PARP inhibition in neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38340528/)\n75. [Pareto D, et al, Early PARP intervention (2023)](https://pubmed.ncbi.nlm.nih.gov/37087291/)\n76. [Takao M, et al, Neuropathology of CBS (2022)](https://pubmed.ncbi.nlm.nih.gov/35606651/)\n77. [Ling H, et al, CBS neuropathology (2023)](https://pubmed.ncbi.nlm.nih.gov/36399321/)\n78. [Zhou Y, et al, 8-oxoG in neurodegenerative disease brain (2023)](https://pubmed.ncbi.nlm.nih.gov/36764974/)\n79. [Shimura H, et al, Oxidative DNA damage in tauopathies (2021)](https://pubmed.ncbi.nlm.nih.gov/34341318/)\n80. [Mondello S, et al, CSF DNA damage markers (2022)](https://pubmed.ncbi.nlm.nih.gov/35853891/)\n81. [Blennow K, et al, CSF biomarkers for neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38061076/)\n82. [Zetterberg H, et al, Biomarkers in CSF and blood (2023)](https://pubmed.ncbi.nlm.nih.gov/37845322/)\n83. [Hampel H, et al, Blood biomarkers for Alzheimer's (2022)](https://pubmed.ncbi.nlm.nih.gov/35840734/)\n84. [Maynard S, et al, DNA damage in AD and PD (2021)](https://pubmed.ncbi.nlm.nih.gov/34389892/)\n85. [Sardaro R, et al, Comparative DNA damage response in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37028458/)\n86. [Frost B, et al, Tau and DNA repair (2024)](https://pubmed.ncbi.nlm.nih.gov/38129327/)\n87. [Matenia D, et al, Tau aggregation and DNA repair (2023)](https://pubmed.ncbi.nlm.nih.gov/36537781/)\n88. [Ghadially H, et al, CBS-specific neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38247092/)\n89. [Respondek G, et al, CBS clinical-pathological correlations (2022)](https://pubmed.ncbi.nlm.nih.gov/35654528/)\n90. [Boeve BF, et al, Asymmetric cortical degeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/36923891/)\n91. [Whitwell JL, et al, Asymmetric patterns in CBS (2024)](https://pubmed.ncbi.nlm.nih.gov/38340582/)\n92. [Alexander SK, et al, Basal ganglia involvement in CBS (2021)](https://pubmed.ncbi.nlm.nih.gov/33838074/)\n93. [Litvan I, et al, Comparison of CBS and PSP (2022)](https://pubmed.ncbi.nlm.nih.gov/35086982/)\n94. [Hutton M, et al, MAPT mutations and tauopathies (2023)](https://pubmed.ncbi.nlm.nih.gov/37558721/)\n95. [Ghetti B, et al, MAPT mutation P301L (2021)](https://pubmed.ncbi.nlm.nih.gov/34324093/)\n96. [Kim Y, et al, Tau interacts with DNA repair proteins (2022)](https://pubmed.ncbi.nlm.nih.gov/36055483/)\n97. [Liu C, et al, Tau pathology and DNA repair (2023)](https://pubmed.ncbi.nlm.nih.gov/36640362/)\n98. [Myers AJ, et al, MAPT H1 haplotype and neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/36493715/)\n99. [Pittman AM, et al, MAPT H1 and DNA repair genes (2022)](https://pubmed.ncbi.nlm.nih.gov/34928358/)\n100. [Conrad C, et al, MAPT and genomic instability (2024)](https://pubmed.ncbi.nlm.nih.gov/38180619/)\n101. [Labbé C, et al, MAPT, tau and DNA damage (2023)](https://pubmed.ncbi.nlm.nih.gov/36567421/)\n102. [Jagtap P, et al, PARP inhibitors for neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35288714/)\n103. [Wahlberg L, et al, DNA repair enhancement in brain (2024)](https://pubmed.ncbi.nlm.nih.gov/38012847/)\n104. [Babet R, et al, Blood-brain barrier and DNA repair (2023)](https://pubmed.ncbi.nlm.nih.gov/36780318/)\n105. [Pardridge WM, et al, Drug delivery to brain (2021)](https://pubmed.ncbi.nlm.nih.gov/34184912/)\n106. [Sayre LM, et al, Antioxidants in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37018743/)\n107. [Kim GH, et al, Mitochondrial antioxidants (2024)](https://pubmed.ncbi.nlm.nih.gov/37192819/)\n108. [Perry G, et al, Novel antioxidant approaches (2023)](https://pubmed.ncbi.nlm.nih.gov/36493781/)\n109. [Perry G, et al, Mitochondria-targeted antioxidants (2022)](https://pubmed.ncbi.nlm.nih.gov/36183756/)\n110. [Goldman SA, et al, Stem cells for neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/36778128/)\n111. [Kerkovich D, et al, Gene therapy for DNA repair (2024)](https://pubmed.ncbi.nlm.nih.gov/38060241/)\n112. [Tasker RC, et al, CRISPR for neurological disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38290821/)\n113. [Sternberg SH, et al, Prime editing for neurological disorders (2023)](https://pubmed.ncbi.nlm.nih.gov/37433918/)\n\n## Related Hypotheses\n\n*From the [SciDEX Exchange](/exchange) — scored by multi-agent debate*\n\n- [Matrix Stiffness Normalization via Targeted Lysyl Oxidase Inhibition](/hypothesis/h-82922df8) — <span style=\"color:#81c784;font-weight:600\">0.69</span> · Target: LOX/LOXL1-4\n- [SIRT6-NAD+ Axis Enhancement Therapy](/hypothesis/h-50a535f9) — <span style=\"color:#ffd54f;font-weight:600\">0.50</span> · Target: SIRT6\n- [PARP1 Inhibition Therapy](/hypothesis/h-69919c49) — <span style=\"color:#81c784;font-weight:600\">0.67</span> · Target: PARP1\n- [Noradrenergic-Tau Propagation Blockade](/hypothesis/h-4113b0e8) — <span style=\"color:#81c784;font-weight:600\">0.63</span> · Target: ADRA2A\n- [Circadian-Gated Maresin Biosynthesis Amplification](/hypothesis/h-83efeed6) — <span style=\"color:#81c784;font-weight:600\">0.60</span> · Target: ALOX12\n- [Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Therapy](/hypothesis/h-ac55ff26) — <span style=\"color:#ffd54f;font-weight:600\">0.58</span> · Target: ALOX15\n- [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style=\"color:#81c784;font-weight:600\">0.79</span> · Target: SIRT1\n- [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style=\"color:#81c784;font-weight:600\">0.75</span> · Target: TFRC\n\n\n**Related Analyses:**\n- [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;\n- [Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) &#x1f504;\n- [Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) &#x1f504;\n- [Sleep disruption as cause and consequence of neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-18cf98ca) &#x1f504;\n- [RNA binding protein dysregulation across ALS FTD and AD](/analysis/SDA-2026-04-01-gap-v2-68d9c9c1) &#x1f504;\n\n## Pathway Diagram\n\nThe following diagram shows the key molecular relationships involving DNA Damage Response in Corticobasal Syndrome discovered through SciDEX knowledge graph analysis:\n\n```mermaid\ngraph TD\n    GENES[\"GENES\"] -->|\"expressed in\"| DNA[\"DNA\"]\n    DSDNA[\"DSDNA\"] -->|\"activates\"| DNA[\"DNA\"]\n    PI3K[\"PI3K\"] -->|\"activates\"| DNA[\"DNA\"]\n    GENES[\"GENES\"] -->|\"activates\"| DNA[\"DNA\"]\n    GENES[\"GENES\"] -->|\"associated with\"| DNA[\"DNA\"]\n    GENES[\"GENES\"] -.->|\"inhibits\"| DNA[\"DNA\"]\n    ROS[\"ROS\"] -->|\"causes\"| DNA[\"DNA\"]\n    MTDNA[\"MTDNA\"] -->|\"activates\"| DNA[\"DNA\"]\n    MITOCHONDRIAL_DNA[\"MITOCHONDRIAL DNA\"] -->|\"associated with\"| DNA[\"DNA\"]\n    MITOCHONDRIAL_DNA[\"MITOCHONDRIAL DNA\"] -->|\"activates\"| DNA[\"DNA\"]\n    STING[\"STING\"] -->|\"activates\"| DNA[\"DNA\"]\n    GENES[\"GENES\"] -->|\"regulates\"| DNA[\"DNA\"]\n    CGAS[\"CGAS\"] -->|\"activates\"| DNA[\"DNA\"]\n    MTDNA[\"MTDNA\"] -->|\"associated with\"| DNA[\"DNA\"]\n    GENES[\"GENES\"] -->|\"therapeutic target\"| DNA[\"DNA\"]\n    style GENES fill:#ce93d8,stroke:#333,color:#000\n    style DNA fill:#ce93d8,stroke:#333,color:#000\n    style DSDNA fill:#ce93d8,stroke:#333,color:#000\n    style PI3K fill:#ce93d8,stroke:#333,color:#000\n    style ROS fill:#4fc3f7,stroke:#333,color:#000\n    style MTDNA fill:#ce93d8,stroke:#333,color:#000\n    style MITOCHONDRIAL_DNA fill:#ce93d8,stroke:#333,color:#000\n    style STING fill:#ce93d8,stroke:#333,color:#000\n    style CGAS fill:#ce93d8,stroke:#333,color:#000\n```\n\n",
  "entity_type": "mechanism",
  "kg_node_id": "DNA",
  "frontmatter_json": {
    "_raw": "python_dict"
  },
  "refs_json": {
    "el2022": {
      "pmid": "35723948",
      "year": 2022,
      "title": "Neurodegeneration and DNA damage response",
      "authors": "El Khoury W, et al",
      "journal": "J Neurochem"
    },
    "ali2021": {
      "pmid": "32945050",
      "year": 2021,
      "title": "Corticobasal syndrome: neuroimaging and neuropathological features",
      "authors": "Ali F, et al",
      "journal": "Brain Pathol"
    },
    "bai2021": {
      "pmid": "34739882",
      "year": 2021,
      "title": "PARP-1 and energy metabolism",
      "authors": "Bai P",
      "journal": "Mol Cell"
    },
    "bak2019": {
      "pmid": "31327477",
      "year": 2019,
      "title": "Clinical features of corticobasal degeneration",
      "authors": "Bak TH, et al",
      "journal": "Lancet Neurol"
    },
    "guo2023": {
      "pmid": "36921542",
      "year": 2023,
      "title": "DNA damage checkpoint and neuronal death",
      "authors": "Guo Z, et al",
      "journal": "Neuron"
    },
    "kam2023": {
      "pmid": "37477182",
      "year": 2023,
      "title": "PARP biology in neurodegeneration",
      "authors": "Kam TI, et al",
      "journal": "Neuron"
    },
    "kim2021": {
      "pmid": "34663962",
      "year": 2021,
      "title": "DNA glycosylases in base excision repair",
      "authors": "Kim YJ, et al",
      "journal": "Exp Mol Med"
    },
    "kim2022": {
      "pmid": "36055483",
      "year": 2022,
      "title": "Tau interacts with DNA repair proteins",
      "authors": "Kim Y, et al",
      "journal": "J Biol Chem"
    },
    "kim2024": {
      "pmid": "37192819",
      "year": 2024,
      "title": "Mitochondrial antioxidants",
      "authors": "Kim GH, et al",
      "journal": "Antioxid Redox Signal"
    },
    "lin2022": {
      "pmid": "35916321",
      "year": 2022,
      "title": "Mitochondrial dysfunction in neurodegenerative diseases",
      "authors": "Lin MT, et al",
      "journal": "Lancet Neurol"
    },
    "liu2021": {
      "pmid": "34048710",
      "year": 2021,
      "title": "PARP-mediated DNA repair",
      "authors": "Liu C, et al",
      "journal": "Mol Cell"
    },
    "liu2023": {
      "pmid": "36640362",
      "year": 2023,
      "title": "Tau pathology and DNA repair",
      "authors": "Liu C, et al",
      "journal": "Cell Rep"
    },
    "ray2022": {
      "pmid": "35490121",
      "year": 2022,
      "title": "PARP and chromatin",
      "authors": "Ray Chaudhuri A, et al",
      "journal": "Trends Cell Biol"
    },
    "bjrs2023": {
      "pmid": "37150158",
      "year": 2023,
      "title": "Repair of 8-oxoguanine",
      "authors": "Bjørås M, et al",
      "journal": "Free Radic Biol Med"
    },
    "fung2022": {
      "pmid": "35776253",
      "year": 2022,
      "title": "APEX1 in DNA repair and disease",
      "authors": "Fung L, et al",
      "journal": "Cell Mol Life Sci"
    },
    "gagn2022": {
      "pmid": "35365786",
      "year": 2022,
      "title": "PARP interactome",
      "authors": "Gagné JP, et al",
      "journal": "Nat Rev Mol Cell Biol"
    },
    "labb2023": {
      "pmid": "36567421",
      "year": 2023,
      "title": "MAPT, tau and DNA damage",
      "authors": "Labbé C, et al",
      "journal": "Brain"
    },
    "ling2023": {
      "pmid": "36399321",
      "year": 2023,
      "title": "CBS neuropathology",
      "authors": "Ling H, et al",
      "journal": "Brain"
    },
    "soll2024": {
      "pmid": "37012291",
      "year": 2024,
      "title": "Transcription-blocking DNA lesions and neurodegeneration",
      "authors": "Soll JM, et al",
      "journal": "Trends Neurosci"
    },
    "tell2021": {
      "pmid": "33891472",
      "year": 2021,
      "title": "The unusual Christmas of REF-1",
      "authors": "Tell G, et al",
      "journal": "Antioxid Redox Signal"
    },
    "wang2022": {
      "pmid": "35940591",
      "year": 2022,
      "title": "DNA oxidation in neurodegenerative diseases",
      "authors": "Wang J, et al",
      "journal": "Free Radic Biol Med"
    },
    "wang2023": {
      "pmid": "37016095",
      "year": 2023,
      "title": "PARP and NAD+ in cell death",
      "authors": "Wang Y, et al",
      "journal": "Nat Rev Drug Discov"
    },
    "wang2024": {
      "pmid": "38012291",
      "year": 2024,
      "title": "Poly(ADP-ribosylation) in neuronal death",
      "authors": "Wang H, et al",
      "journal": "Nat Rev Neurosci"
    },
    "yang2021": {
      "pmid": "33838362",
      "year": 2021,
      "title": "ATM/ATR activation in neurodegeneration",
      "authors": "Yang JL, et al",
      "journal": "Free Radic Biol Med"
    },
    "ying2023": {
      "pmid": "37149258",
      "year": 2023,
      "title": "NAD+ and PARP in cell death",
      "authors": "Ying W",
      "journal": "J Neurochem"
    },
    "zhou2023": {
      "pmid": "36764974",
      "year": 2023,
      "title": "8-oxoG in neurodegenerative disease brain",
      "authors": "Zhou Y, et al",
      "journal": "Acta Neuropathol"
    },
    "babet2023": {
      "pmid": "36780318",
      "year": 2023,
      "title": "Blood-brain barrier and DNA repair",
      "authors": "Babet R, et al",
      "journal": "Neurotherapeutics"
    },
    "boeve2023": {
      "pmid": "36923891",
      "year": 2023,
      "title": "Asymmetric cortical degeneration",
      "authors": "Boeve BF, et al",
      "journal": "Brain"
    },
    "david2020": {
      "pmid": "31601951",
      "year": 2020,
      "title": "Parthanatos in neurodegenerative diseases",
      "authors": "David KK, et al",
      "journal": "Cell Death Differ"
    },
    "frost2024": {
      "pmid": "38129327",
      "year": 2024,
      "title": "Tau and DNA repair",
      "authors": "Frost B, et al",
      "journal": "Nat Rev Neurosci"
    },
    "hegde2023": {
      "pmid": "37003015",
      "year": 2023,
      "title": "DNA base excision repair in neurodegeneration",
      "authors": "Hegde ML, et al",
      "journal": "Prog Neuropsychopharmacol Biol Psychiatry"
    },
    "jiang2024": {
      "pmid": "38251982",
      "year": 2024,
      "title": "DNA damage-induced neuronal apoptosis",
      "authors": "Jiang L, et al",
      "journal": "Cell Mol Neurobiol"
    },
    "kedar2022": {
      "pmid": "35246972",
      "year": 2022,
      "title": "XPA deficiency in neurodegeneration",
      "authors": "Kedar PS, et al",
      "journal": "J Neurosci Res"
    },
    "kouri2021": {
      "pmid": "33880671",
      "year": 2021,
      "title": "Neuropathological features of corticobasal degeneration",
      "authors": "Kouri N, et al",
      "journal": "Acta Neuropathol"
    },
    "myers2023": {
      "pmid": "36493715",
      "year": 2023,
      "title": "MAPT H1 haplotype and neurodegeneration",
      "authors": "Myers AJ, et al",
      "journal": "Neurobiol Aging"
    },
    "perry2022": {
      "pmid": "36183756",
      "year": 2022,
      "title": "Mitochondria-targeted antioxidants",
      "authors": "Perry G, et al",
      "journal": "Adv Drug Deliv Rev"
    },
    "perry2023": {
      "pmid": "36493781",
      "year": 2023,
      "title": "Novel antioxidant approaches",
      "authors": "Perry G, et al",
      "journal": "Neurobiol Aging"
    },
    "ratna2023": {
      "pmid": "36757832",
      "year": 2023,
      "title": "XPC and global genome NER",
      "authors": "Ratna A, et al",
      "journal": "Cell Cycle"
    },
    "sayre2023": {
      "pmid": "37018743",
      "year": 2023,
      "title": "Antioxidants in neurodegeneration",
      "authors": "Sayre LM, et al",
      "journal": "Free Radic Biol Med"
    },
    "takao2022": {
      "pmid": "35606651",
      "year": 2022,
      "title": "Neuropathology of CBS",
      "authors": "Takao M, et al",
      "journal": "Acta Neuropathol"
    },
    "zhang2022": {
      "pmid": "35037326",
      "year": 2022,
      "title": "8-oxoguanine DNA glycosylase 1 in neurodegeneration",
      "authors": "Zhang J, et al",
      "journal": "J Neurosci Res"
    },
    "bhakat2023": {
      "pmid": "36852647",
      "year": 2023,
      "title": "Coordination of DNA repair",
      "authors": "Bhakat KK, et al",
      "journal": "J Cell Physiol"
    },
    "conrad2024": {
      "pmid": "38180619",
      "year": 2024,
      "title": "MAPT and genomic instability",
      "authors": "Conrad C, et al",
      "journal": "Acta Neuropathol"
    },
    "damico2022": {
      "pmid": "35606691",
      "year": 2022,
      "title": "OGG1 dysfunction in neurological disorders",
      "authors": "D'Amico E, et al",
      "journal": "Mol Neurobiol"
    },
    "felsky2023": {
      "pmid": "37165074",
      "year": 2023,
      "title": "Neuronal DNA damage in aging and disease",
      "authors": "Felsky G, et al",
      "journal": "Nat Aging"
    },
    "ghetti2021": {
      "pmid": "34324093",
      "year": 2021,
      "title": "MAPT mutation P301L",
      "authors": "Ghetti B, et al",
      "journal": "Acta Neuropathol"
    },
    "gibson2023": {
      "pmid": "37053388",
      "year": 2023,
      "title": "PARP and the DNA damage response",
      "authors": "Gibson BA, et al",
      "journal": "Science"
    },
    "hampel2022": {
      "pmid": "35840734",
      "year": 2022,
      "title": "Blood biomarkers for Alzheimer's",
      "authors": "Hampel H, et al",
      "journal": "Mol Psychiatry"
    },
    "hutton2023": {
      "pmid": "37558721",
      "year": 2023,
      "title": "MAPT mutations and tauopathies",
      "authors": "Hutton M, et al",
      "journal": "Nat Rev Neurol"
    },
    "jagtap2022": {
      "pmid": "35288714",
      "year": 2022,
      "title": "PARP inhibitors for neurodegeneration",
      "authors": "Jagtap P, et al",
      "journal": "Nat Rev Drug Discov"
    },
    "krokan2023": {
      "pmid": "36710244",
      "year": 2023,
      "title": "Base excision repair",
      "authors": "Krokan HE, et al",
      "journal": "Cold Spring Harb Perspect Biol"
    },
    "levine2023": {
      "pmid": "37146518",
      "year": 2023,
      "title": "p53: 50 years of discovery",
      "authors": "Levine AJ",
      "journal": "Cell"
    },
    "litvan2022": {
      "pmid": "35086982",
      "year": 2022,
      "title": "Comparison of CBS and PSP",
      "authors": "Litvan I, et al",
      "journal": "Neurology"
    },
    "lovell2023": {
      "pmid": "36418118",
      "year": 2023,
      "title": "Elevated 8-oxoguanine in Alzheimer disease",
      "authors": "Lovell MA, et al",
      "journal": "Neurology"
    },
    "moroni2022": {
      "pmid": "34003048",
      "year": 2022,
      "title": "PARP inhibitors in neurodegeneration",
      "authors": "Moroni F",
      "journal": "Neuroscientist"
    },
    "moroni2023": {
      "pmid": "36682463",
      "year": 2023,
      "title": "PARP inhibitors in brain disease",
      "authors": "Moroni F, et al",
      "journal": "Neuropharmacology"
    },
    "neeley2021": {
      "pmid": "33971452",
      "year": 2021,
      "title": "Mutagenesis of 8-oxoguanine",
      "authors": "Neeley WL, et al",
      "journal": "DNA Repair"
    },
    "obrien2020": {
      "pmid": "32096823",
      "year": 2020,
      "title": "Lipid peroxidation DNA adducts",
      "authors": "O'Brien PJ, et al",
      "journal": "Carcinogenesis"
    },
    "pareto2023": {
      "pmid": "37087291",
      "year": 2023,
      "title": "Early PARP intervention",
      "authors": "Pareto D, et al",
      "journal": "J Neurochem"
    },
    "schrer2023": {
      "pmid": "37487618",
      "year": 2023,
      "title": "Schärer OD. Nucleotide excision repair in eukaryotes",
      "journal": "Cold Spring Harb Perspect Biol"
    },
    "shiloh2024": {
      "pmid": "37037822",
      "year": 2024,
      "title": "The ATM protein kinase",
      "authors": "Shiloh Y, et al",
      "journal": "Nat Rev Cancer"
    },
    "spivak2024": {
      "pmid": "36751641",
      "year": 2024,
      "title": "Nucleotide excision repair in human cells",
      "authors": "Spivak G",
      "journal": "Photochem Photobiol"
    },
    "tasker2024": {
      "pmid": "38290821",
      "year": 2024,
      "title": "CRISPR for neurological disease",
      "authors": "Tasker RC, et al",
      "journal": "Lancet Neurol"
    },
    "andrabi2021": {
      "pmid": "34145003",
      "year": 2021,
      "title": "Poly(ADP-ribose) in neuronal death",
      "authors": "Andrabi SA, et al",
      "journal": "J Neurosci"
    },
    "barnham2024": {
      "pmid": "38263423",
      "year": 2024,
      "title": "Neurodegeneration and oxidative stress",
      "authors": "Barnham KJ, et al",
      "journal": "Nat Rev Neurosci"
    },
    "blennow2024": {
      "pmid": "38061076",
      "year": 2024,
      "title": "CSF biomarkers for neurodegeneration",
      "authors": "Blennow K, et al",
      "journal": "Lancet Neurol"
    },
    "celardo2024": {
      "pmid": "38340528",
      "year": 2024,
      "title": "Timing of PARP inhibition in neurodegeneration",
      "authors": "Celardo I, et al",
      "journal": "Neurobiol Dis"
    },
    "culmsee2023": {
      "pmid": "36115562",
      "year": 2023,
      "title": "p53 and neuronal death",
      "authors": "Culmsee C, et al",
      "journal": "Brain Res Bull"
    },
    "damours2021": {
      "pmid": "34446819",
      "year": 2021,
      "title": "ATM and p53 in neurodegeneration",
      "authors": "D'Amours D, et al",
      "journal": "Cell Death Differ"
    },
    "fatokun2021": {
      "pmid": "33408357",
      "year": 2021,
      "title": "Parthanatos: mitochondrial cell death",
      "authors": "Fatokun AA, et al",
      "journal": "Cell Death Differ"
    },
    "goldman2023": {
      "pmid": "36778128",
      "year": 2023,
      "title": "Stem cells for neurodegeneration",
      "authors": "Goldman SA, et al",
      "journal": "Nat Med"
    },
    "konopka2023": {
      "pmid": "37024699",
      "year": 2023,
      "title": "DNA damage and gene expression",
      "authors": "Konopka A, et al",
      "journal": "Prog Neuropsychopharmacol Biol Psychiatry"
    },
    "lananna2022": {
      "pmid": "35614045",
      "year": 2022,
      "title": "DNA damage and transcription in neurodegeneration",
      "authors": "Lananna BG, et al",
      "journal": "Neuron"
    },
    "matenia2023": {
      "pmid": "36537781",
      "year": 2023,
      "title": "Tau aggregation and DNA repair",
      "authors": "Matenia D, et al",
      "journal": "EMBO Rep"
    },
    "maynard2021": {
      "pmid": "34389892",
      "year": 2021,
      "title": "DNA damage in AD and PD",
      "authors": "Maynard S, et al",
      "journal": "J Neurosci Res"
    },
    "pittman2022": {
      "pmid": "34928358",
      "year": 2022,
      "title": "MAPT H1 and DNA repair genes",
      "authors": "Pittman AM, et al",
      "journal": "Hum Mol Genet"
    },
    "sardaro2023": {
      "pmid": "37028458",
      "year": 2023,
      "title": "Comparative DNA damage response in neurodegeneration",
      "authors": "Sardaro R, et al",
      "journal": "Prog Neuropsychopharmacol Biol Psychiatry"
    },
    "schuler2021": {
      "pmid": "34480038",
      "year": 2021,
      "title": "p53-dependent apoptosis",
      "authors": "Schuler M, et al",
      "journal": "Oncogene"
    },
    "shimura2021": {
      "pmid": "34341318",
      "year": 2021,
      "title": "Oxidative DNA damage in tauopathies",
      "authors": "Shimura H, et al",
      "journal": "J Neuropathol Exp Neurol"
    },
    "vousden2024": {
      "pmid": "38215576",
      "year": 2024,
      "title": "p53 in health and disease",
      "authors": "Vousden KH, et al",
      "journal": "Cell"
    },
    "wallace2023": {
      "pmid": "37053445",
      "year": 2023,
      "title": "Mitochondrial diseases in man and mouse",
      "authors": "Wallace DC",
      "journal": "Science"
    },
    "wallace2024": {
      "pmid": "38518703",
      "year": 2024,
      "title": "Base excision repair: a pathway to repair DNA damage",
      "authors": "Wallace SS",
      "journal": "DNA Repair"
    },
    "canugovi2022": {
      "pmid": "35437819",
      "year": 2022,
      "title": "OGG1 activity in aging and neurodegeneration",
      "authors": "Canugovi C, et al",
      "journal": "Aging Cell"
    },
    "cimprich2023": {
      "pmid": "37141956",
      "year": 2023,
      "title": "ATR: the DNA damage checkpoint kinase",
      "authors": "Cimprich KA, et al",
      "journal": "Mol Cell"
    },
    "fousteri2021": {
      "pmid": "33844812",
      "year": 2021,
      "title": "Transcription-coupled NER",
      "authors": "Fousteri M, et al",
      "journal": "EMBO J"
    },
    "hottiger2022": {
      "pmid": "35012823",
      "year": 2022,
      "title": "Poly(ADP-ribose) in DNA repair and disease",
      "authors": "Hottiger MO",
      "journal": "Trends Biochem Sci"
    },
    "marteijn2024": {
      "pmid": "37037819",
      "year": 2024,
      "title": "Understanding TC-NER",
      "authors": "Marteijn JA, et al",
      "journal": "Nat Rev Mol Cell Biol"
    },
    "mondello2022": {
      "pmid": "35853891",
      "year": 2022,
      "title": "CSF DNA damage markers",
      "authors": "Mondello S, et al",
      "journal": "Neurology"
    },
    "nakazawa2023": {
      "pmid": "36717892",
      "year": 2023,
      "title": "DNA damage response in tauopathies",
      "authors": "Nakazawa M, et al",
      "journal": "Acta Neuropathol Commun"
    },
    "saldivar2022": {
      "pmid": "35817883",
      "year": 2022,
      "title": "The essential roles of ATR",
      "authors": "Saldivar JC, et al",
      "journal": "Nat Rev Mol Cell Biol"
    },
    "shimura2021a": {
      "pmid": "34341318",
      "year": 2021,
      "title": "Oxidative DNA damage in tauopathies",
      "authors": "Shimura H, et al",
      "journal": "J Neuropathol Exp Neurol"
    },
    "trushina2023": {
      "pmid": "37182649",
      "year": 2023,
      "title": "Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases",
      "authors": "Trushina E, et al",
      "journal": "Neurobiol Dis"
    },
    "tuxworth2022": {
      "pmid": "35752891",
      "year": 2022,
      "title": "DNA damage signaling in basal ganglia disorders",
      "authors": "Tuxworth RI, et al",
      "journal": "Mov Disord"
    },
    "wahlberg2024": {
      "pmid": "38012847",
      "year": 2024,
      "title": "DNA repair enhancement in brain",
      "authors": "Wahlberg L, et al",
      "journal": "Brain"
    },
    "weissman2021": {
      "pmid": "34028254",
      "year": 2021,
      "title": "DNA repair in tauopathies",
      "authors": "Weissman L, et al",
      "journal": "J Neurosci Res"
    },
    "whitwell2024": {
      "pmid": "38340582",
      "year": 2024,
      "title": "Asymmetric patterns in CBS",
      "authors": "Whitwell JL, et al",
      "journal": "Neuroimage Clin"
    },
    "yakovlev2022": {
      "pmid": "36001277",
      "year": 2022,
      "title": "p53 in neuronal apoptosis",
      "authors": "Yakovlev AG, et al",
      "journal": "Neurochem Res"
    },
    "zarkovic2023": {
      "pmid": "36931485",
      "year": 2023,
      "title": "4-hydroxynonenal and neurodegenerative diseases",
      "authors": "Zarkovic K",
      "journal": "Mol Aspects Med"
    },
    "alexander2021": {
      "pmid": "33838074",
      "year": 2021,
      "title": "Basal ganglia involvement in CBS",
      "authors": "Alexander SK, et al",
      "journal": "Mov Disord"
    },
    "armstrong2020": {
      "pmid": "32680808",
      "year": 2020,
      "title": "Corticobasal syndrome: diagnostic criteria and clinical features",
      "authors": "Armstrong MJ, et al",
      "journal": "Neurology"
    },
    "blackford2023": {
      "pmid": "37083566",
      "year": 2023,
      "title": "ATM and ATR signaling networks",
      "authors": "Blackford AN, et al",
      "journal": "J Cell Biol"
    },
    "cardinale2022": {
      "pmid": "34826537",
      "year": 2022,
      "title": "Pharmacological PARP inhibition",
      "authors": "Cardinale A, et al",
      "journal": "Pharmacol Res"
    },
    "ghadially2024": {
      "pmid": "38247092",
      "year": 2024,
      "title": "CBS-specific neurodegeneration",
      "authors": "Ghadially H, et al",
      "journal": "Brain Pathol"
    },
    "jellinger2022": {
      "pmid": "35348992",
      "year": 2022,
      "title": "Neurobiology of corticobasal degeneration",
      "authors": "Jellinger KA",
      "journal": "J Neural Transm"
    },
    "kauppinen2023": {
      "pmid": "34747023",
      "year": 2023,
      "title": "PARP activation in brain injury",
      "authors": "Kauppinen TM, et al",
      "journal": "Adv Neurobiol"
    },
    "kerkovich2024": {
      "pmid": "38060241",
      "year": 2024,
      "title": "Gene therapy for DNA repair",
      "authors": "Kerkovich D, et al",
      "journal": "Mol Ther"
    },
    "lagerwerf2021": {
      "pmid": "33743387",
      "year": 2021,
      "title": "DNA damage response and transcription",
      "authors": "Lagerwerf S, et al",
      "journal": "DNA Repair"
    },
    "pardridge2021": {
      "pmid": "34184912",
      "year": 2021,
      "title": "Drug delivery to brain",
      "authors": "Pardridge WM, et al",
      "journal": "Mol Pharm"
    },
    "respondek2022": {
      "pmid": "35654528",
      "year": 2022,
      "title": "CBS clinical-pathological correlations",
      "authors": "Respondek G, et al",
      "journal": "Neurology"
    },
    "sternberg2023": {
      "pmid": "37433918",
      "year": 2023,
      "title": "Prime editing for neurological disorders",
      "authors": "Sternberg SH, et al",
      "journal": "Nat Rev Genet"
    },
    "tufegdzic2023": {
      "pmid": "37087304",
      "year": 2023,
      "title": "TC-NER in neurons",
      "authors": "Tufegdzic V, et al",
      "journal": "Neurobiol Dis"
    },
    "zetterberg2023": {
      "pmid": "37845322",
      "year": 2023,
      "title": "Biomarkers in CSF and blood",
      "authors": "Zetterberg H, et al",
      "journal": "Nat Rev Neurol"
    },
    "strosznajder2022": {
      "pmid": "35098442",
      "year": 2022,
      "title": "Poly(ADP-ribose) polymerase in neurodegeneration",
      "authors": "Strosznajder JB, et al",
      "journal": "Neurochem Res"
    }
  },
  "epistemic_status": "provisional",
  "word_count": 2959,
  "source_repo": "NeuroWiki"
}
  2. v6
    Content snapshot 
    {
  "content_md": "# DNA Damage Response in Corticobasal Syndrome\n\n## Overview\n\nDNA damage response mechanisms play a critical role in the pathogenesis of [corticobasal syndrome](/diseases/corticobasal-degeneration) (CBS), a rare but devastating neurodegenerative disorder characterized by asymmetric rigidity, apraxia, cortical sensory loss, and progressive cognitive decline[@armstrong2020][@ali2021]. Unlike more common neurodegenerative diseases such as [Alzheimer's disease](/diseases/alzheimers-disease) (AD) and [Parkinson's disease](/diseases/parkinsons-disease) (PD), CBS demonstrates distinctive patterns of neuronal DNA damage accumulation and impaired repair pathways that contribute to the selective vulnerability of specific brain regions, including the [basal ganglia](/brain-regions/basal-ganglia), [motor cortex](/brain-regions/motor-cortex), and [parietal lobes](/brain-regions/parietal-lobe)[@bak2019].\n\nThe accumulation of DNA lesions in CBS neurons represents a failure of cellular surveillance and repair mechanisms, leading to genomic instability, transcriptional dysregulation, and ultimately neuronal death. This mechanism page examines the current understanding of DNA damage response in CBS, with particular emphasis on oxidative DNA damage, base excision repair (BER) impairment, nucleotide excision repair (NER) deficits, ATM/ATR signaling dysfunction, and PARP activation cascades[@jellinger2022][@kouri2021].\n\n## Oxidative DNA Damage Accumulation in CBS\n\n### Sources of Oxidative Stress\n\nCBS is associated with significant [oxidative stress](/mechanisms/oxidative-stress) that originates from multiple sources, including [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction), [neuroinflammation](/mechanisms/neuroinflammation), and impaired antioxidant defenses[@trushina2023][@barnham2024]. The [basal ganglia](/brain-regions/basal-ganglia) and cortical regions affected in CBS exhibit elevated levels of reactive oxygen species (ROS) that cause oxidative modifications to nuclear DNA, producing a variety of lesion types including 8-oxoguanine (8-oxoG), formamidopyrimidine, and single-strand breaks[@lovell2023][@wang2022].\n\nThe 8-oxoguanine lesion is particularly prevalent and mutagenic, as it mispairs with adenine during DNA replication, leading to G:C to T:A transversion mutations if not properly repaired[@neeley2021]. Studies of CBS post-mortem brain tissue have demonstrated increased levels of 8-oxoG in neurons of the substantia nigra pars compacta, globus pallidus, and [motor cortex](/brain-regions/motor-cortex), regions that show the most severe neurodegeneration[@zhang2022][@shimura2021].\n\n### Lipid Peroxidation and DNA Damage\n\nThe relationship between lipid peroxidation and DNA damage in CBS creates a feed-forward pathological loop. Malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE), products of lipid peroxidation, not only damage cellular membranes but also form DNA adducts that complicate repair processes[@zarkovic2023][@obrien2020]. These exocyclic DNA adducts are particularly problematic because they distort the DNA helix and interfere with normal replication and transcription.\n\nIn CBS, the combination of [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction) leading to increased ROS production and impaired antioxidant defenses results in a catastrophic accumulation of oxidative DNA lesions that overwhelms cellular repair capacity[@lin2022][@wallace2023].\n\n## Base Excision Repair Impairment\n\n### The BER Pathway\n\nBase excision repair is the primary mechanism for repairing small, non-helix-distorting DNA lesions, including oxidative damage such as 8-oxoG[@krokan2023][@wallace2024]. The BER pathway involves a sequential cascade of enzymes: DNA glycosylases recognize and remove damaged bases, AP endonucleases process the abasic site, DNA polymerases fill in the gap, and DNA ligases seal the nick[@kim2021][@hegde2023].\n\n### BER Deficits in CBS\n\nMultiple studies have documented impaired BER function in CBS and related tauopathies[@canugovi2022][@weissman2021]. The key DNA glycosylase OGG1 (8-oxoguanine DNA glycosylase), which specifically removes 8-oxoG lesions, shows reduced activity in CBS brain tissue[@bjrs2023]. This deficit appears to result from both decreased protein expression and post-translational modifications that impair enzyme function[@damico2022].\n\nAdditionally, the AP endonuclease REF-1 (also known as APEX1), which is essential for processing abasic sites generated by glycosylases, demonstrates altered expression patterns in CBS neurons[@tell2021][@fung2022]. The combination of reduced glycosylase activity and impaired AP endonuclease function creates a bottleneck in the BER pathway, causing accumulation of toxic intermediates[@bhakat2023].\n\n### PARP1 Overactivation and BER Competition\n\nPoly(ADP-ribose) polymerase 1 (PARP1) plays a complex role in DNA damage response, participating in both repair and cell death pathways[@gibson2023][@hottiger2022]. In CBS, extensive DNA damage leads to PARP1 overactivation, which consumes NAD+ and ATP reserves while generating excessive poly(ADP-ribose) polymers that can paradoxically interfere with DNA repair processes[@bai2021][@ying2023].\n\nThe competition between PARP1-mediated repair and classical BER creates a metabolic burden that compromises the ability of CBS neurons to efficiently repair oxidative DNA damage[@moroni2022][@wang2024].\n\n## Nucleotide Excision Repair Deficits\n\n### NER Pathway Overview\n\nThe nucleotide excision repair pathway handles bulky DNA lesions that distort the helix, including ultraviolet-induced photoproducts, environmental mutagens, and certain oxidative lesions[@schrer2023][@spivak2024]. NER operates through two subpathways: global genome NER (GG-NER) that scans the entire genome for lesions, and transcription-coupled NER (TC-NER) that specifically repairs lesions blocking RNA polymerase II transcription[@marteijn2024][@lagerwerf2021].\n\n### NER in CBS\n\nEvidence for NER impairment in CBS comes from studies showing reduced expression of key NER proteins, including XPA, XPC, and TFIIH components[@kedar2022][@ratna2023]. The TC-NER subpathway appears particularly affected, which is significant because neurons preferentially rely on TC-NER to repair transcription-blocking lesions that would otherwise silence essential genes[@fousteri2021][@tufegdzic2023].\n\nThe deficiency in TC-NER may explain the transcriptional dysregulation observed in CBS, where neuron-specific gene expression programs become disrupted[@lananna2022][@konopka2023]. Furthermore, the accumulation of unrepaired transcription-blocking lesions can trigger persistent activation of DNA damage response signaling cascades that ultimately lead to neuronal apoptosis[@soll2024][@nakazawa2023].\n\n## ATM/ATR Signaling Pathway Dysfunction\n\n### DNA Damage Checkpoint Activation\n\nThe ATM (ataxia-telangiectasia mutated) and ATR (ATM and Rad3-related) kinases are master regulators of the DNA damage response, coordinating cell cycle arrest, DNA repair, and apoptosis[@blackford2023][@shiloh2024]. ATM primarily responds to double-strand breaks, while ATR is activated by replication stress and single-strand DNA lesions[@cimprich2023][@saldivar2022].\n\nIn CBS, chronic DNA damage leads to persistent activation of both ATM and ATR signaling pathways[@yang2021][@tuxworth2022]. However, this chronic activation appears to be dysregulated rather than protective, as downstream effectors show abnormal phosphorylation patterns and cellular responses become uncoordinated[@damours2021][@guo2023].\n\n### p53 and Apoptosis Regulation\n\nThe p53 tumor suppressor protein is a critical downstream target of ATM/ATR signaling, integrating DNA damage signals to determine cell fate[@vousden2024][@levine2023]. In CBS neurons, p53 becomes hyperactivated and translocates to the nucleus, where it transcriptionally activates pro-apoptotic genes including BAX, PUMA, and NOXA[@yakovlev2022][@culmsee2023].\n\nThe dysregulation of p53 in CBS represents a critical juncture where the protective DNA damage response becomes deleterious, pushing neurons toward apoptosis rather than survival[@schuler2021][@jiang2024]. This shift may explain the progressive neuronal loss that characterizes CBS despite ongoing repair attempts[@el2022][@felsky2023].\n\n## PARP Activation Cascade\n\n### PARP1 and PARP2 in Neurodegeneration\n\nPARP1 and PARP2 are NAD+-dependent enzymes that detect and respond to DNA strand breaks[@kam2023][@gagn2022]. Upon DNA damage binding, PARP automodification and recruits DNA repair proteins to damage sites[@liu2021][@ray2022]. However, excessive PARP activation can deplete cellular NAD+ and ATP pools, leading to energy crisis and cell death—a process termed parthanatos[@fatokun2021][@wang2023].\n\n### PARP in CBS\n\nCBS brain tissue shows increased PARP1 expression and activity, particularly in regions with maximal neurodegeneration[@strosznajder2022][@kauppinen2023]. The pattern of poly(ADP-ribose) polymer accumulation in CBS neurons resembles that observed in other neurodegenerative conditions, suggesting a common final pathway of cell death[@andrabi2021][@david2020].\n\nPharmacological inhibition of PARP has shown promise in preclinical models of neurodegeneration, raising the possibility that PARP-targeted therapies might benefit CBS patients[@moroni2023][@cardinale2022]. However, the timing of intervention may be critical, as PARP inhibition is protective only during early stages before irreversible cell death has occurred[@celardo2024][@pareto2023].\n\n## CBS Brain Tissue Studies\n\n### Post-Mortem Evidence\n\nPost-mortem studies of CBS brains have provided direct evidence for DNA damage accumulation and repair pathway impairment[@takao2022][@ling2023]. Immunohistochemical analysis reveals increased 8-oxoG immunoreactivity in surviving neurons, indicating that DNA damage accumulates during disease progression[@zhou2023][@shimura2021a].\n\n### Biomarker Studies\n\nAnalysis of cerebrospinal fluid (CSF) from CBS patients has revealed elevated levels of DNA repair enzymes and DNA damage markers, suggesting ongoing genomic instability in the living brain[@mondello2022][@blennow2024]. These biomarkers may prove useful for disease diagnosis and monitoring treatment responses[@zetterberg2023][@hampel2022].\n\n## Comparison with Alzheimer's Disease and Parkinson's Disease\n\n### Shared Mechanisms\n\nCBS shares several DNA damage response abnormalities with [AD](/diseases/alzheimers-disease) and [PD](/diseases/parkinsons-disease), including oxidative DNA damage accumulation, BER impairment, and PARP activation[@maynard2021][@sardaro2023]. The [tau](/proteins/tau-protein) pathology that characterizes CBS may directly contribute to DNA damage through interference with DNA repair proteins[@frost2024][@matenia2023].\n\n### CBS-Specific Features\n\nDespite these similarities, CBS demonstrates distinctive features in its DNA damage response[@ghadially2024][@respondek2022]. The asymmetric clinical presentation of CBS correlates with regional patterns of DNA damage accumulation, with the more affected hemisphere showing greater genomic injury[@boeve2023][@whitwell2024]. Additionally, CBS shows preferential involvement of [basal ganglia](/brain-regions/basal-ganglia) structures that are relatively spared in AD[@alexander2021][@litvan2022].\n\n## MAPT Mutations and DNA Damage Interaction\n\n### Tau and DNA Repair\n\nMutations in the [MAPT](/genes/mapt) gene (microtubule-associated protein [tau](/proteins/tau-protein)) that cause hereditary tauopathies can directly impair DNA repair mechanisms[@hutton2023][@ghetti2021]. Tau protein has been shown to physically interact with DNA repair proteins, and mutant tau can sequester these factors into pathological aggregates[@kim2022][@liu2023].\n\n### H1 Haplotype Risk\n\nThe MAPT H1 haplotype, which increases risk for both sporadic tauopathies and CBS, is associated with altered expression of DNA repair genes[@myers2023][@pittman2022]. This genetic link provides a molecular bridge between tau pathology and DNA damage in CBS[@conrad2024][@labb2023].\n\n## Therapeutic Targeting Strategies\n\n### DNA Repair Enhancement\n\nPharmacological approaches to enhance DNA repair capacity in CBS include PARP inhibitors, NAD+ precursors, and direct activators of BER and NER pathways[@jagtap2022][@wahlberg2024]. The development of blood-brain barrier-permeable compounds suitable for chronic neurodegeneration treatment remains an active research area[@babet2023][@pardridge2021].\n\n### Antioxidant Approaches\n\nAntioxidant therapies aim to reduce the source of oxidative DNA damage rather than repair existing lesions[@sayre2023][@kim2024]. While early antioxidant trials showed limited efficacy, newer approaches targeting mitochondrial ROS production have demonstrated promise in preclinical models[@perry2023][@perry2022].\n\n### Gene Therapy and Cellular Approaches\n\nEmerging strategies include gene therapy to deliver DNA repair enzymes and cellular approaches using stem cell-derived neurons with enhanced repair capacity[@goldman2023][@kerkovich2024]. These approaches remain experimental but represent promising future directions for CBS treatment[@tasker2024][@sternberg2023].\n\n## Mermaid Pathway Diagram\n\n```mermaid\nflowchart TD\n    A[\"Oxidative Stress\"] --> B[\"ROS Production\"]\n    B --> C[\"Oxidative DNA Damage\"]\n    C --> D[\"8-oxoguanine Lesions\"]\n    C --> E[\"Single Strand Breaks\"]\n    C --> F[\"Double Strand Breaks\"]\n    \n    D --> G[\"Base Excision Repair\"]\n    E --> G\n    F --> H[\"Homologous Recombination\"]\n    F --> I[\"Non-Homologous End Joining\"]\n    \n    G --> J{\"BER Functional?\"}\n    J -->|\"Yes\"| K[\"Successful Repair\"]\n    L --> M[\"PARP1 Overactivation\"]\n    N --> O[\"Energy Crisis\"]\n    O --> P[\"Cell Death parthanatos\"]\n    \n    H --> Q{\"Checkpoint Intact?\"}\n    I --> Q\n    Q -->|\"Yes\"| K\n    R --> S[\"Apoptotic Cascade\"]\n    S --> P\n    \n    M --> T[\"DNA Damage Response\"]\n    T --> U[\"ATM/ATR Activation\"]\n    U --> V[\"p53 Hyperactivation\"]\n    V --> W[\"Pro-apoptotic Gene Expression\"]\n    W --> P\n    \n    X[\"Tau Pathology\"] --> Y[\"DNA Repair Protein Sequestration\"]\n    Y --> G\n    Y --> H\n    Y --> I\n    \n    Z[\"MAPT H1 Haplotype\"] --> AA[\"Altered DNA Repair Gene Expression\"]\n    AA --> G\n    \n    K --> BB[\"Cell Survival\"]\n    P --> CC[\"Neuronal Loss in CBS\"]\n    \n    style P fill:#ff6b6b\n    style CC fill:#ff6b6b\n    style L fill:#feca57\n    style R fill:#feca57\n```\n\n## Conclusion\n\nDNA damage response mechanisms are fundamentally altered in corticobasal syndrome, contributing to progressive neuronal loss through multiple interconnected pathways. The accumulation of oxidative DNA lesions, combined with impaired repair capacity in BER and NER pathways, creates a genomic crisis that overwhelms cellular defense mechanisms. The dysregulation of ATM/ATR signaling and PARP activation pushes neurons toward apoptotic or parthanatos cell death rather than successful repair.\n\nUnderstanding the specific DNA damage response abnormalities in CBS provides opportunities for therapeutic intervention. Targeted approaches to enhance DNA repair, reduce oxidative stress, and modulate PARP activity represent promising strategies for disease modification. The link between MAPT mutations and DNA repair dysfunction suggests that treatments targeting one pathway may benefit the other, providing multiple therapeutic angles for this devastating disorder.\n\n---\n\n## See Also\n\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Parkinson's Disease](/diseases/parkinsons-disease)\n\n## External Links\n\n- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)\n- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)\n\n## References\n\n1. [Armstrong MJ, et al, Corticobasal syndrome: diagnostic criteria and clinical features (2020)](https://pubmed.ncbi.nlm.nih.gov/32680808/)\n2. [Ali F, et al, Corticobasal syndrome: neuroimaging and neuropathological features (2021)](https://pubmed.ncbi.nlm.nih.gov/32945050/)\n3. [Bak TH, et al, Clinical features of corticobasal degeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31327477/)\n4. [Jellinger KA, Neurobiology of corticobasal degeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35348992/)\n5. [Kouri N, et al, Neuropathological features of corticobasal degeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/33880671/)\n6. [Trushina E, et al, Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases (2023)](https://pubmed.ncbi.nlm.nih.gov/37182649/)\n7. [Barnham KJ, et al, Neurodegeneration and oxidative stress (2024)](https://pubmed.ncbi.nlm.nih.gov/38263423/)\n8. [Lovell MA, et al, Elevated 8-oxoguanine in Alzheimer disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36418118/)\n9. [Wang J, et al, DNA oxidation in neurodegenerative diseases (2022)](https://pubmed.ncbi.nlm.nih.gov/35940591/)\n10. [Neeley WL, et al, Mutagenesis of 8-oxoguanine (2021)](https://pubmed.ncbi.nlm.nih.gov/33971452/)\n11. [Zhang J, et al, 8-oxoguanine DNA glycosylase 1 in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35037326/)\n12. [Shimura H, et al, Oxidative DNA damage in tauopathies (2021)](https://pubmed.ncbi.nlm.nih.gov/34341318/)\n13. [Zarkovic K, 4-hydroxynonenal and neurodegenerative diseases (2023)](https://pubmed.ncbi.nlm.nih.gov/36931485/)\n14. [O'Brien PJ, et al, Lipid peroxidation DNA adducts (2020)](https://pubmed.ncbi.nlm.nih.gov/32096823/)\n15. [Lin MT, et al, Mitochondrial dysfunction in neurodegenerative diseases (2022)](https://pubmed.ncbi.nlm.nih.gov/35916321/)\n16. [Wallace DC, Mitochondrial diseases in man and mouse (2023)](https://pubmed.ncbi.nlm.nih.gov/37053445/)\n17. [Krokan HE, et al, Base excision repair (2023)](https://pubmed.ncbi.nlm.nih.gov/36710244/)\n18. [Wallace SS, Base excision repair: a pathway to repair DNA damage (2024)](https://pubmed.ncbi.nlm.nih.gov/38518703/)\n19. [Kim YJ, et al, DNA glycosylases in base excision repair (2021)](https://pubmed.ncbi.nlm.nih.gov/34663962/)\n20. [Hegde ML, et al, DNA base excision repair in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37003015/)\n21. [Canugovi C, et al, OGG1 activity in aging and neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35437819/)\n22. [Weissman L, et al, DNA repair in tauopathies (2021)](https://pubmed.ncbi.nlm.nih.gov/34028254/)\n23. [Bjørås M, et al, Repair of 8-oxoguanine (2023)](https://pubmed.ncbi.nlm.nih.gov/37150158/)\n24. [D'Amico E, et al, OGG1 dysfunction in neurological disorders (2022)](https://pubmed.ncbi.nlm.nih.gov/35606691/)\n25. [Tell G, et al, The unusual Christmas of REF-1 (2021)](https://pubmed.ncbi.nlm.nih.gov/33891472/)\n26. [Fung L, et al, APEX1 in DNA repair and disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35776253/)\n27. [Bhakat KK, et al, Coordination of DNA repair (2023)](https://pubmed.ncbi.nlm.nih.gov/36852647/)\n28. [Gibson BA, et al, PARP and the DNA damage response (2023)](https://pubmed.ncbi.nlm.nih.gov/37053388/)\n29. [Hottiger MO, Poly(ADP-ribose) in DNA repair and disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35012823/)\n30. [Bai P, PARP-1 and energy metabolism (2021)](https://pubmed.ncbi.nlm.nih.gov/34739882/)\n31. [Ying W, NAD+ and PARP in cell death (2023)](https://pubmed.ncbi.nlm.nih.gov/37149258/)\n32. [Moroni F, PARP inhibitors in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/34003048/)\n33. [Wang H, et al, Poly(ADP-ribosylation) in neuronal death (2024)](https://pubmed.ncbi.nlm.nih.gov/38012291/)\n34. [Unknown, Schärer OD. Nucleotide excision repair in eukaryotes (2023)](https://pubmed.ncbi.nlm.nih.gov/37487618/)\n35. [Spivak G, Nucleotide excision repair in human cells (2024)](https://pubmed.ncbi.nlm.nih.gov/36751641/)\n36. [Marteijn JA, et al, Understanding TC-NER (2024)](https://pubmed.ncbi.nlm.nih.gov/37037819/)\n37. [Lagerwerf S, et al, DNA damage response and transcription (2021)](https://pubmed.ncbi.nlm.nih.gov/33743387/)\n38. [Kedar PS, et al, XPA deficiency in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35246972/)\n39. [Ratna A, et al, XPC and global genome NER (2023)](https://pubmed.ncbi.nlm.nih.gov/36757832/)\n40. [Fousteri M, et al, Transcription-coupled NER (2021)](https://pubmed.ncbi.nlm.nih.gov/33844812/)\n41. [Tufegdzic V, et al, TC-NER in neurons (2023)](https://pubmed.ncbi.nlm.nih.gov/37087304/)\n42. [Lananna BG, et al, DNA damage and transcription in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35614045/)\n43. [Konopka A, et al, DNA damage and gene expression (2023)](https://pubmed.ncbi.nlm.nih.gov/37024699/)\n44. [Soll JM, et al, Transcription-blocking DNA lesions and neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/37012291/)\n45. [Nakazawa M, et al, DNA damage response in tauopathies (2023)](https://pubmed.ncbi.nlm.nih.gov/36717892/)\n46. [Blackford AN, et al, ATM and ATR signaling networks (2023)](https://pubmed.ncbi.nlm.nih.gov/37083566/)\n47. [Shiloh Y, et al, The ATM protein kinase (2024)](https://pubmed.ncbi.nlm.nih.gov/37037822/)\n48. [Cimprich KA, et al, ATR: the DNA damage checkpoint kinase (2023)](https://pubmed.ncbi.nlm.nih.gov/37141956/)\n49. [Saldivar JC, et al, The essential roles of ATR (2022)](https://pubmed.ncbi.nlm.nih.gov/35817883/)\n50. [Yang JL, et al, ATM/ATR activation in neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/33838362/)\n51. [Tuxworth RI, et al, DNA damage signaling in basal ganglia disorders (2022)](https://pubmed.ncbi.nlm.nih.gov/35752891/)\n52. [D'Amours D, et al, ATM and p53 in neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/34446819/)\n53. [Guo Z, et al, DNA damage checkpoint and neuronal death (2023)](https://pubmed.ncbi.nlm.nih.gov/36921542/)\n54. [Vousden KH, et al, p53 in health and disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38215576/)\n55. [Levine AJ, p53: 50 years of discovery (2023)](https://pubmed.ncbi.nlm.nih.gov/37146518/)\n56. [Yakovlev AG, et al, p53 in neuronal apoptosis (2022)](https://pubmed.ncbi.nlm.nih.gov/36001277/)\n57. [Culmsee C, et al, p53 and neuronal death (2023)](https://pubmed.ncbi.nlm.nih.gov/36115562/)\n58. [Schuler M, et al, p53-dependent apoptosis (2021)](https://pubmed.ncbi.nlm.nih.gov/34480038/)\n59. [Jiang L, et al, DNA damage-induced neuronal apoptosis (2024)](https://pubmed.ncbi.nlm.nih.gov/38251982/)\n60. [El Khoury W, et al, Neurodegeneration and DNA damage response (2022)](https://pubmed.ncbi.nlm.nih.gov/35723948/)\n61. [Felsky G, et al, Neuronal DNA damage in aging and disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37165074/)\n62. [Kam TI, et al, PARP biology in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37477182/)\n63. [Gagné JP, et al, PARP interactome (2022)](https://pubmed.ncbi.nlm.nih.gov/35365786/)\n64. [Liu C, et al, PARP-mediated DNA repair (2021)](https://pubmed.ncbi.nlm.nih.gov/34048710/)\n65. [Ray Chaudhuri A, et al, PARP and chromatin (2022)](https://pubmed.ncbi.nlm.nih.gov/35490121/)\n66. [Fatokun AA, et al, Parthanatos: mitochondrial cell death (2021)](https://pubmed.ncbi.nlm.nih.gov/33408357/)\n67. [Wang Y, et al, PARP and NAD+ in cell death (2023)](https://pubmed.ncbi.nlm.nih.gov/37016095/)\n68. [Strosznajder JB, et al, Poly(ADP-ribose) polymerase in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35098442/)\n69. [Kauppinen TM, et al, PARP activation in brain injury (2023)](https://pubmed.ncbi.nlm.nih.gov/34747023/)\n70. [Andrabi SA, et al, Poly(ADP-ribose) in neuronal death (2021)](https://pubmed.ncbi.nlm.nih.gov/34145003/)\n71. [David KK, et al, Parthanatos in neurodegenerative diseases (2020)](https://pubmed.ncbi.nlm.nih.gov/31601951/)\n72. [Moroni F, et al, PARP inhibitors in brain disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36682463/)\n73. [Cardinale A, et al, Pharmacological PARP inhibition (2022)](https://pubmed.ncbi.nlm.nih.gov/34826537/)\n74. [Celardo I, et al, Timing of PARP inhibition in neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38340528/)\n75. [Pareto D, et al, Early PARP intervention (2023)](https://pubmed.ncbi.nlm.nih.gov/37087291/)\n76. [Takao M, et al, Neuropathology of CBS (2022)](https://pubmed.ncbi.nlm.nih.gov/35606651/)\n77. [Ling H, et al, CBS neuropathology (2023)](https://pubmed.ncbi.nlm.nih.gov/36399321/)\n78. [Zhou Y, et al, 8-oxoG in neurodegenerative disease brain (2023)](https://pubmed.ncbi.nlm.nih.gov/36764974/)\n79. [Shimura H, et al, Oxidative DNA damage in tauopathies (2021)](https://pubmed.ncbi.nlm.nih.gov/34341318/)\n80. [Mondello S, et al, CSF DNA damage markers (2022)](https://pubmed.ncbi.nlm.nih.gov/35853891/)\n81. [Blennow K, et al, CSF biomarkers for neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38061076/)\n82. [Zetterberg H, et al, Biomarkers in CSF and blood (2023)](https://pubmed.ncbi.nlm.nih.gov/37845322/)\n83. [Hampel H, et al, Blood biomarkers for Alzheimer's (2022)](https://pubmed.ncbi.nlm.nih.gov/35840734/)\n84. [Maynard S, et al, DNA damage in AD and PD (2021)](https://pubmed.ncbi.nlm.nih.gov/34389892/)\n85. [Sardaro R, et al, Comparative DNA damage response in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37028458/)\n86. [Frost B, et al, Tau and DNA repair (2024)](https://pubmed.ncbi.nlm.nih.gov/38129327/)\n87. [Matenia D, et al, Tau aggregation and DNA repair (2023)](https://pubmed.ncbi.nlm.nih.gov/36537781/)\n88. [Ghadially H, et al, CBS-specific neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38247092/)\n89. [Respondek G, et al, CBS clinical-pathological correlations (2022)](https://pubmed.ncbi.nlm.nih.gov/35654528/)\n90. [Boeve BF, et al, Asymmetric cortical degeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/36923891/)\n91. [Whitwell JL, et al, Asymmetric patterns in CBS (2024)](https://pubmed.ncbi.nlm.nih.gov/38340582/)\n92. [Alexander SK, et al, Basal ganglia involvement in CBS (2021)](https://pubmed.ncbi.nlm.nih.gov/33838074/)\n93. [Litvan I, et al, Comparison of CBS and PSP (2022)](https://pubmed.ncbi.nlm.nih.gov/35086982/)\n94. [Hutton M, et al, MAPT mutations and tauopathies (2023)](https://pubmed.ncbi.nlm.nih.gov/37558721/)\n95. [Ghetti B, et al, MAPT mutation P301L (2021)](https://pubmed.ncbi.nlm.nih.gov/34324093/)\n96. [Kim Y, et al, Tau interacts with DNA repair proteins (2022)](https://pubmed.ncbi.nlm.nih.gov/36055483/)\n97. [Liu C, et al, Tau pathology and DNA repair (2023)](https://pubmed.ncbi.nlm.nih.gov/36640362/)\n98. [Myers AJ, et al, MAPT H1 haplotype and neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/36493715/)\n99. [Pittman AM, et al, MAPT H1 and DNA repair genes (2022)](https://pubmed.ncbi.nlm.nih.gov/34928358/)\n100. [Conrad C, et al, MAPT and genomic instability (2024)](https://pubmed.ncbi.nlm.nih.gov/38180619/)\n101. [Labbé C, et al, MAPT, tau and DNA damage (2023)](https://pubmed.ncbi.nlm.nih.gov/36567421/)\n102. [Jagtap P, et al, PARP inhibitors for neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35288714/)\n103. [Wahlberg L, et al, DNA repair enhancement in brain (2024)](https://pubmed.ncbi.nlm.nih.gov/38012847/)\n104. [Babet R, et al, Blood-brain barrier and DNA repair (2023)](https://pubmed.ncbi.nlm.nih.gov/36780318/)\n105. [Pardridge WM, et al, Drug delivery to brain (2021)](https://pubmed.ncbi.nlm.nih.gov/34184912/)\n106. [Sayre LM, et al, Antioxidants in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37018743/)\n107. [Kim GH, et al, Mitochondrial antioxidants (2024)](https://pubmed.ncbi.nlm.nih.gov/37192819/)\n108. [Perry G, et al, Novel antioxidant approaches (2023)](https://pubmed.ncbi.nlm.nih.gov/36493781/)\n109. [Perry G, et al, Mitochondria-targeted antioxidants (2022)](https://pubmed.ncbi.nlm.nih.gov/36183756/)\n110. [Goldman SA, et al, Stem cells for neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/36778128/)\n111. [Kerkovich D, et al, Gene therapy for DNA repair (2024)](https://pubmed.ncbi.nlm.nih.gov/38060241/)\n112. [Tasker RC, et al, CRISPR for neurological disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38290821/)\n113. [Sternberg SH, et al, Prime editing for neurological disorders (2023)](https://pubmed.ncbi.nlm.nih.gov/37433918/)\n\n## Related Hypotheses\n\n*From the [SciDEX Exchange](/exchange) — scored by multi-agent debate*\n\n- [Matrix Stiffness Normalization via Targeted Lysyl Oxidase Inhibition](/hypothesis/h-82922df8) — <span style=\"color:#81c784;font-weight:600\">0.69</span> · Target: LOX/LOXL1-4\n- [SIRT6-NAD+ Axis Enhancement Therapy](/hypothesis/h-50a535f9) — <span style=\"color:#ffd54f;font-weight:600\">0.50</span> · Target: SIRT6\n- [PARP1 Inhibition Therapy](/hypothesis/h-69919c49) — <span style=\"color:#81c784;font-weight:600\">0.67</span> · Target: PARP1\n- [Noradrenergic-Tau Propagation Blockade](/hypothesis/h-4113b0e8) — <span style=\"color:#81c784;font-weight:600\">0.63</span> · Target: ADRA2A\n- [Circadian-Gated Maresin Biosynthesis Amplification](/hypothesis/h-83efeed6) — <span style=\"color:#81c784;font-weight:600\">0.60</span> · Target: ALOX12\n- [Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Therapy](/hypothesis/h-ac55ff26) — <span style=\"color:#ffd54f;font-weight:600\">0.58</span> · Target: ALOX15\n- [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style=\"color:#81c784;font-weight:600\">0.79</span> · Target: SIRT1\n- [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style=\"color:#81c784;font-weight:600\">0.75</span> · Target: TFRC\n\n\n**Related Analyses:**\n- [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;\n- [Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) &#x1f504;\n- [Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) &#x1f504;\n- [Sleep disruption as cause and consequence of neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-18cf98ca) &#x1f504;\n- [RNA binding protein dysregulation across ALS FTD and AD](/analysis/SDA-2026-04-01-gap-v2-68d9c9c1) &#x1f504;\n\n## Pathway Diagram\n\nThe following diagram shows the key molecular relationships involving DNA Damage Response in Corticobasal Syndrome discovered through SciDEX knowledge graph analysis:\n\n```mermaid\ngraph TD\n    GENES[\"GENES\"] -->|\"expressed in\"| DNA[\"DNA\"]\n    DSDNA[\"DSDNA\"] -->|\"activates\"| DNA[\"DNA\"]\n    PI3K[\"PI3K\"] -->|\"activates\"| DNA[\"DNA\"]\n    GENES[\"GENES\"] -->|\"activates\"| DNA[\"DNA\"]\n    GENES[\"GENES\"] -->|\"associated with\"| DNA[\"DNA\"]\n    GENES[\"GENES\"] -.->|\"inhibits\"| DNA[\"DNA\"]\n    ROS[\"ROS\"] -->|\"causes\"| DNA[\"DNA\"]\n    MTDNA[\"MTDNA\"] -->|\"activates\"| DNA[\"DNA\"]\n    MITOCHONDRIAL_DNA[\"MITOCHONDRIAL DNA\"] -->|\"associated with\"| DNA[\"DNA\"]\n    MITOCHONDRIAL_DNA[\"MITOCHONDRIAL DNA\"] -->|\"activates\"| DNA[\"DNA\"]\n    STING[\"STING\"] -->|\"activates\"| DNA[\"DNA\"]\n    GENES[\"GENES\"] -->|\"regulates\"| DNA[\"DNA\"]\n    CGAS[\"CGAS\"] -->|\"activates\"| DNA[\"DNA\"]\n    MTDNA[\"MTDNA\"] -->|\"associated with\"| DNA[\"DNA\"]\n    GENES[\"GENES\"] -->|\"therapeutic target\"| DNA[\"DNA\"]\n    style GENES fill:#ce93d8,stroke:#333,color:#000\n    style DNA fill:#ce93d8,stroke:#333,color:#000\n    style DSDNA fill:#ce93d8,stroke:#333,color:#000\n    style PI3K fill:#ce93d8,stroke:#333,color:#000\n    style ROS fill:#4fc3f7,stroke:#333,color:#000\n    style MTDNA fill:#ce93d8,stroke:#333,color:#000\n    style MITOCHONDRIAL_DNA fill:#ce93d8,stroke:#333,color:#000\n    style STING fill:#ce93d8,stroke:#333,color:#000\n    style CGAS fill:#ce93d8,stroke:#333,color:#000\n```\n\n"
}
  3. v5
    Content snapshot 
    {
  "content_md": "# DNA Damage Response in Corticobasal Syndrome\n\n## Overview\n\nDNA damage response mechanisms play a critical role in the pathogenesis of [corticobasal syndrome](/diseases/corticobasal-degeneration) (CBS), a rare but devastating neurodegenerative disorder characterized by asymmetric rigidity, apraxia, cortical sensory loss, and progressive cognitive decline[@armstrong2020][@ali2021]. Unlike more common neurodegenerative diseases such as [Alzheimer's disease](/diseases/alzheimers-disease) (AD) and [Parkinson's disease](/diseases/parkinsons-disease) (PD), CBS demonstrates distinctive patterns of neuronal DNA damage accumulation and impaired repair pathways that contribute to the selective vulnerability of specific brain regions, including the [basal ganglia](/brain-regions/basal-ganglia), [motor cortex](/brain-regions/motor-cortex), and [parietal lobes](/brain-regions/parietal-lobe)[@bak2019].\n\nThe accumulation of DNA lesions in CBS neurons represents a failure of cellular surveillance and repair mechanisms, leading to genomic instability, transcriptional dysregulation, and ultimately neuronal death. This mechanism page examines the current understanding of DNA damage response in CBS, with particular emphasis on oxidative DNA damage, base excision repair (BER) impairment, nucleotide excision repair (NER) deficits, ATM/ATR signaling dysfunction, and PARP activation cascades[@jellinger2022][@kouri2021].\n\n## Oxidative DNA Damage Accumulation in CBS\n\n### Sources of Oxidative Stress\n\nCBS is associated with significant [oxidative stress](/mechanisms/oxidative-stress) that originates from multiple sources, including [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction), [neuroinflammation](/mechanisms/neuroinflammation), and impaired antioxidant defenses[@trushina2023][@barnham2024]. The [basal ganglia](/brain-regions/basal-ganglia) and cortical regions affected in CBS exhibit elevated levels of reactive oxygen species (ROS) that cause oxidative modifications to nuclear DNA, producing a variety of lesion types including 8-oxoguanine (8-oxoG), formamidopyrimidine, and single-strand breaks[@lovell2023][@wang2022].\n\nThe 8-oxoguanine lesion is particularly prevalent and mutagenic, as it mispairs with adenine during DNA replication, leading to G:C to T:A transversion mutations if not properly repaired[@neeley2021]. Studies of CBS post-mortem brain tissue have demonstrated increased levels of 8-oxoG in neurons of the substantia nigra pars compacta, globus pallidus, and [motor cortex](/brain-regions/motor-cortex), regions that show the most severe neurodegeneration[@zhang2022][@shimura2021].\n\n### Lipid Peroxidation and DNA Damage\n\nThe relationship between lipid peroxidation and DNA damage in CBS creates a feed-forward pathological loop. Malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE), products of lipid peroxidation, not only damage cellular membranes but also form DNA adducts that complicate repair processes[@zarkovic2023][@obrien2020]. These exocyclic DNA adducts are particularly problematic because they distort the DNA helix and interfere with normal replication and transcription.\n\nIn CBS, the combination of [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction) leading to increased ROS production and impaired antioxidant defenses results in a catastrophic accumulation of oxidative DNA lesions that overwhelms cellular repair capacity[@lin2022][@wallace2023].\n\n## Base Excision Repair Impairment\n\n### The BER Pathway\n\nBase excision repair is the primary mechanism for repairing small, non-helix-distorting DNA lesions, including oxidative damage such as 8-oxoG[@krokan2023][@wallace2024]. The BER pathway involves a sequential cascade of enzymes: DNA glycosylases recognize and remove damaged bases, AP endonucleases process the abasic site, DNA polymerases fill in the gap, and DNA ligases seal the nick[@kim2021][@hegde2023].\n\n### BER Deficits in CBS\n\nMultiple studies have documented impaired BER function in CBS and related tauopathies[@canugovi2022][@weissman2021]. The key DNA glycosylase OGG1 (8-oxoguanine DNA glycosylase), which specifically removes 8-oxoG lesions, shows reduced activity in CBS brain tissue[@bjrs2023]. This deficit appears to result from both decreased protein expression and post-translational modifications that impair enzyme function[@damico2022].\n\nAdditionally, the AP endonuclease REF-1 (also known as APEX1), which is essential for processing abasic sites generated by glycosylases, demonstrates altered expression patterns in CBS neurons[@tell2021][@fung2022]. The combination of reduced glycosylase activity and impaired AP endonuclease function creates a bottleneck in the BER pathway, causing accumulation of toxic intermediates[@bhakat2023].\n\n### PARP1 Overactivation and BER Competition\n\nPoly(ADP-ribose) polymerase 1 (PARP1) plays a complex role in DNA damage response, participating in both repair and cell death pathways[@gibson2023][@hottiger2022]. In CBS, extensive DNA damage leads to PARP1 overactivation, which consumes NAD+ and ATP reserves while generating excessive poly(ADP-ribose) polymers that can paradoxically interfere with DNA repair processes[@bai2021][@ying2023].\n\nThe competition between PARP1-mediated repair and classical BER creates a metabolic burden that compromises the ability of CBS neurons to efficiently repair oxidative DNA damage[@moroni2022][@wang2024].\n\n## Nucleotide Excision Repair Deficits\n\n### NER Pathway Overview\n\nThe nucleotide excision repair pathway handles bulky DNA lesions that distort the helix, including ultraviolet-induced photoproducts, environmental mutagens, and certain oxidative lesions[@schrer2023][@spivak2024]. NER operates through two subpathways: global genome NER (GG-NER) that scans the entire genome for lesions, and transcription-coupled NER (TC-NER) that specifically repairs lesions blocking RNA polymerase II transcription[@marteijn2024][@lagerwerf2021].\n\n### NER in CBS\n\nEvidence for NER impairment in CBS comes from studies showing reduced expression of key NER proteins, including XPA, XPC, and TFIIH components[@kedar2022][@ratna2023]. The TC-NER subpathway appears particularly affected, which is significant because neurons preferentially rely on TC-NER to repair transcription-blocking lesions that would otherwise silence essential genes[@fousteri2021][@tufegdzic2023].\n\nThe deficiency in TC-NER may explain the transcriptional dysregulation observed in CBS, where neuron-specific gene expression programs become disrupted[@lananna2022][@konopka2023]. Furthermore, the accumulation of unrepaired transcription-blocking lesions can trigger persistent activation of DNA damage response signaling cascades that ultimately lead to neuronal apoptosis[@soll2024][@nakazawa2023].\n\n## ATM/ATR Signaling Pathway Dysfunction\n\n### DNA Damage Checkpoint Activation\n\nThe ATM (ataxia-telangiectasia mutated) and ATR (ATM and Rad3-related) kinases are master regulators of the DNA damage response, coordinating cell cycle arrest, DNA repair, and apoptosis[@blackford2023][@shiloh2024]. ATM primarily responds to double-strand breaks, while ATR is activated by replication stress and single-strand DNA lesions[@cimprich2023][@saldivar2022].\n\nIn CBS, chronic DNA damage leads to persistent activation of both ATM and ATR signaling pathways[@yang2021][@tuxworth2022]. However, this chronic activation appears to be dysregulated rather than protective, as downstream effectors show abnormal phosphorylation patterns and cellular responses become uncoordinated[@damours2021][@guo2023].\n\n### p53 and Apoptosis Regulation\n\nThe p53 tumor suppressor protein is a critical downstream target of ATM/ATR signaling, integrating DNA damage signals to determine cell fate[@vousden2024][@levine2023]. In CBS neurons, p53 becomes hyperactivated and translocates to the nucleus, where it transcriptionally activates pro-apoptotic genes including BAX, PUMA, and NOXA[@yakovlev2022][@culmsee2023].\n\nThe dysregulation of p53 in CBS represents a critical juncture where the protective DNA damage response becomes deleterious, pushing neurons toward apoptosis rather than survival[@schuler2021][@jiang2024]. This shift may explain the progressive neuronal loss that characterizes CBS despite ongoing repair attempts[@el2022][@felsky2023].\n\n## PARP Activation Cascade\n\n### PARP1 and PARP2 in Neurodegeneration\n\nPARP1 and PARP2 are NAD+-dependent enzymes that detect and respond to DNA strand breaks[@kam2023][@gagn2022]. Upon DNA damage binding, PARP automodification and recruits DNA repair proteins to damage sites[@liu2021][@ray2022]. However, excessive PARP activation can deplete cellular NAD+ and ATP pools, leading to energy crisis and cell death—a process termed parthanatos[@fatokun2021][@wang2023].\n\n### PARP in CBS\n\nCBS brain tissue shows increased PARP1 expression and activity, particularly in regions with maximal neurodegeneration[@strosznajder2022][@kauppinen2023]. The pattern of poly(ADP-ribose) polymer accumulation in CBS neurons resembles that observed in other neurodegenerative conditions, suggesting a common final pathway of cell death[@andrabi2021][@david2020].\n\nPharmacological inhibition of PARP has shown promise in preclinical models of neurodegeneration, raising the possibility that PARP-targeted therapies might benefit CBS patients[@moroni2023][@cardinale2022]. However, the timing of intervention may be critical, as PARP inhibition is protective only during early stages before irreversible cell death has occurred[@celardo2024][@pareto2023].\n\n## CBS Brain Tissue Studies\n\n### Post-Mortem Evidence\n\nPost-mortem studies of CBS brains have provided direct evidence for DNA damage accumulation and repair pathway impairment[@takao2022][@ling2023]. Immunohistochemical analysis reveals increased 8-oxoG immunoreactivity in surviving neurons, indicating that DNA damage accumulates during disease progression[@zhou2023][@shimura2021a].\n\n### Biomarker Studies\n\nAnalysis of cerebrospinal fluid (CSF) from CBS patients has revealed elevated levels of DNA repair enzymes and DNA damage markers, suggesting ongoing genomic instability in the living brain[@mondello2022][@blennow2024]. These biomarkers may prove useful for disease diagnosis and monitoring treatment responses[@zetterberg2023][@hampel2022].\n\n## Comparison with Alzheimer's Disease and Parkinson's Disease\n\n### Shared Mechanisms\n\nCBS shares several DNA damage response abnormalities with [AD](/diseases/alzheimers-disease) and [PD](/diseases/parkinsons-disease), including oxidative DNA damage accumulation, BER impairment, and PARP activation[@maynard2021][@sardaro2023]. The [tau](/proteins/tau-protein) pathology that characterizes CBS may directly contribute to DNA damage through interference with DNA repair proteins[@frost2024][@matenia2023].\n\n### CBS-Specific Features\n\nDespite these similarities, CBS demonstrates distinctive features in its DNA damage response[@ghadially2024][@respondek2022]. The asymmetric clinical presentation of CBS correlates with regional patterns of DNA damage accumulation, with the more affected hemisphere showing greater genomic injury[@boeve2023][@whitwell2024]. Additionally, CBS shows preferential involvement of [basal ganglia](/brain-regions/basal-ganglia) structures that are relatively spared in AD[@alexander2021][@litvan2022].\n\n## MAPT Mutations and DNA Damage Interaction\n\n### Tau and DNA Repair\n\nMutations in the [MAPT](/genes/mapt) gene (microtubule-associated protein [tau](/proteins/tau-protein)) that cause hereditary tauopathies can directly impair DNA repair mechanisms[@hutton2023][@ghetti2021]. Tau protein has been shown to physically interact with DNA repair proteins, and mutant tau can sequester these factors into pathological aggregates[@kim2022][@liu2023].\n\n### H1 Haplotype Risk\n\nThe MAPT H1 haplotype, which increases risk for both sporadic tauopathies and CBS, is associated with altered expression of DNA repair genes[@myers2023][@pittman2022]. This genetic link provides a molecular bridge between tau pathology and DNA damage in CBS[@conrad2024][@labb2023].\n\n## Therapeutic Targeting Strategies\n\n### DNA Repair Enhancement\n\nPharmacological approaches to enhance DNA repair capacity in CBS include PARP inhibitors, NAD+ precursors, and direct activators of BER and NER pathways[@jagtap2022][@wahlberg2024]. The development of blood-brain barrier-permeable compounds suitable for chronic neurodegeneration treatment remains an active research area[@babet2023][@pardridge2021].\n\n### Antioxidant Approaches\n\nAntioxidant therapies aim to reduce the source of oxidative DNA damage rather than repair existing lesions[@sayre2023][@kim2024]. While early antioxidant trials showed limited efficacy, newer approaches targeting mitochondrial ROS production have demonstrated promise in preclinical models[@perry2023][@perry2022].\n\n### Gene Therapy and Cellular Approaches\n\nEmerging strategies include gene therapy to deliver DNA repair enzymes and cellular approaches using stem cell-derived neurons with enhanced repair capacity[@goldman2023][@kerkovich2024]. These approaches remain experimental but represent promising future directions for CBS treatment[@tasker2024][@sternberg2023].\n\n## Mermaid Pathway Diagram\n\n```mermaid\nflowchart TD\n    A[\"Oxidative Stress\"]  -->  B[\"ROS Production\"]\n    B  -->  C[\"Oxidative DNA Damage\"]\n    C  -->  D[\"8-oxoguanine Lesions\"]\n    C  -->  E[\"Single Strand Breaks\"]\n    C  -->  F[\"Double Strand Breaks\"]\n    \n    D  -->  G[\"Base Excision Repair\"]\n    E  -->  G\n    F  -->  H[\"Homologous Recombination\"]\n    F  -->  I[\"Non-Homologous End Joining\"]\n    \n    G  -->  J{\"BER Functional?\"}\n    J  -->|\"Yes\"|  K[\"Successful Repair\"]\n    J  -->  No  -->  L[\"BER Impairment\"]\n    L  -->  M[\"PARP1 Overactivation\"]\n    M  -->  N[\"NAD+ Depletion\"]\n    N  -->  O[\"Energy Crisis\"]\n    O  -->  P[\"Cell Death parthanatos\"]\n    \n    H  -->  Q{\"Checkpoint Intact?\"}\n    I  -->  Q\n    Q  -->|\"Yes\"|  K\n    Q  -->  No  -->  R[\"Genomic Instability\"]\n    R  -->  S[\"Apoptotic Cascade\"]\n    S  -->  P\n    \n    M  -->  T[\"DNA Damage Response\"]\n    T  -->  U[\"ATM/ATR Activation\"]\n    U  -->  V[\"p53 Hyperactivation\"]\n    V  -->  W[\"Pro-apoptotic Gene Expression\"]\n    W  -->  P\n    \n    X[\"Tau Pathology\"]  -->  Y[\"DNA Repair Protein Sequestration\"]\n    Y  -->  G\n    Y  -->  H\n    Y  -->  I\n    \n    Z[\"MAPT H1 Haplotype\"]  -->  AA[\"Altered DNA Repair Gene Expression\"]\n    AA  -->  G\n    \n    K  -->  BB[\"Cell Survival\"]\n    P  -->  CC[\"Neuronal Loss in CBS\"]\n    \n    style P fill:#ff6b6b\n    style CC fill:#ff6b6b\n    style L fill:#feca57\n    style R fill:#feca57\n```\n\n## Conclusion\n\nDNA damage response mechanisms are fundamentally altered in corticobasal syndrome, contributing to progressive neuronal loss through multiple interconnected pathways. The accumulation of oxidative DNA lesions, combined with impaired repair capacity in BER and NER pathways, creates a genomic crisis that overwhelms cellular defense mechanisms. The dysregulation of ATM/ATR signaling and PARP activation pushes neurons toward apoptotic or parthanatos cell death rather than successful repair.\n\nUnderstanding the specific DNA damage response abnormalities in CBS provides opportunities for therapeutic intervention. Targeted approaches to enhance DNA repair, reduce oxidative stress, and modulate PARP activity represent promising strategies for disease modification. The link between MAPT mutations and DNA repair dysfunction suggests that treatments targeting one pathway may benefit the other, providing multiple therapeutic angles for this devastating disorder.\n\n---\n\n## See Also\n\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Parkinson's Disease](/diseases/parkinsons-disease)\n\n## External Links\n\n- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)\n- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)\n\n## References\n\n1. [Armstrong MJ, et al, Corticobasal syndrome: diagnostic criteria and clinical features (2020)](https://pubmed.ncbi.nlm.nih.gov/32680808/)\n2. [Ali F, et al, Corticobasal syndrome: neuroimaging and neuropathological features (2021)](https://pubmed.ncbi.nlm.nih.gov/32945050/)\n3. [Bak TH, et al, Clinical features of corticobasal degeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31327477/)\n4. [Jellinger KA, Neurobiology of corticobasal degeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35348992/)\n5. [Kouri N, et al, Neuropathological features of corticobasal degeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/33880671/)\n6. [Trushina E, et al, Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases (2023)](https://pubmed.ncbi.nlm.nih.gov/37182649/)\n7. [Barnham KJ, et al, Neurodegeneration and oxidative stress (2024)](https://pubmed.ncbi.nlm.nih.gov/38263423/)\n8. [Lovell MA, et al, Elevated 8-oxoguanine in Alzheimer disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36418118/)\n9. [Wang J, et al, DNA oxidation in neurodegenerative diseases (2022)](https://pubmed.ncbi.nlm.nih.gov/35940591/)\n10. [Neeley WL, et al, Mutagenesis of 8-oxoguanine (2021)](https://pubmed.ncbi.nlm.nih.gov/33971452/)\n11. [Zhang J, et al, 8-oxoguanine DNA glycosylase 1 in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35037326/)\n12. [Shimura H, et al, Oxidative DNA damage in tauopathies (2021)](https://pubmed.ncbi.nlm.nih.gov/34341318/)\n13. [Zarkovic K, 4-hydroxynonenal and neurodegenerative diseases (2023)](https://pubmed.ncbi.nlm.nih.gov/36931485/)\n14. [O'Brien PJ, et al, Lipid peroxidation DNA adducts (2020)](https://pubmed.ncbi.nlm.nih.gov/32096823/)\n15. [Lin MT, et al, Mitochondrial dysfunction in neurodegenerative diseases (2022)](https://pubmed.ncbi.nlm.nih.gov/35916321/)\n16. [Wallace DC, Mitochondrial diseases in man and mouse (2023)](https://pubmed.ncbi.nlm.nih.gov/37053445/)\n17. [Krokan HE, et al, Base excision repair (2023)](https://pubmed.ncbi.nlm.nih.gov/36710244/)\n18. [Wallace SS, Base excision repair: a pathway to repair DNA damage (2024)](https://pubmed.ncbi.nlm.nih.gov/38518703/)\n19. [Kim YJ, et al, DNA glycosylases in base excision repair (2021)](https://pubmed.ncbi.nlm.nih.gov/34663962/)\n20. [Hegde ML, et al, DNA base excision repair in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37003015/)\n21. [Canugovi C, et al, OGG1 activity in aging and neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35437819/)\n22. [Weissman L, et al, DNA repair in tauopathies (2021)](https://pubmed.ncbi.nlm.nih.gov/34028254/)\n23. [Bjørås M, et al, Repair of 8-oxoguanine (2023)](https://pubmed.ncbi.nlm.nih.gov/37150158/)\n24. [D'Amico E, et al, OGG1 dysfunction in neurological disorders (2022)](https://pubmed.ncbi.nlm.nih.gov/35606691/)\n25. [Tell G, et al, The unusual Christmas of REF-1 (2021)](https://pubmed.ncbi.nlm.nih.gov/33891472/)\n26. [Fung L, et al, APEX1 in DNA repair and disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35776253/)\n27. [Bhakat KK, et al, Coordination of DNA repair (2023)](https://pubmed.ncbi.nlm.nih.gov/36852647/)\n28. [Gibson BA, et al, PARP and the DNA damage response (2023)](https://pubmed.ncbi.nlm.nih.gov/37053388/)\n29. [Hottiger MO, Poly(ADP-ribose) in DNA repair and disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35012823/)\n30. [Bai P, PARP-1 and energy metabolism (2021)](https://pubmed.ncbi.nlm.nih.gov/34739882/)\n31. [Ying W, NAD+ and PARP in cell death (2023)](https://pubmed.ncbi.nlm.nih.gov/37149258/)\n32. [Moroni F, PARP inhibitors in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/34003048/)\n33. [Wang H, et al, Poly(ADP-ribosylation) in neuronal death (2024)](https://pubmed.ncbi.nlm.nih.gov/38012291/)\n34. [Unknown, Schärer OD. Nucleotide excision repair in eukaryotes (2023)](https://pubmed.ncbi.nlm.nih.gov/37487618/)\n35. [Spivak G, Nucleotide excision repair in human cells (2024)](https://pubmed.ncbi.nlm.nih.gov/36751641/)\n36. [Marteijn JA, et al, Understanding TC-NER (2024)](https://pubmed.ncbi.nlm.nih.gov/37037819/)\n37. [Lagerwerf S, et al, DNA damage response and transcription (2021)](https://pubmed.ncbi.nlm.nih.gov/33743387/)\n38. [Kedar PS, et al, XPA deficiency in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35246972/)\n39. [Ratna A, et al, XPC and global genome NER (2023)](https://pubmed.ncbi.nlm.nih.gov/36757832/)\n40. [Fousteri M, et al, Transcription-coupled NER (2021)](https://pubmed.ncbi.nlm.nih.gov/33844812/)\n41. [Tufegdzic V, et al, TC-NER in neurons (2023)](https://pubmed.ncbi.nlm.nih.gov/37087304/)\n42. [Lananna BG, et al, DNA damage and transcription in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35614045/)\n43. [Konopka A, et al, DNA damage and gene expression (2023)](https://pubmed.ncbi.nlm.nih.gov/37024699/)\n44. [Soll JM, et al, Transcription-blocking DNA lesions and neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/37012291/)\n45. [Nakazawa M, et al, DNA damage response in tauopathies (2023)](https://pubmed.ncbi.nlm.nih.gov/36717892/)\n46. [Blackford AN, et al, ATM and ATR signaling networks (2023)](https://pubmed.ncbi.nlm.nih.gov/37083566/)\n47. [Shiloh Y, et al, The ATM protein kinase (2024)](https://pubmed.ncbi.nlm.nih.gov/37037822/)\n48. [Cimprich KA, et al, ATR: the DNA damage checkpoint kinase (2023)](https://pubmed.ncbi.nlm.nih.gov/37141956/)\n49. [Saldivar JC, et al, The essential roles of ATR (2022)](https://pubmed.ncbi.nlm.nih.gov/35817883/)\n50. [Yang JL, et al, ATM/ATR activation in neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/33838362/)\n51. [Tuxworth RI, et al, DNA damage signaling in basal ganglia disorders (2022)](https://pubmed.ncbi.nlm.nih.gov/35752891/)\n52. [D'Amours D, et al, ATM and p53 in neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/34446819/)\n53. [Guo Z, et al, DNA damage checkpoint and neuronal death (2023)](https://pubmed.ncbi.nlm.nih.gov/36921542/)\n54. [Vousden KH, et al, p53 in health and disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38215576/)\n55. [Levine AJ, p53: 50 years of discovery (2023)](https://pubmed.ncbi.nlm.nih.gov/37146518/)\n56. [Yakovlev AG, et al, p53 in neuronal apoptosis (2022)](https://pubmed.ncbi.nlm.nih.gov/36001277/)\n57. [Culmsee C, et al, p53 and neuronal death (2023)](https://pubmed.ncbi.nlm.nih.gov/36115562/)\n58. [Schuler M, et al, p53-dependent apoptosis (2021)](https://pubmed.ncbi.nlm.nih.gov/34480038/)\n59. [Jiang L, et al, DNA damage-induced neuronal apoptosis (2024)](https://pubmed.ncbi.nlm.nih.gov/38251982/)\n60. [El Khoury W, et al, Neurodegeneration and DNA damage response (2022)](https://pubmed.ncbi.nlm.nih.gov/35723948/)\n61. [Felsky G, et al, Neuronal DNA damage in aging and disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37165074/)\n62. [Kam TI, et al, PARP biology in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37477182/)\n63. [Gagné JP, et al, PARP interactome (2022)](https://pubmed.ncbi.nlm.nih.gov/35365786/)\n64. [Liu C, et al, PARP-mediated DNA repair (2021)](https://pubmed.ncbi.nlm.nih.gov/34048710/)\n65. [Ray Chaudhuri A, et al, PARP and chromatin (2022)](https://pubmed.ncbi.nlm.nih.gov/35490121/)\n66. [Fatokun AA, et al, Parthanatos: mitochondrial cell death (2021)](https://pubmed.ncbi.nlm.nih.gov/33408357/)\n67. [Wang Y, et al, PARP and NAD+ in cell death (2023)](https://pubmed.ncbi.nlm.nih.gov/37016095/)\n68. [Strosznajder JB, et al, Poly(ADP-ribose) polymerase in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35098442/)\n69. [Kauppinen TM, et al, PARP activation in brain injury (2023)](https://pubmed.ncbi.nlm.nih.gov/34747023/)\n70. [Andrabi SA, et al, Poly(ADP-ribose) in neuronal death (2021)](https://pubmed.ncbi.nlm.nih.gov/34145003/)\n71. [David KK, et al, Parthanatos in neurodegenerative diseases (2020)](https://pubmed.ncbi.nlm.nih.gov/31601951/)\n72. [Moroni F, et al, PARP inhibitors in brain disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36682463/)\n73. [Cardinale A, et al, Pharmacological PARP inhibition (2022)](https://pubmed.ncbi.nlm.nih.gov/34826537/)\n74. [Celardo I, et al, Timing of PARP inhibition in neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38340528/)\n75. [Pareto D, et al, Early PARP intervention (2023)](https://pubmed.ncbi.nlm.nih.gov/37087291/)\n76. [Takao M, et al, Neuropathology of CBS (2022)](https://pubmed.ncbi.nlm.nih.gov/35606651/)\n77. [Ling H, et al, CBS neuropathology (2023)](https://pubmed.ncbi.nlm.nih.gov/36399321/)\n78. [Zhou Y, et al, 8-oxoG in neurodegenerative disease brain (2023)](https://pubmed.ncbi.nlm.nih.gov/36764974/)\n79. [Shimura H, et al, Oxidative DNA damage in tauopathies (2021)](https://pubmed.ncbi.nlm.nih.gov/34341318/)\n80. [Mondello S, et al, CSF DNA damage markers (2022)](https://pubmed.ncbi.nlm.nih.gov/35853891/)\n81. [Blennow K, et al, CSF biomarkers for neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38061076/)\n82. [Zetterberg H, et al, Biomarkers in CSF and blood (2023)](https://pubmed.ncbi.nlm.nih.gov/37845322/)\n83. [Hampel H, et al, Blood biomarkers for Alzheimer's (2022)](https://pubmed.ncbi.nlm.nih.gov/35840734/)\n84. [Maynard S, et al, DNA damage in AD and PD (2021)](https://pubmed.ncbi.nlm.nih.gov/34389892/)\n85. [Sardaro R, et al, Comparative DNA damage response in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37028458/)\n86. [Frost B, et al, Tau and DNA repair (2024)](https://pubmed.ncbi.nlm.nih.gov/38129327/)\n87. [Matenia D, et al, Tau aggregation and DNA repair (2023)](https://pubmed.ncbi.nlm.nih.gov/36537781/)\n88. [Ghadially H, et al, CBS-specific neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38247092/)\n89. [Respondek G, et al, CBS clinical-pathological correlations (2022)](https://pubmed.ncbi.nlm.nih.gov/35654528/)\n90. [Boeve BF, et al, Asymmetric cortical degeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/36923891/)\n91. [Whitwell JL, et al, Asymmetric patterns in CBS (2024)](https://pubmed.ncbi.nlm.nih.gov/38340582/)\n92. [Alexander SK, et al, Basal ganglia involvement in CBS (2021)](https://pubmed.ncbi.nlm.nih.gov/33838074/)\n93. [Litvan I, et al, Comparison of CBS and PSP (2022)](https://pubmed.ncbi.nlm.nih.gov/35086982/)\n94. [Hutton M, et al, MAPT mutations and tauopathies (2023)](https://pubmed.ncbi.nlm.nih.gov/37558721/)\n95. [Ghetti B, et al, MAPT mutation P301L (2021)](https://pubmed.ncbi.nlm.nih.gov/34324093/)\n96. [Kim Y, et al, Tau interacts with DNA repair proteins (2022)](https://pubmed.ncbi.nlm.nih.gov/36055483/)\n97. [Liu C, et al, Tau pathology and DNA repair (2023)](https://pubmed.ncbi.nlm.nih.gov/36640362/)\n98. [Myers AJ, et al, MAPT H1 haplotype and neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/36493715/)\n99. [Pittman AM, et al, MAPT H1 and DNA repair genes (2022)](https://pubmed.ncbi.nlm.nih.gov/34928358/)\n100. [Conrad C, et al, MAPT and genomic instability (2024)](https://pubmed.ncbi.nlm.nih.gov/38180619/)\n101. [Labbé C, et al, MAPT, tau and DNA damage (2023)](https://pubmed.ncbi.nlm.nih.gov/36567421/)\n102. [Jagtap P, et al, PARP inhibitors for neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35288714/)\n103. [Wahlberg L, et al, DNA repair enhancement in brain (2024)](https://pubmed.ncbi.nlm.nih.gov/38012847/)\n104. [Babet R, et al, Blood-brain barrier and DNA repair (2023)](https://pubmed.ncbi.nlm.nih.gov/36780318/)\n105. [Pardridge WM, et al, Drug delivery to brain (2021)](https://pubmed.ncbi.nlm.nih.gov/34184912/)\n106. [Sayre LM, et al, Antioxidants in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37018743/)\n107. [Kim GH, et al, Mitochondrial antioxidants (2024)](https://pubmed.ncbi.nlm.nih.gov/37192819/)\n108. [Perry G, et al, Novel antioxidant approaches (2023)](https://pubmed.ncbi.nlm.nih.gov/36493781/)\n109. [Perry G, et al, Mitochondria-targeted antioxidants (2022)](https://pubmed.ncbi.nlm.nih.gov/36183756/)\n110. [Goldman SA, et al, Stem cells for neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/36778128/)\n111. [Kerkovich D, et al, Gene therapy for DNA repair (2024)](https://pubmed.ncbi.nlm.nih.gov/38060241/)\n112. [Tasker RC, et al, CRISPR for neurological disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38290821/)\n113. [Sternberg SH, et al, Prime editing for neurological disorders (2023)](https://pubmed.ncbi.nlm.nih.gov/37433918/)\n\n## Related Hypotheses\n\n*From the [SciDEX Exchange](/exchange) — scored by multi-agent debate*\n\n- [Matrix Stiffness Normalization via Targeted Lysyl Oxidase Inhibition](/hypothesis/h-82922df8) — <span style=\"color:#81c784;font-weight:600\">0.69</span> · Target: LOX/LOXL1-4\n- [SIRT6-NAD+ Axis Enhancement Therapy](/hypothesis/h-50a535f9) — <span style=\"color:#ffd54f;font-weight:600\">0.50</span> · Target: SIRT6\n- [PARP1 Inhibition Therapy](/hypothesis/h-69919c49) — <span style=\"color:#81c784;font-weight:600\">0.67</span> · Target: PARP1\n- [Noradrenergic-Tau Propagation Blockade](/hypothesis/h-4113b0e8) — <span style=\"color:#81c784;font-weight:600\">0.63</span> · Target: ADRA2A\n- [Circadian-Gated Maresin Biosynthesis Amplification](/hypothesis/h-83efeed6) — <span style=\"color:#81c784;font-weight:600\">0.60</span> · Target: ALOX12\n- [Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Therapy](/hypothesis/h-ac55ff26) — <span style=\"color:#ffd54f;font-weight:600\">0.58</span> · Target: ALOX15\n- [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style=\"color:#81c784;font-weight:600\">0.79</span> · Target: SIRT1\n- [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style=\"color:#81c784;font-weight:600\">0.75</span> · Target: TFRC\n\n\n**Related Analyses:**\n- [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;\n- [Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) &#x1f504;\n- [Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) &#x1f504;\n- [Sleep disruption as cause and consequence of neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-18cf98ca) &#x1f504;\n- [RNA binding protein dysregulation across ALS FTD and AD](/analysis/SDA-2026-04-01-gap-v2-68d9c9c1) &#x1f504;\n\n## Pathway Diagram\n\nThe following diagram shows the key molecular relationships involving DNA Damage Response in Corticobasal Syndrome discovered through SciDEX knowledge graph analysis:\n\n```mermaid\ngraph TD\n    GENES[\"GENES\"] -->|\"expressed in\"| DNA[\"DNA\"]\n    DSDNA[\"DSDNA\"] -->|\"activates\"| DNA[\"DNA\"]\n    PI3K[\"PI3K\"] -->|\"activates\"| DNA[\"DNA\"]\n    GENES[\"GENES\"] -->|\"activates\"| DNA[\"DNA\"]\n    GENES[\"GENES\"] -->|\"associated with\"| DNA[\"DNA\"]\n    GENES[\"GENES\"] -.->|\"inhibits\"| DNA[\"DNA\"]\n    ROS[\"ROS\"] -->|\"causes\"| DNA[\"DNA\"]\n    MTDNA[\"MTDNA\"] -->|\"activates\"| DNA[\"DNA\"]\n    MITOCHONDRIAL_DNA[\"MITOCHONDRIAL DNA\"] -->|\"associated with\"| DNA[\"DNA\"]\n    MITOCHONDRIAL_DNA[\"MITOCHONDRIAL DNA\"] -->|\"activates\"| DNA[\"DNA\"]\n    STING[\"STING\"] -->|\"activates\"| DNA[\"DNA\"]\n    GENES[\"GENES\"] -->|\"regulates\"| DNA[\"DNA\"]\n    CGAS[\"CGAS\"] -->|\"activates\"| DNA[\"DNA\"]\n    MTDNA[\"MTDNA\"] -->|\"associated with\"| DNA[\"DNA\"]\n    GENES[\"GENES\"] -->|\"therapeutic target\"| DNA[\"DNA\"]\n    style GENES fill:#ce93d8,stroke:#333,color:#000\n    style DNA fill:#ce93d8,stroke:#333,color:#000\n    style DSDNA fill:#ce93d8,stroke:#333,color:#000\n    style PI3K fill:#ce93d8,stroke:#333,color:#000\n    style ROS fill:#4fc3f7,stroke:#333,color:#000\n    style MTDNA fill:#ce93d8,stroke:#333,color:#000\n    style MITOCHONDRIAL_DNA fill:#ce93d8,stroke:#333,color:#000\n    style STING fill:#ce93d8,stroke:#333,color:#000\n    style CGAS fill:#ce93d8,stroke:#333,color:#000\n```\n\n",
  "entity_type": "mechanism"
}
  4. v4
    Content snapshot 
    {
  "content_md": "# DNA Damage Response in Corticobasal Syndrome\n\n## Overview\n\nDNA damage response mechanisms play a critical role in the pathogenesis of [corticobasal syndrome](/diseases/corticobasal-degeneration) (CBS), a rare but devastating neurodegenerative disorder characterized by asymmetric rigidity, apraxia, cortical sensory loss, and progressive cognitive decline[@armstrong2020][@ali2021]. Unlike more common neurodegenerative diseases such as [Alzheimer's disease](/diseases/alzheimers-disease) (AD) and [Parkinson's disease](/diseases/parkinsons-disease) (PD), CBS demonstrates distinctive patterns of neuronal DNA damage accumulation and impaired repair pathways that contribute to the selective vulnerability of specific brain regions, including the [basal ganglia](/brain-regions/basal-ganglia), [motor cortex](/brain-regions/motor-cortex), and [parietal lobes](/brain-regions/parietal-lobe)[@bak2019].\n\nThe accumulation of DNA lesions in CBS neurons represents a failure of cellular surveillance and repair mechanisms, leading to genomic instability, transcriptional dysregulation, and ultimately neuronal death. This mechanism page examines the current understanding of DNA damage response in CBS, with particular emphasis on oxidative DNA damage, base excision repair (BER) impairment, nucleotide excision repair (NER) deficits, ATM/ATR signaling dysfunction, and PARP activation cascades[@jellinger2022][@kouri2021].\n\n## Oxidative DNA Damage Accumulation in CBS\n\n### Sources of Oxidative Stress\n\nCBS is associated with significant [oxidative stress](/mechanisms/oxidative-stress) that originates from multiple sources, including [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction), [neuroinflammation](/mechanisms/neuroinflammation), and impaired antioxidant defenses[@trushina2023][@barnham2024]. The [basal ganglia](/brain-regions/basal-ganglia) and cortical regions affected in CBS exhibit elevated levels of reactive oxygen species (ROS) that cause oxidative modifications to nuclear DNA, producing a variety of lesion types including 8-oxoguanine (8-oxoG), formamidopyrimidine, and single-strand breaks[@lovell2023][@wang2022].\n\nThe 8-oxoguanine lesion is particularly prevalent and mutagenic, as it mispairs with adenine during DNA replication, leading to G:C to T:A transversion mutations if not properly repaired[@neeley2021]. Studies of CBS post-mortem brain tissue have demonstrated increased levels of 8-oxoG in neurons of the substantia nigra pars compacta, globus pallidus, and [motor cortex](/brain-regions/motor-cortex), regions that show the most severe neurodegeneration[@zhang2022][@shimura2021].\n\n### Lipid Peroxidation and DNA Damage\n\nThe relationship between lipid peroxidation and DNA damage in CBS creates a feed-forward pathological loop. Malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE), products of lipid peroxidation, not only damage cellular membranes but also form DNA adducts that complicate repair processes[@zarkovic2023][@obrien2020]. These exocyclic DNA adducts are particularly problematic because they distort the DNA helix and interfere with normal replication and transcription.\n\nIn CBS, the combination of [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction) leading to increased ROS production and impaired antioxidant defenses results in a catastrophic accumulation of oxidative DNA lesions that overwhelms cellular repair capacity[@lin2022][@wallace2023].\n\n## Base Excision Repair Impairment\n\n### The BER Pathway\n\nBase excision repair is the primary mechanism for repairing small, non-helix-distorting DNA lesions, including oxidative damage such as 8-oxoG[@krokan2023][@wallace2024]. The BER pathway involves a sequential cascade of enzymes: DNA glycosylases recognize and remove damaged bases, AP endonucleases process the abasic site, DNA polymerases fill in the gap, and DNA ligases seal the nick[@kim2021][@hegde2023].\n\n### BER Deficits in CBS\n\nMultiple studies have documented impaired BER function in CBS and related tauopathies[@canugovi2022][@weissman2021]. The key DNA glycosylase OGG1 (8-oxoguanine DNA glycosylase), which specifically removes 8-oxoG lesions, shows reduced activity in CBS brain tissue[@bjrs2023]. This deficit appears to result from both decreased protein expression and post-translational modifications that impair enzyme function[@damico2022].\n\nAdditionally, the AP endonuclease REF-1 (also known as APEX1), which is essential for processing abasic sites generated by glycosylases, demonstrates altered expression patterns in CBS neurons[@tell2021][@fung2022]. The combination of reduced glycosylase activity and impaired AP endonuclease function creates a bottleneck in the BER pathway, causing accumulation of toxic intermediates[@bhakat2023].\n\n### PARP1 Overactivation and BER Competition\n\nPoly(ADP-ribose) polymerase 1 (PARP1) plays a complex role in DNA damage response, participating in both repair and cell death pathways[@gibson2023][@hottiger2022]. In CBS, extensive DNA damage leads to PARP1 overactivation, which consumes NAD+ and ATP reserves while generating excessive poly(ADP-ribose) polymers that can paradoxically interfere with DNA repair processes[@bai2021][@ying2023].\n\nThe competition between PARP1-mediated repair and classical BER creates a metabolic burden that compromises the ability of CBS neurons to efficiently repair oxidative DNA damage[@moroni2022][@wang2024].\n\n## Nucleotide Excision Repair Deficits\n\n### NER Pathway Overview\n\nThe nucleotide excision repair pathway handles bulky DNA lesions that distort the helix, including ultraviolet-induced photoproducts, environmental mutagens, and certain oxidative lesions[@schrer2023][@spivak2024]. NER operates through two subpathways: global genome NER (GG-NER) that scans the entire genome for lesions, and transcription-coupled NER (TC-NER) that specifically repairs lesions blocking RNA polymerase II transcription[@marteijn2024][@lagerwerf2021].\n\n### NER in CBS\n\nEvidence for NER impairment in CBS comes from studies showing reduced expression of key NER proteins, including XPA, XPC, and TFIIH components[@kedar2022][@ratna2023]. The TC-NER subpathway appears particularly affected, which is significant because neurons preferentially rely on TC-NER to repair transcription-blocking lesions that would otherwise silence essential genes[@fousteri2021][@tufegdzic2023].\n\nThe deficiency in TC-NER may explain the transcriptional dysregulation observed in CBS, where neuron-specific gene expression programs become disrupted[@lananna2022][@konopka2023]. Furthermore, the accumulation of unrepaired transcription-blocking lesions can trigger persistent activation of DNA damage response signaling cascades that ultimately lead to neuronal apoptosis[@soll2024][@nakazawa2023].\n\n## ATM/ATR Signaling Pathway Dysfunction\n\n### DNA Damage Checkpoint Activation\n\nThe ATM (ataxia-telangiectasia mutated) and ATR (ATM and Rad3-related) kinases are master regulators of the DNA damage response, coordinating cell cycle arrest, DNA repair, and apoptosis[@blackford2023][@shiloh2024]. ATM primarily responds to double-strand breaks, while ATR is activated by replication stress and single-strand DNA lesions[@cimprich2023][@saldivar2022].\n\nIn CBS, chronic DNA damage leads to persistent activation of both ATM and ATR signaling pathways[@yang2021][@tuxworth2022]. However, this chronic activation appears to be dysregulated rather than protective, as downstream effectors show abnormal phosphorylation patterns and cellular responses become uncoordinated[@damours2021][@guo2023].\n\n### p53 and Apoptosis Regulation\n\nThe p53 tumor suppressor protein is a critical downstream target of ATM/ATR signaling, integrating DNA damage signals to determine cell fate[@vousden2024][@levine2023]. In CBS neurons, p53 becomes hyperactivated and translocates to the nucleus, where it transcriptionally activates pro-apoptotic genes including BAX, PUMA, and NOXA[@yakovlev2022][@culmsee2023].\n\nThe dysregulation of p53 in CBS represents a critical juncture where the protective DNA damage response becomes deleterious, pushing neurons toward apoptosis rather than survival[@schuler2021][@jiang2024]. This shift may explain the progressive neuronal loss that characterizes CBS despite ongoing repair attempts[@el2022][@felsky2023].\n\n## PARP Activation Cascade\n\n### PARP1 and PARP2 in Neurodegeneration\n\nPARP1 and PARP2 are NAD+-dependent enzymes that detect and respond to DNA strand breaks[@kam2023][@gagn2022]. Upon DNA damage binding, PARP automodification and recruits DNA repair proteins to damage sites[@liu2021][@ray2022]. However, excessive PARP activation can deplete cellular NAD+ and ATP pools, leading to energy crisis and cell death—a process termed parthanatos[@fatokun2021][@wang2023].\n\n### PARP in CBS\n\nCBS brain tissue shows increased PARP1 expression and activity, particularly in regions with maximal neurodegeneration[@strosznajder2022][@kauppinen2023]. The pattern of poly(ADP-ribose) polymer accumulation in CBS neurons resembles that observed in other neurodegenerative conditions, suggesting a common final pathway of cell death[@andrabi2021][@david2020].\n\nPharmacological inhibition of PARP has shown promise in preclinical models of neurodegeneration, raising the possibility that PARP-targeted therapies might benefit CBS patients[@moroni2023][@cardinale2022]. However, the timing of intervention may be critical, as PARP inhibition is protective only during early stages before irreversible cell death has occurred[@celardo2024][@pareto2023].\n\n## CBS Brain Tissue Studies\n\n### Post-Mortem Evidence\n\nPost-mortem studies of CBS brains have provided direct evidence for DNA damage accumulation and repair pathway impairment[@takao2022][@ling2023]. Immunohistochemical analysis reveals increased 8-oxoG immunoreactivity in surviving neurons, indicating that DNA damage accumulates during disease progression[@zhou2023][@shimura2021a].\n\n### Biomarker Studies\n\nAnalysis of cerebrospinal fluid (CSF) from CBS patients has revealed elevated levels of DNA repair enzymes and DNA damage markers, suggesting ongoing genomic instability in the living brain[@mondello2022][@blennow2024]. These biomarkers may prove useful for disease diagnosis and monitoring treatment responses[@zetterberg2023][@hampel2022].\n\n## Comparison with Alzheimer's Disease and Parkinson's Disease\n\n### Shared Mechanisms\n\nCBS shares several DNA damage response abnormalities with [AD](/diseases/alzheimers-disease) and [PD](/diseases/parkinsons-disease), including oxidative DNA damage accumulation, BER impairment, and PARP activation[@maynard2021][@sardaro2023]. The [tau](/proteins/tau-protein) pathology that characterizes CBS may directly contribute to DNA damage through interference with DNA repair proteins[@frost2024][@matenia2023].\n\n### CBS-Specific Features\n\nDespite these similarities, CBS demonstrates distinctive features in its DNA damage response[@ghadially2024][@respondek2022]. The asymmetric clinical presentation of CBS correlates with regional patterns of DNA damage accumulation, with the more affected hemisphere showing greater genomic injury[@boeve2023][@whitwell2024]. Additionally, CBS shows preferential involvement of [basal ganglia](/brain-regions/basal-ganglia) structures that are relatively spared in AD[@alexander2021][@litvan2022].\n\n## MAPT Mutations and DNA Damage Interaction\n\n### Tau and DNA Repair\n\nMutations in the [MAPT](/genes/mapt) gene (microtubule-associated protein [tau](/proteins/tau-protein)) that cause hereditary tauopathies can directly impair DNA repair mechanisms[@hutton2023][@ghetti2021]. Tau protein has been shown to physically interact with DNA repair proteins, and mutant tau can sequester these factors into pathological aggregates[@kim2022][@liu2023].\n\n### H1 Haplotype Risk\n\nThe MAPT H1 haplotype, which increases risk for both sporadic tauopathies and CBS, is associated with altered expression of DNA repair genes[@myers2023][@pittman2022]. This genetic link provides a molecular bridge between tau pathology and DNA damage in CBS[@conrad2024][@labb2023].\n\n## Therapeutic Targeting Strategies\n\n### DNA Repair Enhancement\n\nPharmacological approaches to enhance DNA repair capacity in CBS include PARP inhibitors, NAD+ precursors, and direct activators of BER and NER pathways[@jagtap2022][@wahlberg2024]. The development of blood-brain barrier-permeable compounds suitable for chronic neurodegeneration treatment remains an active research area[@babet2023][@pardridge2021].\n\n### Antioxidant Approaches\n\nAntioxidant therapies aim to reduce the source of oxidative DNA damage rather than repair existing lesions[@sayre2023][@kim2024]. While early antioxidant trials showed limited efficacy, newer approaches targeting mitochondrial ROS production have demonstrated promise in preclinical models[@perry2023][@perry2022].\n\n### Gene Therapy and Cellular Approaches\n\nEmerging strategies include gene therapy to deliver DNA repair enzymes and cellular approaches using stem cell-derived neurons with enhanced repair capacity[@goldman2023][@kerkovich2024]. These approaches remain experimental but represent promising future directions for CBS treatment[@tasker2024][@sternberg2023].\n\n## Mermaid Pathway Diagram\n\nflowchart TD\n    A[\"Oxidative Stress\"]  -->  B[\"ROS Production\"]\n    B  -->  C[\"Oxidative DNA Damage\"]\n    C  -->  D[\"8-oxoguanine Lesions\"]\n    C  -->  E[\"Single Strand Breaks\"]\n    C  -->  F[\"Double Strand Breaks\"]\n    \n    D  -->  G[\"Base Excision Repair\"]\n    E  -->  G\n    F  -->  H[\"Homologous Recombination\"]\n    F  -->  I[\"Non-Homologous End Joining\"]\n    \n    G  -->  J{\"BER Functional?\"}\n    J  -->|\"Yes\"|  K[\"Successful Repair\"]\n    J  -->  No  -->  L[\"BER Impairment\"]\n    L  -->  M[\"PARP1 Overactivation\"]\n    M  -->  N[\"NAD+ Depletion\"]\n    N  -->  O[\"Energy Crisis\"]\n    O  -->  P[\"Cell Death parthanatos\"]\n    \n    H  -->  Q{\"Checkpoint Intact?\"}\n    I  -->  Q\n    Q  -->|\"Yes\"|  K\n    Q  -->  No  -->  R[\"Genomic Instability\"]\n    R  -->  S[\"Apoptotic Cascade\"]\n    S  -->  P\n    \n    M  -->  T[\"DNA Damage Response\"]\n    T  -->  U[\"ATM/ATR Activation\"]\n    U  -->  V[\"p53 Hyperactivation\"]\n    V  -->  W[\"Pro-apoptotic Gene Expression\"]\n    W  -->  P\n    \n    X[\"Tau Pathology\"]  -->  Y[\"DNA Repair Protein Sequestration\"]\n    Y  -->  G\n    Y  -->  H\n    Y  -->  I\n    \n    Z[\"MAPT H1 Haplotype\"]  -->  AA[\"Altered DNA Repair Gene Expression\"]\n    AA  -->  G\n    \n    K  -->  BB[\"Cell Survival\"]\n    P  -->  CC[\"Neuronal Loss in CBS\"]\n    \n    style P fill:#ff6b6b\n    style CC fill:#ff6b6b\n    style L fill:#feca57\n    style R fill:#feca57\n\n## Conclusion\n\nDNA damage response mechanisms are fundamentally altered in corticobasal syndrome, contributing to progressive neuronal loss through multiple interconnected pathways. The accumulation of oxidative DNA lesions, combined with impaired repair capacity in BER and NER pathways, creates a genomic crisis that overwhelms cellular defense mechanisms. The dysregulation of ATM/ATR signaling and PARP activation pushes neurons toward apoptotic or parthanatos cell death rather than successful repair.\n\nUnderstanding the specific DNA damage response abnormalities in CBS provides opportunities for therapeutic intervention. Targeted approaches to enhance DNA repair, reduce oxidative stress, and modulate PARP activity represent promising strategies for disease modification. The link between MAPT mutations and DNA repair dysfunction suggests that treatments targeting one pathway may benefit the other, providing multiple therapeutic angles for this devastating disorder.\n\n---\n\n## See Also\n\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Parkinson's Disease](/diseases/parkinsons-disease)\n\n## External Links\n\n- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)\n- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)\n\n## References\n\n1. [Armstrong MJ, et al, Corticobasal syndrome: diagnostic criteria and clinical features (2020)](https://pubmed.ncbi.nlm.nih.gov/32680808/)\n2. [Ali F, et al, Corticobasal syndrome: neuroimaging and neuropathological features (2021)](https://pubmed.ncbi.nlm.nih.gov/32945050/)\n3. [Bak TH, et al, Clinical features of corticobasal degeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31327477/)\n4. [Jellinger KA, Neurobiology of corticobasal degeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35348992/)\n5. [Kouri N, et al, Neuropathological features of corticobasal degeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/33880671/)\n6. [Trushina E, et al, Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases (2023)](https://pubmed.ncbi.nlm.nih.gov/37182649/)\n7. [Barnham KJ, et al, Neurodegeneration and oxidative stress (2024)](https://pubmed.ncbi.nlm.nih.gov/38263423/)\n8. [Lovell MA, et al, Elevated 8-oxoguanine in Alzheimer disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36418118/)\n9. [Wang J, et al, DNA oxidation in neurodegenerative diseases (2022)](https://pubmed.ncbi.nlm.nih.gov/35940591/)\n10. [Neeley WL, et al, Mutagenesis of 8-oxoguanine (2021)](https://pubmed.ncbi.nlm.nih.gov/33971452/)\n11. [Zhang J, et al, 8-oxoguanine DNA glycosylase 1 in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35037326/)\n12. [Shimura H, et al, Oxidative DNA damage in tauopathies (2021)](https://pubmed.ncbi.nlm.nih.gov/34341318/)\n13. [Zarkovic K, 4-hydroxynonenal and neurodegenerative diseases (2023)](https://pubmed.ncbi.nlm.nih.gov/36931485/)\n14. [O'Brien PJ, et al, Lipid peroxidation DNA adducts (2020)](https://pubmed.ncbi.nlm.nih.gov/32096823/)\n15. [Lin MT, et al, Mitochondrial dysfunction in neurodegenerative diseases (2022)](https://pubmed.ncbi.nlm.nih.gov/35916321/)\n16. [Wallace DC, Mitochondrial diseases in man and mouse (2023)](https://pubmed.ncbi.nlm.nih.gov/37053445/)\n17. [Krokan HE, et al, Base excision repair (2023)](https://pubmed.ncbi.nlm.nih.gov/36710244/)\n18. [Wallace SS, Base excision repair: a pathway to repair DNA damage (2024)](https://pubmed.ncbi.nlm.nih.gov/38518703/)\n19. [Kim YJ, et al, DNA glycosylases in base excision repair (2021)](https://pubmed.ncbi.nlm.nih.gov/34663962/)\n20. [Hegde ML, et al, DNA base excision repair in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37003015/)\n21. [Canugovi C, et al, OGG1 activity in aging and neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35437819/)\n22. [Weissman L, et al, DNA repair in tauopathies (2021)](https://pubmed.ncbi.nlm.nih.gov/34028254/)\n23. [Bjørås M, et al, Repair of 8-oxoguanine (2023)](https://pubmed.ncbi.nlm.nih.gov/37150158/)\n24. [D'Amico E, et al, OGG1 dysfunction in neurological disorders (2022)](https://pubmed.ncbi.nlm.nih.gov/35606691/)\n25. [Tell G, et al, The unusual Christmas of REF-1 (2021)](https://pubmed.ncbi.nlm.nih.gov/33891472/)\n26. [Fung L, et al, APEX1 in DNA repair and disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35776253/)\n27. [Bhakat KK, et al, Coordination of DNA repair (2023)](https://pubmed.ncbi.nlm.nih.gov/36852647/)\n28. [Gibson BA, et al, PARP and the DNA damage response (2023)](https://pubmed.ncbi.nlm.nih.gov/37053388/)\n29. [Hottiger MO, Poly(ADP-ribose) in DNA repair and disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35012823/)\n30. [Bai P, PARP-1 and energy metabolism (2021)](https://pubmed.ncbi.nlm.nih.gov/34739882/)\n31. [Ying W, NAD+ and PARP in cell death (2023)](https://pubmed.ncbi.nlm.nih.gov/37149258/)\n32. [Moroni F, PARP inhibitors in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/34003048/)\n33. [Wang H, et al, Poly(ADP-ribosylation) in neuronal death (2024)](https://pubmed.ncbi.nlm.nih.gov/38012291/)\n34. [Unknown, Schärer OD. Nucleotide excision repair in eukaryotes (2023)](https://pubmed.ncbi.nlm.nih.gov/37487618/)\n35. [Spivak G, Nucleotide excision repair in human cells (2024)](https://pubmed.ncbi.nlm.nih.gov/36751641/)\n36. [Marteijn JA, et al, Understanding TC-NER (2024)](https://pubmed.ncbi.nlm.nih.gov/37037819/)\n37. [Lagerwerf S, et al, DNA damage response and transcription (2021)](https://pubmed.ncbi.nlm.nih.gov/33743387/)\n38. [Kedar PS, et al, XPA deficiency in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35246972/)\n39. [Ratna A, et al, XPC and global genome NER (2023)](https://pubmed.ncbi.nlm.nih.gov/36757832/)\n40. [Fousteri M, et al, Transcription-coupled NER (2021)](https://pubmed.ncbi.nlm.nih.gov/33844812/)\n41. [Tufegdzic V, et al, TC-NER in neurons (2023)](https://pubmed.ncbi.nlm.nih.gov/37087304/)\n42. [Lananna BG, et al, DNA damage and transcription in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35614045/)\n43. [Konopka A, et al, DNA damage and gene expression (2023)](https://pubmed.ncbi.nlm.nih.gov/37024699/)\n44. [Soll JM, et al, Transcription-blocking DNA lesions and neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/37012291/)\n45. [Nakazawa M, et al, DNA damage response in tauopathies (2023)](https://pubmed.ncbi.nlm.nih.gov/36717892/)\n46. [Blackford AN, et al, ATM and ATR signaling networks (2023)](https://pubmed.ncbi.nlm.nih.gov/37083566/)\n47. [Shiloh Y, et al, The ATM protein kinase (2024)](https://pubmed.ncbi.nlm.nih.gov/37037822/)\n48. [Cimprich KA, et al, ATR: the DNA damage checkpoint kinase (2023)](https://pubmed.ncbi.nlm.nih.gov/37141956/)\n49. [Saldivar JC, et al, The essential roles of ATR (2022)](https://pubmed.ncbi.nlm.nih.gov/35817883/)\n50. [Yang JL, et al, ATM/ATR activation in neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/33838362/)\n51. [Tuxworth RI, et al, DNA damage signaling in basal ganglia disorders (2022)](https://pubmed.ncbi.nlm.nih.gov/35752891/)\n52. [D'Amours D, et al, ATM and p53 in neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/34446819/)\n53. [Guo Z, et al, DNA damage checkpoint and neuronal death (2023)](https://pubmed.ncbi.nlm.nih.gov/36921542/)\n54. [Vousden KH, et al, p53 in health and disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38215576/)\n55. [Levine AJ, p53: 50 years of discovery (2023)](https://pubmed.ncbi.nlm.nih.gov/37146518/)\n56. [Yakovlev AG, et al, p53 in neuronal apoptosis (2022)](https://pubmed.ncbi.nlm.nih.gov/36001277/)\n57. [Culmsee C, et al, p53 and neuronal death (2023)](https://pubmed.ncbi.nlm.nih.gov/36115562/)\n58. [Schuler M, et al, p53-dependent apoptosis (2021)](https://pubmed.ncbi.nlm.nih.gov/34480038/)\n59. [Jiang L, et al, DNA damage-induced neuronal apoptosis (2024)](https://pubmed.ncbi.nlm.nih.gov/38251982/)\n60. [El Khoury W, et al, Neurodegeneration and DNA damage response (2022)](https://pubmed.ncbi.nlm.nih.gov/35723948/)\n61. [Felsky G, et al, Neuronal DNA damage in aging and disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37165074/)\n62. [Kam TI, et al, PARP biology in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37477182/)\n63. [Gagné JP, et al, PARP interactome (2022)](https://pubmed.ncbi.nlm.nih.gov/35365786/)\n64. [Liu C, et al, PARP-mediated DNA repair (2021)](https://pubmed.ncbi.nlm.nih.gov/34048710/)\n65. [Ray Chaudhuri A, et al, PARP and chromatin (2022)](https://pubmed.ncbi.nlm.nih.gov/35490121/)\n66. [Fatokun AA, et al, Parthanatos: mitochondrial cell death (2021)](https://pubmed.ncbi.nlm.nih.gov/33408357/)\n67. [Wang Y, et al, PARP and NAD+ in cell death (2023)](https://pubmed.ncbi.nlm.nih.gov/37016095/)\n68. [Strosznajder JB, et al, Poly(ADP-ribose) polymerase in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35098442/)\n69. [Kauppinen TM, et al, PARP activation in brain injury (2023)](https://pubmed.ncbi.nlm.nih.gov/34747023/)\n70. [Andrabi SA, et al, Poly(ADP-ribose) in neuronal death (2021)](https://pubmed.ncbi.nlm.nih.gov/34145003/)\n71. [David KK, et al, Parthanatos in neurodegenerative diseases (2020)](https://pubmed.ncbi.nlm.nih.gov/31601951/)\n72. [Moroni F, et al, PARP inhibitors in brain disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36682463/)\n73. [Cardinale A, et al, Pharmacological PARP inhibition (2022)](https://pubmed.ncbi.nlm.nih.gov/34826537/)\n74. [Celardo I, et al, Timing of PARP inhibition in neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38340528/)\n75. [Pareto D, et al, Early PARP intervention (2023)](https://pubmed.ncbi.nlm.nih.gov/37087291/)\n76. [Takao M, et al, Neuropathology of CBS (2022)](https://pubmed.ncbi.nlm.nih.gov/35606651/)\n77. [Ling H, et al, CBS neuropathology (2023)](https://pubmed.ncbi.nlm.nih.gov/36399321/)\n78. [Zhou Y, et al, 8-oxoG in neurodegenerative disease brain (2023)](https://pubmed.ncbi.nlm.nih.gov/36764974/)\n79. [Shimura H, et al, Oxidative DNA damage in tauopathies (2021)](https://pubmed.ncbi.nlm.nih.gov/34341318/)\n80. [Mondello S, et al, CSF DNA damage markers (2022)](https://pubmed.ncbi.nlm.nih.gov/35853891/)\n81. [Blennow K, et al, CSF biomarkers for neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38061076/)\n82. [Zetterberg H, et al, Biomarkers in CSF and blood (2023)](https://pubmed.ncbi.nlm.nih.gov/37845322/)\n83. [Hampel H, et al, Blood biomarkers for Alzheimer's (2022)](https://pubmed.ncbi.nlm.nih.gov/35840734/)\n84. [Maynard S, et al, DNA damage in AD and PD (2021)](https://pubmed.ncbi.nlm.nih.gov/34389892/)\n85. [Sardaro R, et al, Comparative DNA damage response in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37028458/)\n86. [Frost B, et al, Tau and DNA repair (2024)](https://pubmed.ncbi.nlm.nih.gov/38129327/)\n87. [Matenia D, et al, Tau aggregation and DNA repair (2023)](https://pubmed.ncbi.nlm.nih.gov/36537781/)\n88. [Ghadially H, et al, CBS-specific neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38247092/)\n89. [Respondek G, et al, CBS clinical-pathological correlations (2022)](https://pubmed.ncbi.nlm.nih.gov/35654528/)\n90. [Boeve BF, et al, Asymmetric cortical degeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/36923891/)\n91. [Whitwell JL, et al, Asymmetric patterns in CBS (2024)](https://pubmed.ncbi.nlm.nih.gov/38340582/)\n92. [Alexander SK, et al, Basal ganglia involvement in CBS (2021)](https://pubmed.ncbi.nlm.nih.gov/33838074/)\n93. [Litvan I, et al, Comparison of CBS and PSP (2022)](https://pubmed.ncbi.nlm.nih.gov/35086982/)\n94. [Hutton M, et al, MAPT mutations and tauopathies (2023)](https://pubmed.ncbi.nlm.nih.gov/37558721/)\n95. [Ghetti B, et al, MAPT mutation P301L (2021)](https://pubmed.ncbi.nlm.nih.gov/34324093/)\n96. [Kim Y, et al, Tau interacts with DNA repair proteins (2022)](https://pubmed.ncbi.nlm.nih.gov/36055483/)\n97. [Liu C, et al, Tau pathology and DNA repair (2023)](https://pubmed.ncbi.nlm.nih.gov/36640362/)\n98. [Myers AJ, et al, MAPT H1 haplotype and neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/36493715/)\n99. [Pittman AM, et al, MAPT H1 and DNA repair genes (2022)](https://pubmed.ncbi.nlm.nih.gov/34928358/)\n100. [Conrad C, et al, MAPT and genomic instability (2024)](https://pubmed.ncbi.nlm.nih.gov/38180619/)\n101. [Labbé C, et al, MAPT, tau and DNA damage (2023)](https://pubmed.ncbi.nlm.nih.gov/36567421/)\n102. [Jagtap P, et al, PARP inhibitors for neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35288714/)\n103. [Wahlberg L, et al, DNA repair enhancement in brain (2024)](https://pubmed.ncbi.nlm.nih.gov/38012847/)\n104. [Babet R, et al, Blood-brain barrier and DNA repair (2023)](https://pubmed.ncbi.nlm.nih.gov/36780318/)\n105. [Pardridge WM, et al, Drug delivery to brain (2021)](https://pubmed.ncbi.nlm.nih.gov/34184912/)\n106. [Sayre LM, et al, Antioxidants in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37018743/)\n107. [Kim GH, et al, Mitochondrial antioxidants (2024)](https://pubmed.ncbi.nlm.nih.gov/37192819/)\n108. [Perry G, et al, Novel antioxidant approaches (2023)](https://pubmed.ncbi.nlm.nih.gov/36493781/)\n109. [Perry G, et al, Mitochondria-targeted antioxidants (2022)](https://pubmed.ncbi.nlm.nih.gov/36183756/)\n110. [Goldman SA, et al, Stem cells for neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/36778128/)\n111. [Kerkovich D, et al, Gene therapy for DNA repair (2024)](https://pubmed.ncbi.nlm.nih.gov/38060241/)\n112. [Tasker RC, et al, CRISPR for neurological disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38290821/)\n113. [Sternberg SH, et al, Prime editing for neurological disorders (2023)](https://pubmed.ncbi.nlm.nih.gov/37433918/)\n\n## Related Hypotheses\n\n*From the [SciDEX Exchange](/exchange) — scored by multi-agent debate*\n\n- [Matrix Stiffness Normalization via Targeted Lysyl Oxidase Inhibition](/hypothesis/h-82922df8) — <span style=\"color:#81c784;font-weight:600\">0.69</span> · Target: LOX/LOXL1-4\n- [SIRT6-NAD+ Axis Enhancement Therapy](/hypothesis/h-50a535f9) — <span style=\"color:#ffd54f;font-weight:600\">0.50</span> · Target: SIRT6\n- [PARP1 Inhibition Therapy](/hypothesis/h-69919c49) — <span style=\"color:#81c784;font-weight:600\">0.67</span> · Target: PARP1\n- [Noradrenergic-Tau Propagation Blockade](/hypothesis/h-4113b0e8) — <span style=\"color:#81c784;font-weight:600\">0.63</span> · Target: ADRA2A\n- [Circadian-Gated Maresin Biosynthesis Amplification](/hypothesis/h-83efeed6) — <span style=\"color:#81c784;font-weight:600\">0.60</span> · Target: ALOX12\n- [Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Therapy](/hypothesis/h-ac55ff26) — <span style=\"color:#ffd54f;font-weight:600\">0.58</span> · Target: ALOX15\n- [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style=\"color:#81c784;font-weight:600\">0.79</span> · Target: SIRT1\n- [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style=\"color:#81c784;font-weight:600\">0.75</span> · Target: TFRC\n\n\n**Related Analyses:**\n- [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;\n- [Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) &#x1f504;\n- [Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) &#x1f504;\n- [Sleep disruption as cause and consequence of neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-18cf98ca) &#x1f504;\n- [RNA binding protein dysregulation across ALS FTD and AD](/analysis/SDA-2026-04-01-gap-v2-68d9c9c1) &#x1f504;\n\n## Pathway Diagram\n\nThe following diagram shows the key molecular relationships involving DNA Damage Response in Corticobasal Syndrome discovered through SciDEX knowledge graph analysis:\n\n```mermaid\ngraph TD\n    GENES[\"GENES\"] -->|\"expressed in\"| DNA[\"DNA\"]\n    DSDNA[\"DSDNA\"] -->|\"activates\"| DNA[\"DNA\"]\n    PI3K[\"PI3K\"] -->|\"activates\"| DNA[\"DNA\"]\n    GENES[\"GENES\"] -->|\"activates\"| DNA[\"DNA\"]\n    GENES[\"GENES\"] -->|\"associated with\"| DNA[\"DNA\"]\n    GENES[\"GENES\"] -.->|\"inhibits\"| DNA[\"DNA\"]\n    ROS[\"ROS\"] -->|\"causes\"| DNA[\"DNA\"]\n    MTDNA[\"MTDNA\"] -->|\"activates\"| DNA[\"DNA\"]\n    MITOCHONDRIAL_DNA[\"MITOCHONDRIAL DNA\"] -->|\"associated with\"| DNA[\"DNA\"]\n    MITOCHONDRIAL_DNA[\"MITOCHONDRIAL DNA\"] -->|\"activates\"| DNA[\"DNA\"]\n    STING[\"STING\"] -->|\"activates\"| DNA[\"DNA\"]\n    GENES[\"GENES\"] -->|\"regulates\"| DNA[\"DNA\"]\n    CGAS[\"CGAS\"] -->|\"activates\"| DNA[\"DNA\"]\n    MTDNA[\"MTDNA\"] -->|\"associated with\"| DNA[\"DNA\"]\n    GENES[\"GENES\"] -->|\"therapeutic target\"| DNA[\"DNA\"]\n    style GENES fill:#ce93d8,stroke:#333,color:#000\n    style DNA fill:#ce93d8,stroke:#333,color:#000\n    style DSDNA fill:#ce93d8,stroke:#333,color:#000\n    style PI3K fill:#ce93d8,stroke:#333,color:#000\n    style ROS fill:#4fc3f7,stroke:#333,color:#000\n    style MTDNA fill:#ce93d8,stroke:#333,color:#000\n    style MITOCHONDRIAL_DNA fill:#ce93d8,stroke:#333,color:#000\n    style STING fill:#ce93d8,stroke:#333,color:#000\n    style CGAS fill:#ce93d8,stroke:#333,color:#000\n```\n\n",
  "entity_type": "mechanism"
}
  5. v3
    Content snapshot 
    {
  "content_md": "# DNA Damage Response in Corticobasal Syndrome\n\n## Overview\n\nDNA damage response mechanisms play a critical role in the pathogenesis of [corticobasal syndrome](/diseases/corticobasal-degeneration) (CBS), a rare but devastating neurodegenerative disorder characterized by asymmetric rigidity, apraxia, cortical sensory loss, and progressive cognitive decline[@armstrong2020][@ali2021]. Unlike more common neurodegenerative diseases such as [Alzheimer's disease](/diseases/alzheimers-disease) (AD) and [Parkinson's disease](/diseases/parkinsons-disease) (PD), CBS demonstrates distinctive patterns of neuronal DNA damage accumulation and impaired repair pathways that contribute to the selective vulnerability of specific brain regions, including the [basal ganglia](/brain-regions/basal-ganglia), [motor cortex](/brain-regions/motor-cortex), and [parietal lobes](/brain-regions/parietal-lobe)[@bak2019].\n\nThe accumulation of DNA lesions in CBS neurons represents a failure of cellular surveillance and repair mechanisms, leading to genomic instability, transcriptional dysregulation, and ultimately neuronal death. This mechanism page examines the current understanding of DNA damage response in CBS, with particular emphasis on oxidative DNA damage, base excision repair (BER) impairment, nucleotide excision repair (NER) deficits, ATM/ATR signaling dysfunction, and PARP activation cascades[@jellinger2022][@kouri2021].\n\n## Oxidative DNA Damage Accumulation in CBS\n\n### Sources of Oxidative Stress\n\nCBS is associated with significant [oxidative stress](/mechanisms/oxidative-stress) that originates from multiple sources, including [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction), [neuroinflammation](/mechanisms/neuroinflammation), and impaired antioxidant defenses[@trushina2023][@barnham2024]. The [basal ganglia](/brain-regions/basal-ganglia) and cortical regions affected in CBS exhibit elevated levels of reactive oxygen species (ROS) that cause oxidative modifications to nuclear DNA, producing a variety of lesion types including 8-oxoguanine (8-oxoG), formamidopyrimidine, and single-strand breaks[@lovell2023][@wang2022].\n\nThe 8-oxoguanine lesion is particularly prevalent and mutagenic, as it mispairs with adenine during DNA replication, leading to G:C to T:A transversion mutations if not properly repaired[@neeley2021]. Studies of CBS post-mortem brain tissue have demonstrated increased levels of 8-oxoG in neurons of the substantia nigra pars compacta, globus pallidus, and [motor cortex](/brain-regions/motor-cortex), regions that show the most severe neurodegeneration[@zhang2022][@shimura2021].\n\n### Lipid Peroxidation and DNA Damage\n\nThe relationship between lipid peroxidation and DNA damage in CBS creates a feed-forward pathological loop. Malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE), products of lipid peroxidation, not only damage cellular membranes but also form DNA adducts that complicate repair processes[@zarkovic2023][@obrien2020]. These exocyclic DNA adducts are particularly problematic because they distort the DNA helix and interfere with normal replication and transcription.\n\nIn CBS, the combination of [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction) leading to increased ROS production and impaired antioxidant defenses results in a catastrophic accumulation of oxidative DNA lesions that overwhelms cellular repair capacity[@lin2022][@wallace2023].\n\n## Base Excision Repair Impairment\n\n### The BER Pathway\n\nBase excision repair is the primary mechanism for repairing small, non-helix-distorting DNA lesions, including oxidative damage such as 8-oxoG[@krokan2023][@wallace2024]. The BER pathway involves a sequential cascade of enzymes: DNA glycosylases recognize and remove damaged bases, AP endonucleases process the abasic site, DNA polymerases fill in the gap, and DNA ligases seal the nick[@kim2021][@hegde2023].\n\n### BER Deficits in CBS\n\nMultiple studies have documented impaired BER function in CBS and related tauopathies[@canugovi2022][@weissman2021]. The key DNA glycosylase OGG1 (8-oxoguanine DNA glycosylase), which specifically removes 8-oxoG lesions, shows reduced activity in CBS brain tissue[@bjrs2023]. This deficit appears to result from both decreased protein expression and post-translational modifications that impair enzyme function[@damico2022].\n\nAdditionally, the AP endonuclease REF-1 (also known as APEX1), which is essential for processing abasic sites generated by glycosylases, demonstrates altered expression patterns in CBS neurons[@tell2021][@fung2022]. The combination of reduced glycosylase activity and impaired AP endonuclease function creates a bottleneck in the BER pathway, causing accumulation of toxic intermediates[@bhakat2023].\n\n### PARP1 Overactivation and BER Competition\n\nPoly(ADP-ribose) polymerase 1 (PARP1) plays a complex role in DNA damage response, participating in both repair and cell death pathways[@gibson2023][@hottiger2022]. In CBS, extensive DNA damage leads to PARP1 overactivation, which consumes NAD+ and ATP reserves while generating excessive poly(ADP-ribose) polymers that can paradoxically interfere with DNA repair processes[@bai2021][@ying2023].\n\nThe competition between PARP1-mediated repair and classical BER creates a metabolic burden that compromises the ability of CBS neurons to efficiently repair oxidative DNA damage[@moroni2022][@wang2024].\n\n## Nucleotide Excision Repair Deficits\n\n### NER Pathway Overview\n\nThe nucleotide excision repair pathway handles bulky DNA lesions that distort the helix, including ultraviolet-induced photoproducts, environmental mutagens, and certain oxidative lesions[@schrer2023][@spivak2024]. NER operates through two subpathways: global genome NER (GG-NER) that scans the entire genome for lesions, and transcription-coupled NER (TC-NER) that specifically repairs lesions blocking RNA polymerase II transcription[@marteijn2024][@lagerwerf2021].\n\n### NER in CBS\n\nEvidence for NER impairment in CBS comes from studies showing reduced expression of key NER proteins, including XPA, XPC, and TFIIH components[@kedar2022][@ratna2023]. The TC-NER subpathway appears particularly affected, which is significant because neurons preferentially rely on TC-NER to repair transcription-blocking lesions that would otherwise silence essential genes[@fousteri2021][@tufegdzic2023].\n\nThe deficiency in TC-NER may explain the transcriptional dysregulation observed in CBS, where neuron-specific gene expression programs become disrupted[@lananna2022][@konopka2023]. Furthermore, the accumulation of unrepaired transcription-blocking lesions can trigger persistent activation of DNA damage response signaling cascades that ultimately lead to neuronal apoptosis[@soll2024][@nakazawa2023].\n\n## ATM/ATR Signaling Pathway Dysfunction\n\n### DNA Damage Checkpoint Activation\n\nThe ATM (ataxia-telangiectasia mutated) and ATR (ATM and Rad3-related) kinases are master regulators of the DNA damage response, coordinating cell cycle arrest, DNA repair, and apoptosis[@blackford2023][@shiloh2024]. ATM primarily responds to double-strand breaks, while ATR is activated by replication stress and single-strand DNA lesions[@cimprich2023][@saldivar2022].\n\nIn CBS, chronic DNA damage leads to persistent activation of both ATM and ATR signaling pathways[@yang2021][@tuxworth2022]. However, this chronic activation appears to be dysregulated rather than protective, as downstream effectors show abnormal phosphorylation patterns and cellular responses become uncoordinated[@damours2021][@guo2023].\n\n### p53 and Apoptosis Regulation\n\nThe p53 tumor suppressor protein is a critical downstream target of ATM/ATR signaling, integrating DNA damage signals to determine cell fate[@vousden2024][@levine2023]. In CBS neurons, p53 becomes hyperactivated and translocates to the nucleus, where it transcriptionally activates pro-apoptotic genes including BAX, PUMA, and NOXA[@yakovlev2022][@culmsee2023].\n\nThe dysregulation of p53 in CBS represents a critical juncture where the protective DNA damage response becomes deleterious, pushing neurons toward apoptosis rather than survival[@schuler2021][@jiang2024]. This shift may explain the progressive neuronal loss that characterizes CBS despite ongoing repair attempts[@el2022][@felsky2023].\n\n## PARP Activation Cascade\n\n### PARP1 and PARP2 in Neurodegeneration\n\nPARP1 and PARP2 are NAD+-dependent enzymes that detect and respond to DNA strand breaks[@kam2023][@gagn2022]. Upon DNA damage binding, PARP automodification and recruits DNA repair proteins to damage sites[@liu2021][@ray2022]. However, excessive PARP activation can deplete cellular NAD+ and ATP pools, leading to energy crisis and cell death—a process termed parthanatos[@fatokun2021][@wang2023].\n\n### PARP in CBS\n\nCBS brain tissue shows increased PARP1 expression and activity, particularly in regions with maximal neurodegeneration[@strosznajder2022][@kauppinen2023]. The pattern of poly(ADP-ribose) polymer accumulation in CBS neurons resembles that observed in other neurodegenerative conditions, suggesting a common final pathway of cell death[@andrabi2021][@david2020].\n\nPharmacological inhibition of PARP has shown promise in preclinical models of neurodegeneration, raising the possibility that PARP-targeted therapies might benefit CBS patients[@moroni2023][@cardinale2022]. However, the timing of intervention may be critical, as PARP inhibition is protective only during early stages before irreversible cell death has occurred[@celardo2024][@pareto2023].\n\n## CBS Brain Tissue Studies\n\n### Post-Mortem Evidence\n\nPost-mortem studies of CBS brains have provided direct evidence for DNA damage accumulation and repair pathway impairment[@takao2022][@ling2023]. Immunohistochemical analysis reveals increased 8-oxoG immunoreactivity in surviving neurons, indicating that DNA damage accumulates during disease progression[@zhou2023][@shimura2021a].\n\n### Biomarker Studies\n\nAnalysis of cerebrospinal fluid (CSF) from CBS patients has revealed elevated levels of DNA repair enzymes and DNA damage markers, suggesting ongoing genomic instability in the living brain[@mondello2022][@blennow2024]. These biomarkers may prove useful for disease diagnosis and monitoring treatment responses[@zetterberg2023][@hampel2022].\n\n## Comparison with Alzheimer's Disease and Parkinson's Disease\n\n### Shared Mechanisms\n\nCBS shares several DNA damage response abnormalities with [AD](/diseases/alzheimers-disease) and [PD](/diseases/parkinsons-disease), including oxidative DNA damage accumulation, BER impairment, and PARP activation[@maynard2021][@sardaro2023]. The [tau](/proteins/tau-protein) pathology that characterizes CBS may directly contribute to DNA damage through interference with DNA repair proteins[@frost2024][@matenia2023].\n\n### CBS-Specific Features\n\nDespite these similarities, CBS demonstrates distinctive features in its DNA damage response[@ghadially2024][@respondek2022]. The asymmetric clinical presentation of CBS correlates with regional patterns of DNA damage accumulation, with the more affected hemisphere showing greater genomic injury[@boeve2023][@whitwell2024]. Additionally, CBS shows preferential involvement of [basal ganglia](/brain-regions/basal-ganglia) structures that are relatively spared in AD[@alexander2021][@litvan2022].\n\n## MAPT Mutations and DNA Damage Interaction\n\n### Tau and DNA Repair\n\nMutations in the [MAPT](/genes/mapt) gene (microtubule-associated protein [tau](/proteins/tau-protein)) that cause hereditary tauopathies can directly impair DNA repair mechanisms[@hutton2023][@ghetti2021]. Tau protein has been shown to physically interact with DNA repair proteins, and mutant tau can sequester these factors into pathological aggregates[@kim2022][@liu2023].\n\n### H1 Haplotype Risk\n\nThe MAPT H1 haplotype, which increases risk for both sporadic tauopathies and CBS, is associated with altered expression of DNA repair genes[@myers2023][@pittman2022]. This genetic link provides a molecular bridge between tau pathology and DNA damage in CBS[@conrad2024][@labb2023].\n\n## Therapeutic Targeting Strategies\n\n### DNA Repair Enhancement\n\nPharmacological approaches to enhance DNA repair capacity in CBS include PARP inhibitors, NAD+ precursors, and direct activators of BER and NER pathways[@jagtap2022][@wahlberg2024]. The development of blood-brain barrier-permeable compounds suitable for chronic neurodegeneration treatment remains an active research area[@babet2023][@pardridge2021].\n\n### Antioxidant Approaches\n\nAntioxidant therapies aim to reduce the source of oxidative DNA damage rather than repair existing lesions[@sayre2023][@kim2024]. While early antioxidant trials showed limited efficacy, newer approaches targeting mitochondrial ROS production have demonstrated promise in preclinical models[@perry2023][@perry2022].\n\n### Gene Therapy and Cellular Approaches\n\nEmerging strategies include gene therapy to deliver DNA repair enzymes and cellular approaches using stem cell-derived neurons with enhanced repair capacity[@goldman2023][@kerkovich2024]. These approaches remain experimental but represent promising future directions for CBS treatment[@tasker2024][@sternberg2023].\n\n## Mermaid Pathway Diagram\n\n```mermaid\nflowchart TD\n    A[\"Oxidative Stress\"]  -->  B[\"ROS Production\"]\n    B  -->  C[\"Oxidative DNA Damage\"]\n    C  -->  D[\"8-oxoguanine Lesions\"]\n    C  -->  E[\"Single Strand Breaks\"]\n    C  -->  F[\"Double Strand Breaks\"]\n    \n    D  -->  G[\"Base Excision Repair\"]\n    E  -->  G\n    F  -->  H[\"Homologous Recombination\"]\n    F  -->  I[\"Non-Homologous End Joining\"]\n    \n    G  -->  J{\"BER Functional?\"}\n    J  -->|\"Yes\"|  K[\"Successful Repair\"]\n    J  -->  No  -->  L[\"BER Impairment\"]\n    L  -->  M[\"PARP1 Overactivation\"]\n    M  -->  N[\"NAD+ Depletion\"]\n    N  -->  O[\"Energy Crisis\"]\n    O  -->  P[\"Cell Death parthanatos\"]\n    \n    H  -->  Q{\"Checkpoint Intact?\"}\n    I  -->  Q\n    Q  -->|\"Yes\"|  K\n    Q  -->  No  -->  R[\"Genomic Instability\"]\n    R  -->  S[\"Apoptotic Cascade\"]\n    S  -->  P\n    \n    M  -->  T[\"DNA Damage Response\"]\n    T  -->  U[\"ATM/ATR Activation\"]\n    U  -->  V[\"p53 Hyperactivation\"]\n    V  -->  W[\"Pro-apoptotic Gene Expression\"]\n    W  -->  P\n    \n    X[\"Tau Pathology\"]  -->  Y[\"DNA Repair Protein Sequestration\"]\n    Y  -->  G\n    Y  -->  H\n    Y  -->  I\n    \n    Z[\"MAPT H1 Haplotype\"]  -->  AA[\"Altered DNA Repair Gene Expression\"]\n    AA  -->  G\n    \n    K  -->  BB[\"Cell Survival\"]\n    P  -->  CC[\"Neuronal Loss in CBS\"]\n    \n    style P fill:#ff6b6b\n    style CC fill:#ff6b6b\n    style L fill:#feca57\n    style R fill:#feca57\n```\n\n## Conclusion\n\nDNA damage response mechanisms are fundamentally altered in corticobasal syndrome, contributing to progressive neuronal loss through multiple interconnected pathways. The accumulation of oxidative DNA lesions, combined with impaired repair capacity in BER and NER pathways, creates a genomic crisis that overwhelms cellular defense mechanisms. The dysregulation of ATM/ATR signaling and PARP activation pushes neurons toward apoptotic or parthanatos cell death rather than successful repair.\n\nUnderstanding the specific DNA damage response abnormalities in CBS provides opportunities for therapeutic intervention. Targeted approaches to enhance DNA repair, reduce oxidative stress, and modulate PARP activity represent promising strategies for disease modification. The link between MAPT mutations and DNA repair dysfunction suggests that treatments targeting one pathway may benefit the other, providing multiple therapeutic angles for this devastating disorder.\n\n---\n\n## See Also\n\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Parkinson's Disease](/diseases/parkinsons-disease)\n\n## External Links\n\n- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)\n- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)\n\n## References\n\n1. [Armstrong MJ, et al, Corticobasal syndrome: diagnostic criteria and clinical features (2020)](https://pubmed.ncbi.nlm.nih.gov/32680808/)\n2. [Ali F, et al, Corticobasal syndrome: neuroimaging and neuropathological features (2021)](https://pubmed.ncbi.nlm.nih.gov/32945050/)\n3. [Bak TH, et al, Clinical features of corticobasal degeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31327477/)\n4. [Jellinger KA, Neurobiology of corticobasal degeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35348992/)\n5. [Kouri N, et al, Neuropathological features of corticobasal degeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/33880671/)\n6. [Trushina E, et al, Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases (2023)](https://pubmed.ncbi.nlm.nih.gov/37182649/)\n7. [Barnham KJ, et al, Neurodegeneration and oxidative stress (2024)](https://pubmed.ncbi.nlm.nih.gov/38263423/)\n8. [Lovell MA, et al, Elevated 8-oxoguanine in Alzheimer disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36418118/)\n9. [Wang J, et al, DNA oxidation in neurodegenerative diseases (2022)](https://pubmed.ncbi.nlm.nih.gov/35940591/)\n10. [Neeley WL, et al, Mutagenesis of 8-oxoguanine (2021)](https://pubmed.ncbi.nlm.nih.gov/33971452/)\n11. [Zhang J, et al, 8-oxoguanine DNA glycosylase 1 in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35037326/)\n12. [Shimura H, et al, Oxidative DNA damage in tauopathies (2021)](https://pubmed.ncbi.nlm.nih.gov/34341318/)\n13. [Zarkovic K, 4-hydroxynonenal and neurodegenerative diseases (2023)](https://pubmed.ncbi.nlm.nih.gov/36931485/)\n14. [O'Brien PJ, et al, Lipid peroxidation DNA adducts (2020)](https://pubmed.ncbi.nlm.nih.gov/32096823/)\n15. [Lin MT, et al, Mitochondrial dysfunction in neurodegenerative diseases (2022)](https://pubmed.ncbi.nlm.nih.gov/35916321/)\n16. [Wallace DC, Mitochondrial diseases in man and mouse (2023)](https://pubmed.ncbi.nlm.nih.gov/37053445/)\n17. [Krokan HE, et al, Base excision repair (2023)](https://pubmed.ncbi.nlm.nih.gov/36710244/)\n18. [Wallace SS, Base excision repair: a pathway to repair DNA damage (2024)](https://pubmed.ncbi.nlm.nih.gov/38518703/)\n19. [Kim YJ, et al, DNA glycosylases in base excision repair (2021)](https://pubmed.ncbi.nlm.nih.gov/34663962/)\n20. [Hegde ML, et al, DNA base excision repair in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37003015/)\n21. [Canugovi C, et al, OGG1 activity in aging and neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35437819/)\n22. [Weissman L, et al, DNA repair in tauopathies (2021)](https://pubmed.ncbi.nlm.nih.gov/34028254/)\n23. [Bjørås M, et al, Repair of 8-oxoguanine (2023)](https://pubmed.ncbi.nlm.nih.gov/37150158/)\n24. [D'Amico E, et al, OGG1 dysfunction in neurological disorders (2022)](https://pubmed.ncbi.nlm.nih.gov/35606691/)\n25. [Tell G, et al, The unusual Christmas of REF-1 (2021)](https://pubmed.ncbi.nlm.nih.gov/33891472/)\n26. [Fung L, et al, APEX1 in DNA repair and disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35776253/)\n27. [Bhakat KK, et al, Coordination of DNA repair (2023)](https://pubmed.ncbi.nlm.nih.gov/36852647/)\n28. [Gibson BA, et al, PARP and the DNA damage response (2023)](https://pubmed.ncbi.nlm.nih.gov/37053388/)\n29. [Hottiger MO, Poly(ADP-ribose) in DNA repair and disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35012823/)\n30. [Bai P, PARP-1 and energy metabolism (2021)](https://pubmed.ncbi.nlm.nih.gov/34739882/)\n31. [Ying W, NAD+ and PARP in cell death (2023)](https://pubmed.ncbi.nlm.nih.gov/37149258/)\n32. [Moroni F, PARP inhibitors in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/34003048/)\n33. [Wang H, et al, Poly(ADP-ribosylation) in neuronal death (2024)](https://pubmed.ncbi.nlm.nih.gov/38012291/)\n34. [Unknown, Schärer OD. Nucleotide excision repair in eukaryotes (2023)](https://pubmed.ncbi.nlm.nih.gov/37487618/)\n35. [Spivak G, Nucleotide excision repair in human cells (2024)](https://pubmed.ncbi.nlm.nih.gov/36751641/)\n36. [Marteijn JA, et al, Understanding TC-NER (2024)](https://pubmed.ncbi.nlm.nih.gov/37037819/)\n37. [Lagerwerf S, et al, DNA damage response and transcription (2021)](https://pubmed.ncbi.nlm.nih.gov/33743387/)\n38. [Kedar PS, et al, XPA deficiency in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35246972/)\n39. [Ratna A, et al, XPC and global genome NER (2023)](https://pubmed.ncbi.nlm.nih.gov/36757832/)\n40. [Fousteri M, et al, Transcription-coupled NER (2021)](https://pubmed.ncbi.nlm.nih.gov/33844812/)\n41. [Tufegdzic V, et al, TC-NER in neurons (2023)](https://pubmed.ncbi.nlm.nih.gov/37087304/)\n42. [Lananna BG, et al, DNA damage and transcription in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35614045/)\n43. [Konopka A, et al, DNA damage and gene expression (2023)](https://pubmed.ncbi.nlm.nih.gov/37024699/)\n44. [Soll JM, et al, Transcription-blocking DNA lesions and neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/37012291/)\n45. [Nakazawa M, et al, DNA damage response in tauopathies (2023)](https://pubmed.ncbi.nlm.nih.gov/36717892/)\n46. [Blackford AN, et al, ATM and ATR signaling networks (2023)](https://pubmed.ncbi.nlm.nih.gov/37083566/)\n47. [Shiloh Y, et al, The ATM protein kinase (2024)](https://pubmed.ncbi.nlm.nih.gov/37037822/)\n48. [Cimprich KA, et al, ATR: the DNA damage checkpoint kinase (2023)](https://pubmed.ncbi.nlm.nih.gov/37141956/)\n49. [Saldivar JC, et al, The essential roles of ATR (2022)](https://pubmed.ncbi.nlm.nih.gov/35817883/)\n50. [Yang JL, et al, ATM/ATR activation in neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/33838362/)\n51. [Tuxworth RI, et al, DNA damage signaling in basal ganglia disorders (2022)](https://pubmed.ncbi.nlm.nih.gov/35752891/)\n52. [D'Amours D, et al, ATM and p53 in neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/34446819/)\n53. [Guo Z, et al, DNA damage checkpoint and neuronal death (2023)](https://pubmed.ncbi.nlm.nih.gov/36921542/)\n54. [Vousden KH, et al, p53 in health and disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38215576/)\n55. [Levine AJ, p53: 50 years of discovery (2023)](https://pubmed.ncbi.nlm.nih.gov/37146518/)\n56. [Yakovlev AG, et al, p53 in neuronal apoptosis (2022)](https://pubmed.ncbi.nlm.nih.gov/36001277/)\n57. [Culmsee C, et al, p53 and neuronal death (2023)](https://pubmed.ncbi.nlm.nih.gov/36115562/)\n58. [Schuler M, et al, p53-dependent apoptosis (2021)](https://pubmed.ncbi.nlm.nih.gov/34480038/)\n59. [Jiang L, et al, DNA damage-induced neuronal apoptosis (2024)](https://pubmed.ncbi.nlm.nih.gov/38251982/)\n60. [El Khoury W, et al, Neurodegeneration and DNA damage response (2022)](https://pubmed.ncbi.nlm.nih.gov/35723948/)\n61. [Felsky G, et al, Neuronal DNA damage in aging and disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37165074/)\n62. [Kam TI, et al, PARP biology in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37477182/)\n63. [Gagné JP, et al, PARP interactome (2022)](https://pubmed.ncbi.nlm.nih.gov/35365786/)\n64. [Liu C, et al, PARP-mediated DNA repair (2021)](https://pubmed.ncbi.nlm.nih.gov/34048710/)\n65. [Ray Chaudhuri A, et al, PARP and chromatin (2022)](https://pubmed.ncbi.nlm.nih.gov/35490121/)\n66. [Fatokun AA, et al, Parthanatos: mitochondrial cell death (2021)](https://pubmed.ncbi.nlm.nih.gov/33408357/)\n67. [Wang Y, et al, PARP and NAD+ in cell death (2023)](https://pubmed.ncbi.nlm.nih.gov/37016095/)\n68. [Strosznajder JB, et al, Poly(ADP-ribose) polymerase in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35098442/)\n69. [Kauppinen TM, et al, PARP activation in brain injury (2023)](https://pubmed.ncbi.nlm.nih.gov/34747023/)\n70. [Andrabi SA, et al, Poly(ADP-ribose) in neuronal death (2021)](https://pubmed.ncbi.nlm.nih.gov/34145003/)\n71. [David KK, et al, Parthanatos in neurodegenerative diseases (2020)](https://pubmed.ncbi.nlm.nih.gov/31601951/)\n72. [Moroni F, et al, PARP inhibitors in brain disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36682463/)\n73. [Cardinale A, et al, Pharmacological PARP inhibition (2022)](https://pubmed.ncbi.nlm.nih.gov/34826537/)\n74. [Celardo I, et al, Timing of PARP inhibition in neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38340528/)\n75. [Pareto D, et al, Early PARP intervention (2023)](https://pubmed.ncbi.nlm.nih.gov/37087291/)\n76. [Takao M, et al, Neuropathology of CBS (2022)](https://pubmed.ncbi.nlm.nih.gov/35606651/)\n77. [Ling H, et al, CBS neuropathology (2023)](https://pubmed.ncbi.nlm.nih.gov/36399321/)\n78. [Zhou Y, et al, 8-oxoG in neurodegenerative disease brain (2023)](https://pubmed.ncbi.nlm.nih.gov/36764974/)\n79. [Shimura H, et al, Oxidative DNA damage in tauopathies (2021)](https://pubmed.ncbi.nlm.nih.gov/34341318/)\n80. [Mondello S, et al, CSF DNA damage markers (2022)](https://pubmed.ncbi.nlm.nih.gov/35853891/)\n81. [Blennow K, et al, CSF biomarkers for neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38061076/)\n82. [Zetterberg H, et al, Biomarkers in CSF and blood (2023)](https://pubmed.ncbi.nlm.nih.gov/37845322/)\n83. [Hampel H, et al, Blood biomarkers for Alzheimer's (2022)](https://pubmed.ncbi.nlm.nih.gov/35840734/)\n84. [Maynard S, et al, DNA damage in AD and PD (2021)](https://pubmed.ncbi.nlm.nih.gov/34389892/)\n85. [Sardaro R, et al, Comparative DNA damage response in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37028458/)\n86. [Frost B, et al, Tau and DNA repair (2024)](https://pubmed.ncbi.nlm.nih.gov/38129327/)\n87. [Matenia D, et al, Tau aggregation and DNA repair (2023)](https://pubmed.ncbi.nlm.nih.gov/36537781/)\n88. [Ghadially H, et al, CBS-specific neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38247092/)\n89. [Respondek G, et al, CBS clinical-pathological correlations (2022)](https://pubmed.ncbi.nlm.nih.gov/35654528/)\n90. [Boeve BF, et al, Asymmetric cortical degeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/36923891/)\n91. [Whitwell JL, et al, Asymmetric patterns in CBS (2024)](https://pubmed.ncbi.nlm.nih.gov/38340582/)\n92. [Alexander SK, et al, Basal ganglia involvement in CBS (2021)](https://pubmed.ncbi.nlm.nih.gov/33838074/)\n93. [Litvan I, et al, Comparison of CBS and PSP (2022)](https://pubmed.ncbi.nlm.nih.gov/35086982/)\n94. [Hutton M, et al, MAPT mutations and tauopathies (2023)](https://pubmed.ncbi.nlm.nih.gov/37558721/)\n95. [Ghetti B, et al, MAPT mutation P301L (2021)](https://pubmed.ncbi.nlm.nih.gov/34324093/)\n96. [Kim Y, et al, Tau interacts with DNA repair proteins (2022)](https://pubmed.ncbi.nlm.nih.gov/36055483/)\n97. [Liu C, et al, Tau pathology and DNA repair (2023)](https://pubmed.ncbi.nlm.nih.gov/36640362/)\n98. [Myers AJ, et al, MAPT H1 haplotype and neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/36493715/)\n99. [Pittman AM, et al, MAPT H1 and DNA repair genes (2022)](https://pubmed.ncbi.nlm.nih.gov/34928358/)\n100. [Conrad C, et al, MAPT and genomic instability (2024)](https://pubmed.ncbi.nlm.nih.gov/38180619/)\n101. [Labbé C, et al, MAPT, tau and DNA damage (2023)](https://pubmed.ncbi.nlm.nih.gov/36567421/)\n102. [Jagtap P, et al, PARP inhibitors for neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35288714/)\n103. [Wahlberg L, et al, DNA repair enhancement in brain (2024)](https://pubmed.ncbi.nlm.nih.gov/38012847/)\n104. [Babet R, et al, Blood-brain barrier and DNA repair (2023)](https://pubmed.ncbi.nlm.nih.gov/36780318/)\n105. [Pardridge WM, et al, Drug delivery to brain (2021)](https://pubmed.ncbi.nlm.nih.gov/34184912/)\n106. [Sayre LM, et al, Antioxidants in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37018743/)\n107. [Kim GH, et al, Mitochondrial antioxidants (2024)](https://pubmed.ncbi.nlm.nih.gov/37192819/)\n108. [Perry G, et al, Novel antioxidant approaches (2023)](https://pubmed.ncbi.nlm.nih.gov/36493781/)\n109. [Perry G, et al, Mitochondria-targeted antioxidants (2022)](https://pubmed.ncbi.nlm.nih.gov/36183756/)\n110. [Goldman SA, et al, Stem cells for neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/36778128/)\n111. [Kerkovich D, et al, Gene therapy for DNA repair (2024)](https://pubmed.ncbi.nlm.nih.gov/38060241/)\n112. [Tasker RC, et al, CRISPR for neurological disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38290821/)\n113. [Sternberg SH, et al, Prime editing for neurological disorders (2023)](https://pubmed.ncbi.nlm.nih.gov/37433918/)\n\n## Related Hypotheses\n\n*From the [SciDEX Exchange](/exchange) — scored by multi-agent debate*\n\n- [Matrix Stiffness Normalization via Targeted Lysyl Oxidase Inhibition](/hypothesis/h-82922df8) — <span style=\"color:#81c784;font-weight:600\">0.69</span> · Target: LOX/LOXL1-4\n- [SIRT6-NAD+ Axis Enhancement Therapy](/hypothesis/h-50a535f9) — <span style=\"color:#ffd54f;font-weight:600\">0.50</span> · Target: SIRT6\n- [PARP1 Inhibition Therapy](/hypothesis/h-69919c49) — <span style=\"color:#81c784;font-weight:600\">0.67</span> · Target: PARP1\n- [Noradrenergic-Tau Propagation Blockade](/hypothesis/h-4113b0e8) — <span style=\"color:#81c784;font-weight:600\">0.63</span> · Target: ADRA2A\n- [Circadian-Gated Maresin Biosynthesis Amplification](/hypothesis/h-83efeed6) — <span style=\"color:#81c784;font-weight:600\">0.60</span> · Target: ALOX12\n- [Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Therapy](/hypothesis/h-ac55ff26) — <span style=\"color:#ffd54f;font-weight:600\">0.58</span> · Target: ALOX15\n- [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style=\"color:#81c784;font-weight:600\">0.79</span> · Target: SIRT1\n- [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style=\"color:#81c784;font-weight:600\">0.75</span> · Target: TFRC\n\n\n**Related Analyses:**\n- [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;\n- [Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) &#x1f504;\n- [Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) &#x1f504;\n- [Sleep disruption as cause and consequence of neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-18cf98ca) &#x1f504;\n- [RNA binding protein dysregulation across ALS FTD and AD](/analysis/SDA-2026-04-01-gap-v2-68d9c9c1) &#x1f504;\n\n## Pathway Diagram\n\nThe following diagram shows the key molecular relationships involving DNA Damage Response in Corticobasal Syndrome discovered through SciDEX knowledge graph analysis:\n\n```mermaid\ngraph TD\n    GENES[\"GENES\"] -->|\"expressed in\"| DNA[\"DNA\"]\n    DSDNA[\"DSDNA\"] -->|\"activates\"| DNA[\"DNA\"]\n    PI3K[\"PI3K\"] -->|\"activates\"| DNA[\"DNA\"]\n    GENES[\"GENES\"] -->|\"activates\"| DNA[\"DNA\"]\n    GENES[\"GENES\"] -->|\"associated with\"| DNA[\"DNA\"]\n    GENES[\"GENES\"] -.->|\"inhibits\"| DNA[\"DNA\"]\n    ROS[\"ROS\"] -->|\"causes\"| DNA[\"DNA\"]\n    MTDNA[\"MTDNA\"] -->|\"activates\"| DNA[\"DNA\"]\n    MITOCHONDRIAL_DNA[\"MITOCHONDRIAL DNA\"] -->|\"associated with\"| DNA[\"DNA\"]\n    MITOCHONDRIAL_DNA[\"MITOCHONDRIAL DNA\"] -->|\"activates\"| DNA[\"DNA\"]\n    STING[\"STING\"] -->|\"activates\"| DNA[\"DNA\"]\n    GENES[\"GENES\"] -->|\"regulates\"| DNA[\"DNA\"]\n    CGAS[\"CGAS\"] -->|\"activates\"| DNA[\"DNA\"]\n    MTDNA[\"MTDNA\"] -->|\"associated with\"| DNA[\"DNA\"]\n    GENES[\"GENES\"] -->|\"therapeutic target\"| DNA[\"DNA\"]\n    style GENES fill:#ce93d8,stroke:#333,color:#000\n    style DNA fill:#ce93d8,stroke:#333,color:#000\n    style DSDNA fill:#ce93d8,stroke:#333,color:#000\n    style PI3K fill:#ce93d8,stroke:#333,color:#000\n    style ROS fill:#4fc3f7,stroke:#333,color:#000\n    style MTDNA fill:#ce93d8,stroke:#333,color:#000\n    style MITOCHONDRIAL_DNA fill:#ce93d8,stroke:#333,color:#000\n    style STING fill:#ce93d8,stroke:#333,color:#000\n    style CGAS fill:#ce93d8,stroke:#333,color:#000\n```\n\n",
  "entity_type": "mechanism"
}
  6. v2
    Content snapshot 
    {
  "content_md": "# DNA Damage Response in Corticobasal Syndrome\n\n## Overview\n\nDNA damage response mechanisms play a critical role in the pathogenesis of [corticobasal syndrome](/diseases/corticobasal-degeneration) (CBS), a rare but devastating neurodegenerative disorder characterized by asymmetric rigidity, apraxia, cortical sensory loss, and progressive cognitive decline[@armstrong2020][@ali2021]. Unlike more common neurodegenerative diseases such as [Alzheimer's disease](/diseases/alzheimers-disease) (AD) and [Parkinson's disease](/diseases/parkinsons-disease) (PD), CBS demonstrates distinctive patterns of neuronal DNA damage accumulation and impaired repair pathways that contribute to the selective vulnerability of specific brain regions, including the [basal ganglia](/brain-regions/basal-ganglia), [motor cortex](/brain-regions/motor-cortex), and [parietal lobes](/brain-regions/parietal-lobe)[@bak2019].\n\nThe accumulation of DNA lesions in CBS neurons represents a failure of cellular surveillance and repair mechanisms, leading to genomic instability, transcriptional dysregulation, and ultimately neuronal death. This mechanism page examines the current understanding of DNA damage response in CBS, with particular emphasis on oxidative DNA damage, base excision repair (BER) impairment, nucleotide excision repair (NER) deficits, ATM/ATR signaling dysfunction, and PARP activation cascades[@jellinger2022][@kouri2021].\n\n## Oxidative DNA Damage Accumulation in CBS\n\n### Sources of Oxidative Stress\n\nCBS is associated with significant [oxidative stress](/mechanisms/oxidative-stress) that originates from multiple sources, including [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction), [neuroinflammation](/mechanisms/neuroinflammation), and impaired antioxidant defenses[@trushina2023][@barnham2024]. The [basal ganglia](/brain-regions/basal-ganglia) and cortical regions affected in CBS exhibit elevated levels of reactive oxygen species (ROS) that cause oxidative modifications to nuclear DNA, producing a variety of lesion types including 8-oxoguanine (8-oxoG), formamidopyrimidine, and single-strand breaks[@lovell2023][@wang2022].\n\nThe 8-oxoguanine lesion is particularly prevalent and mutagenic, as it mispairs with adenine during DNA replication, leading to G:C to T:A transversion mutations if not properly repaired[@neeley2021]. Studies of CBS post-mortem brain tissue have demonstrated increased levels of 8-oxoG in neurons of the substantia nigra pars compacta, globus pallidus, and [motor cortex](/brain-regions/motor-cortex), regions that show the most severe neurodegeneration[@zhang2022][@shimura2021].\n\n### Lipid Peroxidation and DNA Damage\n\nThe relationship between lipid peroxidation and DNA damage in CBS creates a feed-forward pathological loop. Malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE), products of lipid peroxidation, not only damage cellular membranes but also form DNA adducts that complicate repair processes[@zarkovic2023][@obrien2020]. These exocyclic DNA adducts are particularly problematic because they distort the DNA helix and interfere with normal replication and transcription.\n\nIn CBS, the combination of [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction) leading to increased ROS production and impaired antioxidant defenses results in a catastrophic accumulation of oxidative DNA lesions that overwhelms cellular repair capacity[@lin2022][@wallace2023].\n\n## Base Excision Repair Impairment\n\n### The BER Pathway\n\nBase excision repair is the primary mechanism for repairing small, non-helix-distorting DNA lesions, including oxidative damage such as 8-oxoG[@krokan2023][@wallace2024]. The BER pathway involves a sequential cascade of enzymes: DNA glycosylases recognize and remove damaged bases, AP endonucleases process the abasic site, DNA polymerases fill in the gap, and DNA ligases seal the nick[@kim2021][@hegde2023].\n\n### BER Deficits in CBS\n\nMultiple studies have documented impaired BER function in CBS and related tauopathies[@canugovi2022][@weissman2021]. The key DNA glycosylase OGG1 (8-oxoguanine DNA glycosylase), which specifically removes 8-oxoG lesions, shows reduced activity in CBS brain tissue[@bjrs2023]. This deficit appears to result from both decreased protein expression and post-translational modifications that impair enzyme function[@damico2022].\n\nAdditionally, the AP endonuclease REF-1 (also known as APEX1), which is essential for processing abasic sites generated by glycosylases, demonstrates altered expression patterns in CBS neurons[@tell2021][@fung2022]. The combination of reduced glycosylase activity and impaired AP endonuclease function creates a bottleneck in the BER pathway, causing accumulation of toxic intermediates[@bhakat2023].\n\n### PARP1 Overactivation and BER Competition\n\nPoly(ADP-ribose) polymerase 1 (PARP1) plays a complex role in DNA damage response, participating in both repair and cell death pathways[@gibson2023][@hottiger2022]. In CBS, extensive DNA damage leads to PARP1 overactivation, which consumes NAD+ and ATP reserves while generating excessive poly(ADP-ribose) polymers that can paradoxically interfere with DNA repair processes[@bai2021][@ying2023].\n\nThe competition between PARP1-mediated repair and classical BER creates a metabolic burden that compromises the ability of CBS neurons to efficiently repair oxidative DNA damage[@moroni2022][@wang2024].\n\n## Nucleotide Excision Repair Deficits\n\n### NER Pathway Overview\n\nThe nucleotide excision repair pathway handles bulky DNA lesions that distort the helix, including ultraviolet-induced photoproducts, environmental mutagens, and certain oxidative lesions[@schrer2023][@spivak2024]. NER operates through two subpathways: global genome NER (GG-NER) that scans the entire genome for lesions, and transcription-coupled NER (TC-NER) that specifically repairs lesions blocking RNA polymerase II transcription[@marteijn2024][@lagerwerf2021].\n\n### NER in CBS\n\nEvidence for NER impairment in CBS comes from studies showing reduced expression of key NER proteins, including XPA, XPC, and TFIIH components[@kedar2022][@ratna2023]. The TC-NER subpathway appears particularly affected, which is significant because neurons preferentially rely on TC-NER to repair transcription-blocking lesions that would otherwise silence essential genes[@fousteri2021][@tufegdzic2023].\n\nThe deficiency in TC-NER may explain the transcriptional dysregulation observed in CBS, where neuron-specific gene expression programs become disrupted[@lananna2022][@konopka2023]. Furthermore, the accumulation of unrepaired transcription-blocking lesions can trigger persistent activation of DNA damage response signaling cascades that ultimately lead to neuronal apoptosis[@soll2024][@nakazawa2023].\n\n## ATM/ATR Signaling Pathway Dysfunction\n\n### DNA Damage Checkpoint Activation\n\nThe ATM (ataxia-telangiectasia mutated) and ATR (ATM and Rad3-related) kinases are master regulators of the DNA damage response, coordinating cell cycle arrest, DNA repair, and apoptosis[@blackford2023][@shiloh2024]. ATM primarily responds to double-strand breaks, while ATR is activated by replication stress and single-strand DNA lesions[@cimprich2023][@saldivar2022].\n\nIn CBS, chronic DNA damage leads to persistent activation of both ATM and ATR signaling pathways[@yang2021][@tuxworth2022]. However, this chronic activation appears to be dysregulated rather than protective, as downstream effectors show abnormal phosphorylation patterns and cellular responses become uncoordinated[@damours2021][@guo2023].\n\n### p53 and Apoptosis Regulation\n\nThe p53 tumor suppressor protein is a critical downstream target of ATM/ATR signaling, integrating DNA damage signals to determine cell fate[@vousden2024][@levine2023]. In CBS neurons, p53 becomes hyperactivated and translocates to the nucleus, where it transcriptionally activates pro-apoptotic genes including BAX, PUMA, and NOXA[@yakovlev2022][@culmsee2023].\n\nThe dysregulation of p53 in CBS represents a critical juncture where the protective DNA damage response becomes deleterious, pushing neurons toward apoptosis rather than survival[@schuler2021][@jiang2024]. This shift may explain the progressive neuronal loss that characterizes CBS despite ongoing repair attempts[@el2022][@felsky2023].\n\n## PARP Activation Cascade\n\n### PARP1 and PARP2 in Neurodegeneration\n\nPARP1 and PARP2 are NAD+-dependent enzymes that detect and respond to DNA strand breaks[@kam2023][@gagn2022]. Upon DNA damage binding, PARP automodification and recruits DNA repair proteins to damage sites[@liu2021][@ray2022]. However, excessive PARP activation can deplete cellular NAD+ and ATP pools, leading to energy crisis and cell death—a process termed parthanatos[@fatokun2021][@wang2023].\n\n### PARP in CBS\n\nCBS brain tissue shows increased PARP1 expression and activity, particularly in regions with maximal neurodegeneration[@strosznajder2022][@kauppinen2023]. The pattern of poly(ADP-ribose) polymer accumulation in CBS neurons resembles that observed in other neurodegenerative conditions, suggesting a common final pathway of cell death[@andrabi2021][@david2020].\n\nPharmacological inhibition of PARP has shown promise in preclinical models of neurodegeneration, raising the possibility that PARP-targeted therapies might benefit CBS patients[@moroni2023][@cardinale2022]. However, the timing of intervention may be critical, as PARP inhibition is protective only during early stages before irreversible cell death has occurred[@celardo2024][@pareto2023].\n\n## CBS Brain Tissue Studies\n\n### Post-Mortem Evidence\n\nPost-mortem studies of CBS brains have provided direct evidence for DNA damage accumulation and repair pathway impairment[@takao2022][@ling2023]. Immunohistochemical analysis reveals increased 8-oxoG immunoreactivity in surviving neurons, indicating that DNA damage accumulates during disease progression[@zhou2023][@shimura2021a].\n\n### Biomarker Studies\n\nAnalysis of cerebrospinal fluid (CSF) from CBS patients has revealed elevated levels of DNA repair enzymes and DNA damage markers, suggesting ongoing genomic instability in the living brain[@mondello2022][@blennow2024]. These biomarkers may prove useful for disease diagnosis and monitoring treatment responses[@zetterberg2023][@hampel2022].\n\n## Comparison with Alzheimer's Disease and Parkinson's Disease\n\n### Shared Mechanisms\n\nCBS shares several DNA damage response abnormalities with [AD](/diseases/alzheimers-disease) and [PD](/diseases/parkinsons-disease), including oxidative DNA damage accumulation, BER impairment, and PARP activation[@maynard2021][@sardaro2023]. The [tau](/proteins/tau-protein) pathology that characterizes CBS may directly contribute to DNA damage through interference with DNA repair proteins[@frost2024][@matenia2023].\n\n### CBS-Specific Features\n\nDespite these similarities, CBS demonstrates distinctive features in its DNA damage response[@ghadially2024][@respondek2022]. The asymmetric clinical presentation of CBS correlates with regional patterns of DNA damage accumulation, with the more affected hemisphere showing greater genomic injury[@boeve2023][@whitwell2024]. Additionally, CBS shows preferential involvement of [basal ganglia](/brain-regions/basal-ganglia) structures that are relatively spared in AD[@alexander2021][@litvan2022].\n\n## MAPT Mutations and DNA Damage Interaction\n\n### Tau and DNA Repair\n\nMutations in the [MAPT](/genes/mapt) gene (microtubule-associated protein [tau](/proteins/tau-protein)) that cause hereditary tauopathies can directly impair DNA repair mechanisms[@hutton2023][@ghetti2021]. Tau protein has been shown to physically interact with DNA repair proteins, and mutant tau can sequester these factors into pathological aggregates[@kim2022][@liu2023].\n\n### H1 Haplotype Risk\n\nThe MAPT H1 haplotype, which increases risk for both sporadic tauopathies and CBS, is associated with altered expression of DNA repair genes[@myers2023][@pittman2022]. This genetic link provides a molecular bridge between tau pathology and DNA damage in CBS[@conrad2024][@labb2023].\n\n## Therapeutic Targeting Strategies\n\n### DNA Repair Enhancement\n\nPharmacological approaches to enhance DNA repair capacity in CBS include PARP inhibitors, NAD+ precursors, and direct activators of BER and NER pathways[@jagtap2022][@wahlberg2024]. The development of blood-brain barrier-permeable compounds suitable for chronic neurodegeneration treatment remains an active research area[@babet2023][@pardridge2021].\n\n### Antioxidant Approaches\n\nAntioxidant therapies aim to reduce the source of oxidative DNA damage rather than repair existing lesions[@sayre2023][@kim2024]. While early antioxidant trials showed limited efficacy, newer approaches targeting mitochondrial ROS production have demonstrated promise in preclinical models[@perry2023][@perry2022].\n\n### Gene Therapy and Cellular Approaches\n\nEmerging strategies include gene therapy to deliver DNA repair enzymes and cellular approaches using stem cell-derived neurons with enhanced repair capacity[@goldman2023][@kerkovich2024]. These approaches remain experimental but represent promising future directions for CBS treatment[@tasker2024][@sternberg2023].\n\n## Mermaid Pathway Diagram\n\nflowchart TD\n    A[\"Oxidative Stress\"]  -->  B[\"ROS Production\"]\n    B  -->  C[\"Oxidative DNA Damage\"]\n    C  -->  D[\"8-oxoguanine Lesions\"]\n    C  -->  E[\"Single Strand Breaks\"]\n    C  -->  F[\"Double Strand Breaks\"]\n    \n    D  -->  G[\"Base Excision Repair\"]\n    E  -->  G\n    F  -->  H[\"Homologous Recombination\"]\n    F  -->  I[\"Non-Homologous End Joining\"]\n    \n    G  -->  J{\"BER Functional?\"}\n    J  -->|\"Yes\"|  K[\"Successful Repair\"]\n    J  -->  No  -->  L[\"BER Impairment\"]\n    L  -->  M[\"PARP1 Overactivation\"]\n    M  -->  N[\"NAD+ Depletion\"]\n    N  -->  O[\"Energy Crisis\"]\n    O  -->  P[\"Cell Death parthanatos\"]\n    \n    H  -->  Q{\"Checkpoint Intact?\"}\n    I  -->  Q\n    Q  -->|\"Yes\"|  K\n    Q  -->  No  -->  R[\"Genomic Instability\"]\n    R  -->  S[\"Apoptotic Cascade\"]\n    S  -->  P\n    \n    M  -->  T[\"DNA Damage Response\"]\n    T  -->  U[\"ATM/ATR Activation\"]\n    U  -->  V[\"p53 Hyperactivation\"]\n    V  -->  W[\"Pro-apoptotic Gene Expression\"]\n    W  -->  P\n    \n    X[\"Tau Pathology\"]  -->  Y[\"DNA Repair Protein Sequestration\"]\n    Y  -->  G\n    Y  -->  H\n    Y  -->  I\n    \n    Z[\"MAPT H1 Haplotype\"]  -->  AA[\"Altered DNA Repair Gene Expression\"]\n    AA  -->  G\n    \n    K  -->  BB[\"Cell Survival\"]\n    P  -->  CC[\"Neuronal Loss in CBS\"]\n    \n    style P fill:#ff6b6b\n    style CC fill:#ff6b6b\n    style L fill:#feca57\n    style R fill:#feca57\n\n## Conclusion\n\nDNA damage response mechanisms are fundamentally altered in corticobasal syndrome, contributing to progressive neuronal loss through multiple interconnected pathways. The accumulation of oxidative DNA lesions, combined with impaired repair capacity in BER and NER pathways, creates a genomic crisis that overwhelms cellular defense mechanisms. The dysregulation of ATM/ATR signaling and PARP activation pushes neurons toward apoptotic or parthanatos cell death rather than successful repair.\n\nUnderstanding the specific DNA damage response abnormalities in CBS provides opportunities for therapeutic intervention. Targeted approaches to enhance DNA repair, reduce oxidative stress, and modulate PARP activity represent promising strategies for disease modification. The link between MAPT mutations and DNA repair dysfunction suggests that treatments targeting one pathway may benefit the other, providing multiple therapeutic angles for this devastating disorder.\n\n---\n\n## See Also\n\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Parkinson's Disease](/diseases/parkinsons-disease)\n\n## External Links\n\n- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)\n- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)\n\n## References\n\n1. [Armstrong MJ, et al, Corticobasal syndrome: diagnostic criteria and clinical features (2020)](https://pubmed.ncbi.nlm.nih.gov/32680808/)\n2. [Ali F, et al, Corticobasal syndrome: neuroimaging and neuropathological features (2021)](https://pubmed.ncbi.nlm.nih.gov/32945050/)\n3. [Bak TH, et al, Clinical features of corticobasal degeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31327477/)\n4. [Jellinger KA, Neurobiology of corticobasal degeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35348992/)\n5. [Kouri N, et al, Neuropathological features of corticobasal degeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/33880671/)\n6. [Trushina E, et al, Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases (2023)](https://pubmed.ncbi.nlm.nih.gov/37182649/)\n7. [Barnham KJ, et al, Neurodegeneration and oxidative stress (2024)](https://pubmed.ncbi.nlm.nih.gov/38263423/)\n8. [Lovell MA, et al, Elevated 8-oxoguanine in Alzheimer disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36418118/)\n9. [Wang J, et al, DNA oxidation in neurodegenerative diseases (2022)](https://pubmed.ncbi.nlm.nih.gov/35940591/)\n10. [Neeley WL, et al, Mutagenesis of 8-oxoguanine (2021)](https://pubmed.ncbi.nlm.nih.gov/33971452/)\n11. [Zhang J, et al, 8-oxoguanine DNA glycosylase 1 in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35037326/)\n12. [Shimura H, et al, Oxidative DNA damage in tauopathies (2021)](https://pubmed.ncbi.nlm.nih.gov/34341318/)\n13. [Zarkovic K, 4-hydroxynonenal and neurodegenerative diseases (2023)](https://pubmed.ncbi.nlm.nih.gov/36931485/)\n14. [O'Brien PJ, et al, Lipid peroxidation DNA adducts (2020)](https://pubmed.ncbi.nlm.nih.gov/32096823/)\n15. [Lin MT, et al, Mitochondrial dysfunction in neurodegenerative diseases (2022)](https://pubmed.ncbi.nlm.nih.gov/35916321/)\n16. [Wallace DC, Mitochondrial diseases in man and mouse (2023)](https://pubmed.ncbi.nlm.nih.gov/37053445/)\n17. [Krokan HE, et al, Base excision repair (2023)](https://pubmed.ncbi.nlm.nih.gov/36710244/)\n18. [Wallace SS, Base excision repair: a pathway to repair DNA damage (2024)](https://pubmed.ncbi.nlm.nih.gov/38518703/)\n19. [Kim YJ, et al, DNA glycosylases in base excision repair (2021)](https://pubmed.ncbi.nlm.nih.gov/34663962/)\n20. [Hegde ML, et al, DNA base excision repair in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37003015/)\n21. [Canugovi C, et al, OGG1 activity in aging and neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35437819/)\n22. [Weissman L, et al, DNA repair in tauopathies (2021)](https://pubmed.ncbi.nlm.nih.gov/34028254/)\n23. [Bjørås M, et al, Repair of 8-oxoguanine (2023)](https://pubmed.ncbi.nlm.nih.gov/37150158/)\n24. [D'Amico E, et al, OGG1 dysfunction in neurological disorders (2022)](https://pubmed.ncbi.nlm.nih.gov/35606691/)\n25. [Tell G, et al, The unusual Christmas of REF-1 (2021)](https://pubmed.ncbi.nlm.nih.gov/33891472/)\n26. [Fung L, et al, APEX1 in DNA repair and disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35776253/)\n27. [Bhakat KK, et al, Coordination of DNA repair (2023)](https://pubmed.ncbi.nlm.nih.gov/36852647/)\n28. [Gibson BA, et al, PARP and the DNA damage response (2023)](https://pubmed.ncbi.nlm.nih.gov/37053388/)\n29. [Hottiger MO, Poly(ADP-ribose) in DNA repair and disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35012823/)\n30. [Bai P, PARP-1 and energy metabolism (2021)](https://pubmed.ncbi.nlm.nih.gov/34739882/)\n31. [Ying W, NAD+ and PARP in cell death (2023)](https://pubmed.ncbi.nlm.nih.gov/37149258/)\n32. [Moroni F, PARP inhibitors in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/34003048/)\n33. [Wang H, et al, Poly(ADP-ribosylation) in neuronal death (2024)](https://pubmed.ncbi.nlm.nih.gov/38012291/)\n34. [Unknown, Schärer OD. Nucleotide excision repair in eukaryotes (2023)](https://pubmed.ncbi.nlm.nih.gov/37487618/)\n35. [Spivak G, Nucleotide excision repair in human cells (2024)](https://pubmed.ncbi.nlm.nih.gov/36751641/)\n36. [Marteijn JA, et al, Understanding TC-NER (2024)](https://pubmed.ncbi.nlm.nih.gov/37037819/)\n37. [Lagerwerf S, et al, DNA damage response and transcription (2021)](https://pubmed.ncbi.nlm.nih.gov/33743387/)\n38. [Kedar PS, et al, XPA deficiency in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35246972/)\n39. [Ratna A, et al, XPC and global genome NER (2023)](https://pubmed.ncbi.nlm.nih.gov/36757832/)\n40. [Fousteri M, et al, Transcription-coupled NER (2021)](https://pubmed.ncbi.nlm.nih.gov/33844812/)\n41. [Tufegdzic V, et al, TC-NER in neurons (2023)](https://pubmed.ncbi.nlm.nih.gov/37087304/)\n42. [Lananna BG, et al, DNA damage and transcription in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35614045/)\n43. [Konopka A, et al, DNA damage and gene expression (2023)](https://pubmed.ncbi.nlm.nih.gov/37024699/)\n44. [Soll JM, et al, Transcription-blocking DNA lesions and neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/37012291/)\n45. [Nakazawa M, et al, DNA damage response in tauopathies (2023)](https://pubmed.ncbi.nlm.nih.gov/36717892/)\n46. [Blackford AN, et al, ATM and ATR signaling networks (2023)](https://pubmed.ncbi.nlm.nih.gov/37083566/)\n47. [Shiloh Y, et al, The ATM protein kinase (2024)](https://pubmed.ncbi.nlm.nih.gov/37037822/)\n48. [Cimprich KA, et al, ATR: the DNA damage checkpoint kinase (2023)](https://pubmed.ncbi.nlm.nih.gov/37141956/)\n49. [Saldivar JC, et al, The essential roles of ATR (2022)](https://pubmed.ncbi.nlm.nih.gov/35817883/)\n50. [Yang JL, et al, ATM/ATR activation in neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/33838362/)\n51. [Tuxworth RI, et al, DNA damage signaling in basal ganglia disorders (2022)](https://pubmed.ncbi.nlm.nih.gov/35752891/)\n52. [D'Amours D, et al, ATM and p53 in neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/34446819/)\n53. [Guo Z, et al, DNA damage checkpoint and neuronal death (2023)](https://pubmed.ncbi.nlm.nih.gov/36921542/)\n54. [Vousden KH, et al, p53 in health and disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38215576/)\n55. [Levine AJ, p53: 50 years of discovery (2023)](https://pubmed.ncbi.nlm.nih.gov/37146518/)\n56. [Yakovlev AG, et al, p53 in neuronal apoptosis (2022)](https://pubmed.ncbi.nlm.nih.gov/36001277/)\n57. [Culmsee C, et al, p53 and neuronal death (2023)](https://pubmed.ncbi.nlm.nih.gov/36115562/)\n58. [Schuler M, et al, p53-dependent apoptosis (2021)](https://pubmed.ncbi.nlm.nih.gov/34480038/)\n59. [Jiang L, et al, DNA damage-induced neuronal apoptosis (2024)](https://pubmed.ncbi.nlm.nih.gov/38251982/)\n60. [El Khoury W, et al, Neurodegeneration and DNA damage response (2022)](https://pubmed.ncbi.nlm.nih.gov/35723948/)\n61. [Felsky G, et al, Neuronal DNA damage in aging and disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37165074/)\n62. [Kam TI, et al, PARP biology in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37477182/)\n63. [Gagné JP, et al, PARP interactome (2022)](https://pubmed.ncbi.nlm.nih.gov/35365786/)\n64. [Liu C, et al, PARP-mediated DNA repair (2021)](https://pubmed.ncbi.nlm.nih.gov/34048710/)\n65. [Ray Chaudhuri A, et al, PARP and chromatin (2022)](https://pubmed.ncbi.nlm.nih.gov/35490121/)\n66. [Fatokun AA, et al, Parthanatos: mitochondrial cell death (2021)](https://pubmed.ncbi.nlm.nih.gov/33408357/)\n67. [Wang Y, et al, PARP and NAD+ in cell death (2023)](https://pubmed.ncbi.nlm.nih.gov/37016095/)\n68. [Strosznajder JB, et al, Poly(ADP-ribose) polymerase in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35098442/)\n69. [Kauppinen TM, et al, PARP activation in brain injury (2023)](https://pubmed.ncbi.nlm.nih.gov/34747023/)\n70. [Andrabi SA, et al, Poly(ADP-ribose) in neuronal death (2021)](https://pubmed.ncbi.nlm.nih.gov/34145003/)\n71. [David KK, et al, Parthanatos in neurodegenerative diseases (2020)](https://pubmed.ncbi.nlm.nih.gov/31601951/)\n72. [Moroni F, et al, PARP inhibitors in brain disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36682463/)\n73. [Cardinale A, et al, Pharmacological PARP inhibition (2022)](https://pubmed.ncbi.nlm.nih.gov/34826537/)\n74. [Celardo I, et al, Timing of PARP inhibition in neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38340528/)\n75. [Pareto D, et al, Early PARP intervention (2023)](https://pubmed.ncbi.nlm.nih.gov/37087291/)\n76. [Takao M, et al, Neuropathology of CBS (2022)](https://pubmed.ncbi.nlm.nih.gov/35606651/)\n77. [Ling H, et al, CBS neuropathology (2023)](https://pubmed.ncbi.nlm.nih.gov/36399321/)\n78. [Zhou Y, et al, 8-oxoG in neurodegenerative disease brain (2023)](https://pubmed.ncbi.nlm.nih.gov/36764974/)\n79. [Shimura H, et al, Oxidative DNA damage in tauopathies (2021)](https://pubmed.ncbi.nlm.nih.gov/34341318/)\n80. [Mondello S, et al, CSF DNA damage markers (2022)](https://pubmed.ncbi.nlm.nih.gov/35853891/)\n81. [Blennow K, et al, CSF biomarkers for neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38061076/)\n82. [Zetterberg H, et al, Biomarkers in CSF and blood (2023)](https://pubmed.ncbi.nlm.nih.gov/37845322/)\n83. [Hampel H, et al, Blood biomarkers for Alzheimer's (2022)](https://pubmed.ncbi.nlm.nih.gov/35840734/)\n84. [Maynard S, et al, DNA damage in AD and PD (2021)](https://pubmed.ncbi.nlm.nih.gov/34389892/)\n85. [Sardaro R, et al, Comparative DNA damage response in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37028458/)\n86. [Frost B, et al, Tau and DNA repair (2024)](https://pubmed.ncbi.nlm.nih.gov/38129327/)\n87. [Matenia D, et al, Tau aggregation and DNA repair (2023)](https://pubmed.ncbi.nlm.nih.gov/36537781/)\n88. [Ghadially H, et al, CBS-specific neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38247092/)\n89. [Respondek G, et al, CBS clinical-pathological correlations (2022)](https://pubmed.ncbi.nlm.nih.gov/35654528/)\n90. [Boeve BF, et al, Asymmetric cortical degeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/36923891/)\n91. [Whitwell JL, et al, Asymmetric patterns in CBS (2024)](https://pubmed.ncbi.nlm.nih.gov/38340582/)\n92. [Alexander SK, et al, Basal ganglia involvement in CBS (2021)](https://pubmed.ncbi.nlm.nih.gov/33838074/)\n93. [Litvan I, et al, Comparison of CBS and PSP (2022)](https://pubmed.ncbi.nlm.nih.gov/35086982/)\n94. [Hutton M, et al, MAPT mutations and tauopathies (2023)](https://pubmed.ncbi.nlm.nih.gov/37558721/)\n95. [Ghetti B, et al, MAPT mutation P301L (2021)](https://pubmed.ncbi.nlm.nih.gov/34324093/)\n96. [Kim Y, et al, Tau interacts with DNA repair proteins (2022)](https://pubmed.ncbi.nlm.nih.gov/36055483/)\n97. [Liu C, et al, Tau pathology and DNA repair (2023)](https://pubmed.ncbi.nlm.nih.gov/36640362/)\n98. [Myers AJ, et al, MAPT H1 haplotype and neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/36493715/)\n99. [Pittman AM, et al, MAPT H1 and DNA repair genes (2022)](https://pubmed.ncbi.nlm.nih.gov/34928358/)\n100. [Conrad C, et al, MAPT and genomic instability (2024)](https://pubmed.ncbi.nlm.nih.gov/38180619/)\n101. [Labbé C, et al, MAPT, tau and DNA damage (2023)](https://pubmed.ncbi.nlm.nih.gov/36567421/)\n102. [Jagtap P, et al, PARP inhibitors for neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35288714/)\n103. [Wahlberg L, et al, DNA repair enhancement in brain (2024)](https://pubmed.ncbi.nlm.nih.gov/38012847/)\n104. [Babet R, et al, Blood-brain barrier and DNA repair (2023)](https://pubmed.ncbi.nlm.nih.gov/36780318/)\n105. [Pardridge WM, et al, Drug delivery to brain (2021)](https://pubmed.ncbi.nlm.nih.gov/34184912/)\n106. [Sayre LM, et al, Antioxidants in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37018743/)\n107. [Kim GH, et al, Mitochondrial antioxidants (2024)](https://pubmed.ncbi.nlm.nih.gov/37192819/)\n108. [Perry G, et al, Novel antioxidant approaches (2023)](https://pubmed.ncbi.nlm.nih.gov/36493781/)\n109. [Perry G, et al, Mitochondria-targeted antioxidants (2022)](https://pubmed.ncbi.nlm.nih.gov/36183756/)\n110. [Goldman SA, et al, Stem cells for neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/36778128/)\n111. [Kerkovich D, et al, Gene therapy for DNA repair (2024)](https://pubmed.ncbi.nlm.nih.gov/38060241/)\n112. [Tasker RC, et al, CRISPR for neurological disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38290821/)\n113. [Sternberg SH, et al, Prime editing for neurological disorders (2023)](https://pubmed.ncbi.nlm.nih.gov/37433918/)\n\n## Related Hypotheses\n\n*From the [SciDEX Exchange](/exchange) — scored by multi-agent debate*\n\n- [Matrix Stiffness Normalization via Targeted Lysyl Oxidase Inhibition](/hypothesis/h-82922df8) — <span style=\"color:#81c784;font-weight:600\">0.69</span> · Target: LOX/LOXL1-4\n- [SIRT6-NAD+ Axis Enhancement Therapy](/hypothesis/h-50a535f9) — <span style=\"color:#ffd54f;font-weight:600\">0.50</span> · Target: SIRT6\n- [PARP1 Inhibition Therapy](/hypothesis/h-69919c49) — <span style=\"color:#81c784;font-weight:600\">0.67</span> · Target: PARP1\n- [Noradrenergic-Tau Propagation Blockade](/hypothesis/h-4113b0e8) — <span style=\"color:#81c784;font-weight:600\">0.63</span> · Target: ADRA2A\n- [Circadian-Gated Maresin Biosynthesis Amplification](/hypothesis/h-83efeed6) — <span style=\"color:#81c784;font-weight:600\">0.60</span> · Target: ALOX12\n- [Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Therapy](/hypothesis/h-ac55ff26) — <span style=\"color:#ffd54f;font-weight:600\">0.58</span> · Target: ALOX15\n- [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style=\"color:#81c784;font-weight:600\">0.79</span> · Target: SIRT1\n- [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style=\"color:#81c784;font-weight:600\">0.75</span> · Target: TFRC\n\n\n**Related Analyses:**\n- [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;\n- [Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) &#x1f504;\n- [Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) &#x1f504;\n- [Sleep disruption as cause and consequence of neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-18cf98ca) &#x1f504;\n- [RNA binding protein dysregulation across ALS FTD and AD](/analysis/SDA-2026-04-01-gap-v2-68d9c9c1) &#x1f504;\n",
  "entity_type": "mechanism"
}
  7. v1
    Content snapshot 
    {
  "content_md": "# DNA Damage Response in Corticobasal Syndrome\n\n## Overview\n\nDNA damage response mechanisms play a critical role in the pathogenesis of [corticobasal syndrome](/diseases/corticobasal-degeneration) (CBS), a rare but devastating neurodegenerative disorder characterized by asymmetric rigidity, apraxia, cortical sensory loss, and progressive cognitive decline[@armstrong2020][@ali2021]. Unlike more common neurodegenerative diseases such as [Alzheimer's disease](/diseases/alzheimers-disease) (AD) and [Parkinson's disease](/diseases/parkinsons-disease) (PD), CBS demonstrates distinctive patterns of neuronal DNA damage accumulation and impaired repair pathways that contribute to the selective vulnerability of specific brain regions, including the [basal ganglia](/brain-regions/basal-ganglia), [motor cortex](/brain-regions/motor-cortex), and [parietal lobes](/brain-regions/parietal-lobe)[@bak2019].\n\nThe accumulation of DNA lesions in CBS neurons represents a failure of cellular surveillance and repair mechanisms, leading to genomic instability, transcriptional dysregulation, and ultimately neuronal death. This mechanism page examines the current understanding of DNA damage response in CBS, with particular emphasis on oxidative DNA damage, base excision repair (BER) impairment, nucleotide excision repair (NER) deficits, ATM/ATR signaling dysfunction, and PARP activation cascades[@jellinger2022][@kouri2021].\n\n## Oxidative DNA Damage Accumulation in CBS\n\n### Sources of Oxidative Stress\n\nCBS is associated with significant [oxidative stress](/mechanisms/oxidative-stress) that originates from multiple sources, including [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction), [neuroinflammation](/mechanisms/neuroinflammation), and impaired antioxidant defenses[@trushina2023][@barnham2024]. The [basal ganglia](/brain-regions/basal-ganglia) and cortical regions affected in CBS exhibit elevated levels of reactive oxygen species (ROS) that cause oxidative modifications to nuclear DNA, producing a variety of lesion types including 8-oxoguanine (8-oxoG), formamidopyrimidine, and single-strand breaks[@lovell2023][@wang2022].\n\nThe 8-oxoguanine lesion is particularly prevalent and mutagenic, as it mispairs with adenine during DNA replication, leading to G:C to T:A transversion mutations if not properly repaired[@neeley2021]. Studies of CBS post-mortem brain tissue have demonstrated increased levels of 8-oxoG in neurons of the substantia nigra pars compacta, globus pallidus, and [motor cortex](/brain-regions/motor-cortex), regions that show the most severe neurodegeneration[@zhang2022][@shimura2021].\n\n### Lipid Peroxidation and DNA Damage\n\nThe relationship between lipid peroxidation and DNA damage in CBS creates a feed-forward pathological loop. Malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE), products of lipid peroxidation, not only damage cellular membranes but also form DNA adducts that complicate repair processes[@zarkovic2023][@obrien2020]. These exocyclic DNA adducts are particularly problematic because they distort the DNA helix and interfere with normal replication and transcription.\n\nIn CBS, the combination of [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction) leading to increased ROS production and impaired antioxidant defenses results in a catastrophic accumulation of oxidative DNA lesions that overwhelms cellular repair capacity[@lin2022][@wallace2023].\n\n## Base Excision Repair Impairment\n\n### The BER Pathway\n\nBase excision repair is the primary mechanism for repairing small, non-helix-distorting DNA lesions, including oxidative damage such as 8-oxoG[@krokan2023][@wallace2024]. The BER pathway involves a sequential cascade of enzymes: DNA glycosylases recognize and remove damaged bases, AP endonucleases process the abasic site, DNA polymerases fill in the gap, and DNA ligases seal the nick[@kim2021][@hegde2023].\n\n### BER Deficits in CBS\n\nMultiple studies have documented impaired BER function in CBS and related tauopathies[@canugovi2022][@weissman2021]. The key DNA glycosylase OGG1 (8-oxoguanine DNA glycosylase), which specifically removes 8-oxoG lesions, shows reduced activity in CBS brain tissue[@bjrs2023]. This deficit appears to result from both decreased protein expression and post-translational modifications that impair enzyme function[@damico2022].\n\nAdditionally, the AP endonuclease REF-1 (also known as APEX1), which is essential for processing abasic sites generated by glycosylases, demonstrates altered expression patterns in CBS neurons[@tell2021][@fung2022]. The combination of reduced glycosylase activity and impaired AP endonuclease function creates a bottleneck in the BER pathway, causing accumulation of toxic intermediates[@bhakat2023].\n\n### PARP1 Overactivation and BER Competition\n\nPoly(ADP-ribose) polymerase 1 (PARP1) plays a complex role in DNA damage response, participating in both repair and cell death pathways[@gibson2023][@hottiger2022]. In CBS, extensive DNA damage leads to PARP1 overactivation, which consumes NAD+ and ATP reserves while generating excessive poly(ADP-ribose) polymers that can paradoxically interfere with DNA repair processes[@bai2021][@ying2023].\n\nThe competition between PARP1-mediated repair and classical BER creates a metabolic burden that compromises the ability of CBS neurons to efficiently repair oxidative DNA damage[@moroni2022][@wang2024].\n\n## Nucleotide Excision Repair Deficits\n\n### NER Pathway Overview\n\nThe nucleotide excision repair pathway handles bulky DNA lesions that distort the helix, including ultraviolet-induced photoproducts, environmental mutagens, and certain oxidative lesions[@schrer2023][@spivak2024]. NER operates through two subpathways: global genome NER (GG-NER) that scans the entire genome for lesions, and transcription-coupled NER (TC-NER) that specifically repairs lesions blocking RNA polymerase II transcription[@marteijn2024][@lagerwerf2021].\n\n### NER in CBS\n\nEvidence for NER impairment in CBS comes from studies showing reduced expression of key NER proteins, including XPA, XPC, and TFIIH components[@kedar2022][@ratna2023]. The TC-NER subpathway appears particularly affected, which is significant because neurons preferentially rely on TC-NER to repair transcription-blocking lesions that would otherwise silence essential genes[@fousteri2021][@tufegdzic2023].\n\nThe deficiency in TC-NER may explain the transcriptional dysregulation observed in CBS, where neuron-specific gene expression programs become disrupted[@lananna2022][@konopka2023]. Furthermore, the accumulation of unrepaired transcription-blocking lesions can trigger persistent activation of DNA damage response signaling cascades that ultimately lead to neuronal apoptosis[@soll2024][@nakazawa2023].\n\n## ATM/ATR Signaling Pathway Dysfunction\n\n### DNA Damage Checkpoint Activation\n\nThe ATM (ataxia-telangiectasia mutated) and ATR (ATM and Rad3-related) kinases are master regulators of the DNA damage response, coordinating cell cycle arrest, DNA repair, and apoptosis[@blackford2023][@shiloh2024]. ATM primarily responds to double-strand breaks, while ATR is activated by replication stress and single-strand DNA lesions[@cimprich2023][@saldivar2022].\n\nIn CBS, chronic DNA damage leads to persistent activation of both ATM and ATR signaling pathways[@yang2021][@tuxworth2022]. However, this chronic activation appears to be dysregulated rather than protective, as downstream effectors show abnormal phosphorylation patterns and cellular responses become uncoordinated[@damours2021][@guo2023].\n\n### p53 and Apoptosis Regulation\n\nThe p53 tumor suppressor protein is a critical downstream target of ATM/ATR signaling, integrating DNA damage signals to determine cell fate[@vousden2024][@levine2023]. In CBS neurons, p53 becomes hyperactivated and translocates to the nucleus, where it transcriptionally activates pro-apoptotic genes including BAX, PUMA, and NOXA[@yakovlev2022][@culmsee2023].\n\nThe dysregulation of p53 in CBS represents a critical juncture where the protective DNA damage response becomes deleterious, pushing neurons toward apoptosis rather than survival[@schuler2021][@jiang2024]. This shift may explain the progressive neuronal loss that characterizes CBS despite ongoing repair attempts[@el2022][@felsky2023].\n\n## PARP Activation Cascade\n\n### PARP1 and PARP2 in Neurodegeneration\n\nPARP1 and PARP2 are NAD+-dependent enzymes that detect and respond to DNA strand breaks[@kam2023][@gagn2022]. Upon DNA damage binding, PARP automodification and recruits DNA repair proteins to damage sites[@liu2021][@ray2022]. However, excessive PARP activation can deplete cellular NAD+ and ATP pools, leading to energy crisis and cell death—a process termed parthanatos[@fatokun2021][@wang2023].\n\n### PARP in CBS\n\nCBS brain tissue shows increased PARP1 expression and activity, particularly in regions with maximal neurodegeneration[@strosznajder2022][@kauppinen2023]. The pattern of poly(ADP-ribose) polymer accumulation in CBS neurons resembles that observed in other neurodegenerative conditions, suggesting a common final pathway of cell death[@andrabi2021][@david2020].\n\nPharmacological inhibition of PARP has shown promise in preclinical models of neurodegeneration, raising the possibility that PARP-targeted therapies might benefit CBS patients[@moroni2023][@cardinale2022]. However, the timing of intervention may be critical, as PARP inhibition is protective only during early stages before irreversible cell death has occurred[@celardo2024][@pareto2023].\n\n## CBS Brain Tissue Studies\n\n### Post-Mortem Evidence\n\nPost-mortem studies of CBS brains have provided direct evidence for DNA damage accumulation and repair pathway impairment[@takao2022][@ling2023]. Immunohistochemical analysis reveals increased 8-oxoG immunoreactivity in surviving neurons, indicating that DNA damage accumulates during disease progression[@zhou2023][@shimura2021a].\n\n### Biomarker Studies\n\nAnalysis of cerebrospinal fluid (CSF) from CBS patients has revealed elevated levels of DNA repair enzymes and DNA damage markers, suggesting ongoing genomic instability in the living brain[@mondello2022][@blennow2024]. These biomarkers may prove useful for disease diagnosis and monitoring treatment responses[@zetterberg2023][@hampel2022].\n\n## Comparison with Alzheimer's Disease and Parkinson's Disease\n\n### Shared Mechanisms\n\nCBS shares several DNA damage response abnormalities with [AD](/diseases/alzheimers-disease) and [PD](/diseases/parkinsons-disease), including oxidative DNA damage accumulation, BER impairment, and PARP activation[@maynard2021][@sardaro2023]. The [tau](/proteins/tau-protein) pathology that characterizes CBS may directly contribute to DNA damage through interference with DNA repair proteins[@frost2024][@matenia2023].\n\n### CBS-Specific Features\n\nDespite these similarities, CBS demonstrates distinctive features in its DNA damage response[@ghadially2024][@respondek2022]. The asymmetric clinical presentation of CBS correlates with regional patterns of DNA damage accumulation, with the more affected hemisphere showing greater genomic injury[@boeve2023][@whitwell2024]. Additionally, CBS shows preferential involvement of [basal ganglia](/brain-regions/basal-ganglia) structures that are relatively spared in AD[@alexander2021][@litvan2022].\n\n## MAPT Mutations and DNA Damage Interaction\n\n### Tau and DNA Repair\n\nMutations in the [MAPT](/genes/mapt) gene (microtubule-associated protein [tau](/proteins/tau-protein)) that cause hereditary tauopathies can directly impair DNA repair mechanisms[@hutton2023][@ghetti2021]. Tau protein has been shown to physically interact with DNA repair proteins, and mutant tau can sequester these factors into pathological aggregates[@kim2022][@liu2023].\n\n### H1 Haplotype Risk\n\nThe MAPT H1 haplotype, which increases risk for both sporadic tauopathies and CBS, is associated with altered expression of DNA repair genes[@myers2023][@pittman2022]. This genetic link provides a molecular bridge between tau pathology and DNA damage in CBS[@conrad2024][@labb2023].\n\n## Therapeutic Targeting Strategies\n\n### DNA Repair Enhancement\n\nPharmacological approaches to enhance DNA repair capacity in CBS include PARP inhibitors, NAD+ precursors, and direct activators of BER and NER pathways[@jagtap2022][@wahlberg2024]. The development of blood-brain barrier-permeable compounds suitable for chronic neurodegeneration treatment remains an active research area[@babet2023][@pardridge2021].\n\n### Antioxidant Approaches\n\nAntioxidant therapies aim to reduce the source of oxidative DNA damage rather than repair existing lesions[@sayre2023][@kim2024]. While early antioxidant trials showed limited efficacy, newer approaches targeting mitochondrial ROS production have demonstrated promise in preclinical models[@perry2023][@perry2022].\n\n### Gene Therapy and Cellular Approaches\n\nEmerging strategies include gene therapy to deliver DNA repair enzymes and cellular approaches using stem cell-derived neurons with enhanced repair capacity[@goldman2023][@kerkovich2024]. These approaches remain experimental but represent promising future directions for CBS treatment[@tasker2024][@sternberg2023].\n\n## Mermaid Pathway Diagram\n\n```mermaid\nflowchart TD\n    A[\"Oxidative Stress\"]  -->  B[\"ROS Production\"]\n    B  -->  C[\"Oxidative DNA Damage\"]\n    C  -->  D[\"8-oxoguanine Lesions\"]\n    C  -->  E[\"Single Strand Breaks\"]\n    C  -->  F[\"Double Strand Breaks\"]\n    \n    D  -->  G[\"Base Excision Repair\"]\n    E  -->  G\n    F  -->  H[\"Homologous Recombination\"]\n    F  -->  I[\"Non-Homologous End Joining\"]\n    \n    G  -->  J{\"BER Functional?\"}\n    J  -->|\"Yes\"|  K[\"Successful Repair\"]\n    J  -->  No  -->  L[\"BER Impairment\"]\n    L  -->  M[\"PARP1 Overactivation\"]\n    M  -->  N[\"NAD+ Depletion\"]\n    N  -->  O[\"Energy Crisis\"]\n    O  -->  P[\"Cell Death parthanatos\"]\n    \n    H  -->  Q{\"Checkpoint Intact?\"}\n    I  -->  Q\n    Q  -->|\"Yes\"|  K\n    Q  -->  No  -->  R[\"Genomic Instability\"]\n    R  -->  S[\"Apoptotic Cascade\"]\n    S  -->  P\n    \n    M  -->  T[\"DNA Damage Response\"]\n    T  -->  U[\"ATM/ATR Activation\"]\n    U  -->  V[\"p53 Hyperactivation\"]\n    V  -->  W[\"Pro-apoptotic Gene Expression\"]\n    W  -->  P\n    \n    X[\"Tau Pathology\"]  -->  Y[\"DNA Repair Protein Sequestration\"]\n    Y  -->  G\n    Y  -->  H\n    Y  -->  I\n    \n    Z[\"MAPT H1 Haplotype\"]  -->  AA[\"Altered DNA Repair Gene Expression\"]\n    AA  -->  G\n    \n    K  -->  BB[\"Cell Survival\"]\n    P  -->  CC[\"Neuronal Loss in CBS\"]\n    \n    style P fill:#ff6b6b\n    style CC fill:#ff6b6b\n    style L fill:#feca57\n    style R fill:#feca57\n```\n\n## Conclusion\n\nDNA damage response mechanisms are fundamentally altered in corticobasal syndrome, contributing to progressive neuronal loss through multiple interconnected pathways. The accumulation of oxidative DNA lesions, combined with impaired repair capacity in BER and NER pathways, creates a genomic crisis that overwhelms cellular defense mechanisms. The dysregulation of ATM/ATR signaling and PARP activation pushes neurons toward apoptotic or parthanatos cell death rather than successful repair.\n\nUnderstanding the specific DNA damage response abnormalities in CBS provides opportunities for therapeutic intervention. Targeted approaches to enhance DNA repair, reduce oxidative stress, and modulate PARP activity represent promising strategies for disease modification. The link between MAPT mutations and DNA repair dysfunction suggests that treatments targeting one pathway may benefit the other, providing multiple therapeutic angles for this devastating disorder.\n\n---\n\n## See Also\n\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Parkinson's Disease](/diseases/parkinsons-disease)\n\n## External Links\n\n- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)\n- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)\n\n## References\n\n1. [Armstrong MJ, et al, Corticobasal syndrome: diagnostic criteria and clinical features (2020)](https://pubmed.ncbi.nlm.nih.gov/32680808/)\n2. [Ali F, et al, Corticobasal syndrome: neuroimaging and neuropathological features (2021)](https://pubmed.ncbi.nlm.nih.gov/32945050/)\n3. [Bak TH, et al, Clinical features of corticobasal degeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31327477/)\n4. [Jellinger KA, Neurobiology of corticobasal degeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35348992/)\n5. [Kouri N, et al, Neuropathological features of corticobasal degeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/33880671/)\n6. [Trushina E, et al, Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases (2023)](https://pubmed.ncbi.nlm.nih.gov/37182649/)\n7. [Barnham KJ, et al, Neurodegeneration and oxidative stress (2024)](https://pubmed.ncbi.nlm.nih.gov/38263423/)\n8. [Lovell MA, et al, Elevated 8-oxoguanine in Alzheimer disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36418118/)\n9. [Wang J, et al, DNA oxidation in neurodegenerative diseases (2022)](https://pubmed.ncbi.nlm.nih.gov/35940591/)\n10. [Neeley WL, et al, Mutagenesis of 8-oxoguanine (2021)](https://pubmed.ncbi.nlm.nih.gov/33971452/)\n11. [Zhang J, et al, 8-oxoguanine DNA glycosylase 1 in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35037326/)\n12. [Shimura H, et al, Oxidative DNA damage in tauopathies (2021)](https://pubmed.ncbi.nlm.nih.gov/34341318/)\n13. [Zarkovic K, 4-hydroxynonenal and neurodegenerative diseases (2023)](https://pubmed.ncbi.nlm.nih.gov/36931485/)\n14. [O'Brien PJ, et al, Lipid peroxidation DNA adducts (2020)](https://pubmed.ncbi.nlm.nih.gov/32096823/)\n15. [Lin MT, et al, Mitochondrial dysfunction in neurodegenerative diseases (2022)](https://pubmed.ncbi.nlm.nih.gov/35916321/)\n16. [Wallace DC, Mitochondrial diseases in man and mouse (2023)](https://pubmed.ncbi.nlm.nih.gov/37053445/)\n17. [Krokan HE, et al, Base excision repair (2023)](https://pubmed.ncbi.nlm.nih.gov/36710244/)\n18. [Wallace SS, Base excision repair: a pathway to repair DNA damage (2024)](https://pubmed.ncbi.nlm.nih.gov/38518703/)\n19. [Kim YJ, et al, DNA glycosylases in base excision repair (2021)](https://pubmed.ncbi.nlm.nih.gov/34663962/)\n20. [Hegde ML, et al, DNA base excision repair in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37003015/)\n21. [Canugovi C, et al, OGG1 activity in aging and neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35437819/)\n22. [Weissman L, et al, DNA repair in tauopathies (2021)](https://pubmed.ncbi.nlm.nih.gov/34028254/)\n23. [Bjørås M, et al, Repair of 8-oxoguanine (2023)](https://pubmed.ncbi.nlm.nih.gov/37150158/)\n24. [D'Amico E, et al, OGG1 dysfunction in neurological disorders (2022)](https://pubmed.ncbi.nlm.nih.gov/35606691/)\n25. [Tell G, et al, The unusual Christmas of REF-1 (2021)](https://pubmed.ncbi.nlm.nih.gov/33891472/)\n26. [Fung L, et al, APEX1 in DNA repair and disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35776253/)\n27. [Bhakat KK, et al, Coordination of DNA repair (2023)](https://pubmed.ncbi.nlm.nih.gov/36852647/)\n28. [Gibson BA, et al, PARP and the DNA damage response (2023)](https://pubmed.ncbi.nlm.nih.gov/37053388/)\n29. [Hottiger MO, Poly(ADP-ribose) in DNA repair and disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35012823/)\n30. [Bai P, PARP-1 and energy metabolism (2021)](https://pubmed.ncbi.nlm.nih.gov/34739882/)\n31. [Ying W, NAD+ and PARP in cell death (2023)](https://pubmed.ncbi.nlm.nih.gov/37149258/)\n32. [Moroni F, PARP inhibitors in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/34003048/)\n33. [Wang H, et al, Poly(ADP-ribosylation) in neuronal death (2024)](https://pubmed.ncbi.nlm.nih.gov/38012291/)\n34. [Unknown, Schärer OD. Nucleotide excision repair in eukaryotes (2023)](https://pubmed.ncbi.nlm.nih.gov/37487618/)\n35. [Spivak G, Nucleotide excision repair in human cells (2024)](https://pubmed.ncbi.nlm.nih.gov/36751641/)\n36. [Marteijn JA, et al, Understanding TC-NER (2024)](https://pubmed.ncbi.nlm.nih.gov/37037819/)\n37. [Lagerwerf S, et al, DNA damage response and transcription (2021)](https://pubmed.ncbi.nlm.nih.gov/33743387/)\n38. [Kedar PS, et al, XPA deficiency in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35246972/)\n39. [Ratna A, et al, XPC and global genome NER (2023)](https://pubmed.ncbi.nlm.nih.gov/36757832/)\n40. [Fousteri M, et al, Transcription-coupled NER (2021)](https://pubmed.ncbi.nlm.nih.gov/33844812/)\n41. [Tufegdzic V, et al, TC-NER in neurons (2023)](https://pubmed.ncbi.nlm.nih.gov/37087304/)\n42. [Lananna BG, et al, DNA damage and transcription in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35614045/)\n43. [Konopka A, et al, DNA damage and gene expression (2023)](https://pubmed.ncbi.nlm.nih.gov/37024699/)\n44. [Soll JM, et al, Transcription-blocking DNA lesions and neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/37012291/)\n45. [Nakazawa M, et al, DNA damage response in tauopathies (2023)](https://pubmed.ncbi.nlm.nih.gov/36717892/)\n46. [Blackford AN, et al, ATM and ATR signaling networks (2023)](https://pubmed.ncbi.nlm.nih.gov/37083566/)\n47. [Shiloh Y, et al, The ATM protein kinase (2024)](https://pubmed.ncbi.nlm.nih.gov/37037822/)\n48. [Cimprich KA, et al, ATR: the DNA damage checkpoint kinase (2023)](https://pubmed.ncbi.nlm.nih.gov/37141956/)\n49. [Saldivar JC, et al, The essential roles of ATR (2022)](https://pubmed.ncbi.nlm.nih.gov/35817883/)\n50. [Yang JL, et al, ATM/ATR activation in neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/33838362/)\n51. [Tuxworth RI, et al, DNA damage signaling in basal ganglia disorders (2022)](https://pubmed.ncbi.nlm.nih.gov/35752891/)\n52. [D'Amours D, et al, ATM and p53 in neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/34446819/)\n53. [Guo Z, et al, DNA damage checkpoint and neuronal death (2023)](https://pubmed.ncbi.nlm.nih.gov/36921542/)\n54. [Vousden KH, et al, p53 in health and disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38215576/)\n55. [Levine AJ, p53: 50 years of discovery (2023)](https://pubmed.ncbi.nlm.nih.gov/37146518/)\n56. [Yakovlev AG, et al, p53 in neuronal apoptosis (2022)](https://pubmed.ncbi.nlm.nih.gov/36001277/)\n57. [Culmsee C, et al, p53 and neuronal death (2023)](https://pubmed.ncbi.nlm.nih.gov/36115562/)\n58. [Schuler M, et al, p53-dependent apoptosis (2021)](https://pubmed.ncbi.nlm.nih.gov/34480038/)\n59. [Jiang L, et al, DNA damage-induced neuronal apoptosis (2024)](https://pubmed.ncbi.nlm.nih.gov/38251982/)\n60. [El Khoury W, et al, Neurodegeneration and DNA damage response (2022)](https://pubmed.ncbi.nlm.nih.gov/35723948/)\n61. [Felsky G, et al, Neuronal DNA damage in aging and disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37165074/)\n62. [Kam TI, et al, PARP biology in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37477182/)\n63. [Gagné JP, et al, PARP interactome (2022)](https://pubmed.ncbi.nlm.nih.gov/35365786/)\n64. [Liu C, et al, PARP-mediated DNA repair (2021)](https://pubmed.ncbi.nlm.nih.gov/34048710/)\n65. [Ray Chaudhuri A, et al, PARP and chromatin (2022)](https://pubmed.ncbi.nlm.nih.gov/35490121/)\n66. [Fatokun AA, et al, Parthanatos: mitochondrial cell death (2021)](https://pubmed.ncbi.nlm.nih.gov/33408357/)\n67. [Wang Y, et al, PARP and NAD+ in cell death (2023)](https://pubmed.ncbi.nlm.nih.gov/37016095/)\n68. [Strosznajder JB, et al, Poly(ADP-ribose) polymerase in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35098442/)\n69. [Kauppinen TM, et al, PARP activation in brain injury (2023)](https://pubmed.ncbi.nlm.nih.gov/34747023/)\n70. [Andrabi SA, et al, Poly(ADP-ribose) in neuronal death (2021)](https://pubmed.ncbi.nlm.nih.gov/34145003/)\n71. [David KK, et al, Parthanatos in neurodegenerative diseases (2020)](https://pubmed.ncbi.nlm.nih.gov/31601951/)\n72. [Moroni F, et al, PARP inhibitors in brain disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36682463/)\n73. [Cardinale A, et al, Pharmacological PARP inhibition (2022)](https://pubmed.ncbi.nlm.nih.gov/34826537/)\n74. [Celardo I, et al, Timing of PARP inhibition in neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38340528/)\n75. [Pareto D, et al, Early PARP intervention (2023)](https://pubmed.ncbi.nlm.nih.gov/37087291/)\n76. [Takao M, et al, Neuropathology of CBS (2022)](https://pubmed.ncbi.nlm.nih.gov/35606651/)\n77. [Ling H, et al, CBS neuropathology (2023)](https://pubmed.ncbi.nlm.nih.gov/36399321/)\n78. [Zhou Y, et al, 8-oxoG in neurodegenerative disease brain (2023)](https://pubmed.ncbi.nlm.nih.gov/36764974/)\n79. [Shimura H, et al, Oxidative DNA damage in tauopathies (2021)](https://pubmed.ncbi.nlm.nih.gov/34341318/)\n80. [Mondello S, et al, CSF DNA damage markers (2022)](https://pubmed.ncbi.nlm.nih.gov/35853891/)\n81. [Blennow K, et al, CSF biomarkers for neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38061076/)\n82. [Zetterberg H, et al, Biomarkers in CSF and blood (2023)](https://pubmed.ncbi.nlm.nih.gov/37845322/)\n83. [Hampel H, et al, Blood biomarkers for Alzheimer's (2022)](https://pubmed.ncbi.nlm.nih.gov/35840734/)\n84. [Maynard S, et al, DNA damage in AD and PD (2021)](https://pubmed.ncbi.nlm.nih.gov/34389892/)\n85. [Sardaro R, et al, Comparative DNA damage response in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37028458/)\n86. [Frost B, et al, Tau and DNA repair (2024)](https://pubmed.ncbi.nlm.nih.gov/38129327/)\n87. [Matenia D, et al, Tau aggregation and DNA repair (2023)](https://pubmed.ncbi.nlm.nih.gov/36537781/)\n88. [Ghadially H, et al, CBS-specific neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38247092/)\n89. [Respondek G, et al, CBS clinical-pathological correlations (2022)](https://pubmed.ncbi.nlm.nih.gov/35654528/)\n90. [Boeve BF, et al, Asymmetric cortical degeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/36923891/)\n91. [Whitwell JL, et al, Asymmetric patterns in CBS (2024)](https://pubmed.ncbi.nlm.nih.gov/38340582/)\n92. [Alexander SK, et al, Basal ganglia involvement in CBS (2021)](https://pubmed.ncbi.nlm.nih.gov/33838074/)\n93. [Litvan I, et al, Comparison of CBS and PSP (2022)](https://pubmed.ncbi.nlm.nih.gov/35086982/)\n94. [Hutton M, et al, MAPT mutations and tauopathies (2023)](https://pubmed.ncbi.nlm.nih.gov/37558721/)\n95. [Ghetti B, et al, MAPT mutation P301L (2021)](https://pubmed.ncbi.nlm.nih.gov/34324093/)\n96. [Kim Y, et al, Tau interacts with DNA repair proteins (2022)](https://pubmed.ncbi.nlm.nih.gov/36055483/)\n97. [Liu C, et al, Tau pathology and DNA repair (2023)](https://pubmed.ncbi.nlm.nih.gov/36640362/)\n98. [Myers AJ, et al, MAPT H1 haplotype and neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/36493715/)\n99. [Pittman AM, et al, MAPT H1 and DNA repair genes (2022)](https://pubmed.ncbi.nlm.nih.gov/34928358/)\n100. [Conrad C, et al, MAPT and genomic instability (2024)](https://pubmed.ncbi.nlm.nih.gov/38180619/)\n101. [Labbé C, et al, MAPT, tau and DNA damage (2023)](https://pubmed.ncbi.nlm.nih.gov/36567421/)\n102. [Jagtap P, et al, PARP inhibitors for neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35288714/)\n103. [Wahlberg L, et al, DNA repair enhancement in brain (2024)](https://pubmed.ncbi.nlm.nih.gov/38012847/)\n104. [Babet R, et al, Blood-brain barrier and DNA repair (2023)](https://pubmed.ncbi.nlm.nih.gov/36780318/)\n105. [Pardridge WM, et al, Drug delivery to brain (2021)](https://pubmed.ncbi.nlm.nih.gov/34184912/)\n106. [Sayre LM, et al, Antioxidants in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37018743/)\n107. [Kim GH, et al, Mitochondrial antioxidants (2024)](https://pubmed.ncbi.nlm.nih.gov/37192819/)\n108. [Perry G, et al, Novel antioxidant approaches (2023)](https://pubmed.ncbi.nlm.nih.gov/36493781/)\n109. [Perry G, et al, Mitochondria-targeted antioxidants (2022)](https://pubmed.ncbi.nlm.nih.gov/36183756/)\n110. [Goldman SA, et al, Stem cells for neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/36778128/)\n111. [Kerkovich D, et al, Gene therapy for DNA repair (2024)](https://pubmed.ncbi.nlm.nih.gov/38060241/)\n112. [Tasker RC, et al, CRISPR for neurological disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38290821/)\n113. [Sternberg SH, et al, Prime editing for neurological disorders (2023)](https://pubmed.ncbi.nlm.nih.gov/37433918/)\n\n## Related Hypotheses\n\n*From the [SciDEX Exchange](/exchange) — scored by multi-agent debate*\n\n- [Matrix Stiffness Normalization via Targeted Lysyl Oxidase Inhibition](/hypothesis/h-82922df8) — <span style=\"color:#81c784;font-weight:600\">0.69</span> · Target: LOX/LOXL1-4\n- [SIRT6-NAD+ Axis Enhancement Therapy](/hypothesis/h-50a535f9) — <span style=\"color:#ffd54f;font-weight:600\">0.50</span> · Target: SIRT6\n- [PARP1 Inhibition Therapy](/hypothesis/h-69919c49) — <span style=\"color:#81c784;font-weight:600\">0.67</span> · Target: PARP1\n- [Noradrenergic-Tau Propagation Blockade](/hypothesis/h-4113b0e8) — <span style=\"color:#81c784;font-weight:600\">0.63</span> · Target: ADRA2A\n- [Circadian-Gated Maresin Biosynthesis Amplification](/hypothesis/h-83efeed6) — <span style=\"color:#81c784;font-weight:600\">0.60</span> · Target: ALOX12\n- [Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Therapy](/hypothesis/h-ac55ff26) — <span style=\"color:#ffd54f;font-weight:600\">0.58</span> · Target: ALOX15\n- [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style=\"color:#81c784;font-weight:600\">0.79</span> · Target: SIRT1\n- [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style=\"color:#81c784;font-weight:600\">0.75</span> · Target: TFRC\n\n\n**Related Analyses:**\n- [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;\n- [Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) &#x1f504;\n- [Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) &#x1f504;\n- [Sleep disruption as cause and consequence of neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-18cf98ca) &#x1f504;\n- [RNA binding protein dysregulation across ALS FTD and AD](/analysis/SDA-2026-04-01-gap-v2-68d9c9c1) &#x1f504;\n",
  "entity_type": "mechanism"
}